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General introduction 
 
 
8 Chapter 1 
Patients with a chronic disease, like asthma and Chronic Obstructive Pulmonary 
Disease (COPD), do not always take their medication in the frequency and dosage as 
prescribed by their healthcare provider. This can result in, for instance, uncontrolled 
disease and high healthcare costs. Several factors are associated with this 
suboptimal adherence, of which patients’ beliefs about their medication appear to 
be one of the most potentially modifiable factors. The quality of the communication 
between healthcare providers and patients might also play a role. When 
communicating in an effective, open and patient-centered way, healthcare 
providers have the opportunity to change patients’ medication-taking behavior and 
related beliefs. By their profession, community pharmacists are one of the 
designated healthcare providers to educate and counsel patients. However, we do 
not know whether they have sufficient communication skills for this part of their 
work. In this thesis, some keystones related to optimal adherence to inhaled 
corticosteroids are explored with the aim to get insight into the state of the art and 
related points of improvement regarding the communication of pharmacists and 
pharmacy technicians with patients with asthma or COPD. 
 
Adherence to medication for chronic diseases 
Chronic diseases are a major health burden. Worldwide, almost 70% of mortalities 
can be attributed to chronic diseases, and this proportion is expected to rise in the 
following years.1 To manage their chronic disease, patients often have to adopt a 
healthy lifestyle, which is characterized by, e.g. a healthy diet and sufficient physical 
activity, and they often need to follow long-term drug treatment. However, 
medication adherence - defined as the extent to which patients take their 
medications as prescribed - is suboptimal in a large group of patients. A 
comprehensive meta-analysis by DiMatteo reported that around 20% of chronically 
ill patients do not adhere to the prescribed medication regimens.2 The actual 
adherence rate might be even lower as non-adherent patients can be expected to 
participate less in research than adherent patients do. Suboptimal adherence is 
expected to have negative consequences for the patient and the society as it is 
related to poor health outcomes, reduced quality of life, higher healthcare costs, 
and higher mortality.3 
 
Terminology 
Next to the term adherence, the words compliance and concordance are often used 
interchangeably in literature when describing patients’ medication-taking behavior, 
although they actually refer to different concepts. Adherence can be seen as a 
general, overarching term for patients’ medication-taking behavior related to 
providers’ instructions, whereas the terms compliance and concordance also take 
the relationship between healthcare providers and patients into account.4,5 
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Compliance refers to the degree to which patients obey the providers’ 
recommendations. This term has a negative and outdated connotation as it assumes 
that patients have to follow the providers’ recommendations passively, without any 
agreement between the provider and the patient. Concordance covers a more 
complex concept, “[…] relating to the patient/prescriber relationship and the degree 
to which the prescription represents a shared decision, in which the beliefs and 
preferences of the patient have been taken into consideration”.4 Adherence is a 
more neutral term, not essentially referring to obedience or agreement, and is used 
as a term for medication-taking behavior in this thesis. Furthermore, non-adherence 
and suboptimal adherence are both terms used for not being adherent.  
 
Phases of medication adherence 
Medication adherence is not simply about taking or not taking the medication. 
Vrijens et al. distinguish three phases in the process of medication adherence: 
initiation, implementation and discontinuation.6 The first phase is initiation, taking 
the first dose of the medication. The second phase includes the implementation of 
the therapy, referring to a patient’s actual medication-taking behavior relative to the 
prescribed therapy, from the first until the last dose. Discontinuation is the last 
phase of the process, indicating that the patient has taken the last dose of the 
regimen and has ceased the therapy. Persistence covers the period between 
initiation and discontinuation. Suboptimal adherence can occur during each of the 
three phases. There can be, for instance, delayed or no initiation or the 
implementation can be suboptimal. Underuse of medication frequently occurs, but 
overuse of medication can take place as well. Some patients only take their 
medication as prescribed a few days before visiting their healthcare provider, which 
is called white coat adherence. In addition, so called drug holidays exist; then a 
patient temporarily interrupts therapy at least three subsequent days, and starts to 
continue the drug therapy at a later time point. Finally, patients can discontinue the 
therapy too early. Regarding patients using long-term medication for a chronic 
disease, discontinuation is by definition, ideally, out of the question.  
By communicating openly with their patients, healthcare providers might be able 
to detect what type of adherence a patient has and come up with appropriate 
actions to improve it. 
 
 10 Chapter 1 
Figure 1.1 Different phases of medication taking behavior (Vrijens et al.6)  
 
Intentional and unintentional non-adherence 
We can distinguish between two types of non-adherence to medication: intentional 
and unintentional non-adherence. Intentional non-adherence reflects a deliberate 
choice to change, to stop, or fail to start the treatment. This decision can be based 
on several reasons, like beliefs (e.g. the fear of side effects), suffering from side 
effects or a relief of symptoms. In case of intentional non-adherence, the patient 
does not want to adhere. Unintentional non-adherence, on the contrary, means that 
the patient is in some way not able to adhere. This can be a result of several reasons 
like forgetfulness, carelessness, misunderstanding of the proper use of the 
medication (e.g. poor understanding of dosing regimen details or performing 
incorrect inhaler technique), or misunderstanding the need for adherence (e.g. 
because of low health literacy). Overlaps and alternations between the types are 
possible.7-9 
Interventions to improve adherence and prevent non-adherence largely should 
be flexible to the extent to which the non-adherence is intentional or not. Especially, 
but not exclusively, attention to patients’ beliefs about medication seems crucial for 
changing (intentional and unintentional) non-adherence. Patient-related factors, 
such as beliefs about medication and personality traits, are one of the five main 
categories associated with medication adherence as identified by the World Health 
Organization (WHO).3 Together with healthcare providers’ beliefs and 
communication (which are included in the WHO category ‘healthcare team and 
system-related factors’), patients’ medication beliefs are part of the research 
described in this thesis. 
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Patients’ beliefs about medication  
Patients have several medication perceptions. Horne and colleagues make a 
distinction between general medication beliefs and specific medication beliefs.10,11 
General medication beliefs refer to patients’ perceptions of the benefits and 
harmfulness of medicines in general and overprescribing by healthcare providers. 
Several studies found an association between general medication beliefs and 
medication adherence (see e.g. Chapman et al.12 and Mardby et al.13). Specific 
medication beliefs are about perceptions of medications for a particular disease. 
These specific medication beliefs can be divided into necessity beliefs and concerns. 
Necessity beliefs refer to patients’ perceptions of personal need for treatment. For 
instance, patients can have doubts about the need for treatment. Furthermore, 
patients can have concerns about potential adverse consequences of taking the 
medication, like side effects or long-term effects of the treatment, or drug 
dependency. According to the Necessity-Concerns Framework of Horne and 
colleagues, patients’ necessity beliefs and concerns about the treatment influence 
adherence, in which higher necessity beliefs are associated with higher adherence, 
and higher concerns with lower adherence.14  
 
Patient-provider communication 
Another factor related to medication adherence is the communication between 
patients and healthcare providers. Good communication is important because 
patients have several beliefs (as explained above), needs and preferences, which 
need to be explored repeatedly by the provider before and during medication 
treatment. Patients have two sorts of needs: informational needs, i.e. “the need to 
know and to understand”, and emotional needs, i.e. “the need to feel known and 
understood”.15,16 The first sort means that patients have a need for medical 
information about their illness and treatment. The second sort includes patients’ 
needs for e.g. expressing concerns, understanding, support and reassurance. The 
stress-coping model of Bensing and colleagues emphasizes that healthcare providers 
have to meet these two sorts of needs.17 Instrumental communication is important 
in fulfilling patients’ informational needs, by providing appropriate medical and 
therapeutic information. By using affective communication, the patients’ emotional 
needs can be met through e.g. showing empathy, paying attention to concerns, and 
reassurance.17,18 It is expected that fulfilling the patients’ needs by instrumental and 
affective communication supports the patients’ problem-oriented and emotional 
coping, respectively (Figure 1.2). 
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Figure 1.2 The stress-coping model (Bensing and Verhaak17) 
 
Previous research indicated that consultations in general practice are largely 
instrumental and that less attention is being paid to affective communication.19,20 
Patients’ emotional needs thus seem to be overlooked, thereby risking persisting 
dysfunctional cognitions and emotions, such as unnecessary concerns about 
medication. More attention to patient-centered communication, i.e. communication 
with attention to both patients’ instrumental and emotional needs (often expressed 
implicitly through cues21), and the patients’ conversational contribution, is needed 
to turn this tide (see e.g. Mead & Bower22, Zandbelt et al.23, and Wolters et al.24). 
This might also help in enhancing communication about non-adherence, which, so 
far, has been a largely neglected topic in the communication between physicians 
and patients.25 It is unknown whether the same is also true for the communication 
between community pharmacists and patients.  
 
Role of the community pharmacy 
Patients with chronic diseases have contact with several healthcare providers. This 
thesis focuses on the community pharmacists and their pharmacy technicians. One 
of the major tasks of pharmacists is to deliver pharmaceutical care to patients. The 
Pharmaceutical Care Network Europe defined pharmaceutical care as “[…] the 
pharmacist’s contribution to the care of individuals in order to optimize medicines 
use and improve health outcomes”.26 In the Netherlands, community pharmacists 
acceded to the Dutch Medical Treatment Act in 2007, an act which was originally 
designed in 1995 for medical professionals to regulate medical practice. This act 
states that patients have the right to receive clear and understandable information 
about their condition, possible (pharmacological) treatments, and their side effects, 
on the basis of which they can make their own, well-informed treatment decisions. 
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By acceding to this act, pharmacists have taken up an explicit role in counselling 
patients about their pharmacological treatments.27 
Currently, the community pharmacist’s role is changing beyond the intentions of 
the Dutch Medical Treatment Act. It has been extended from product-centered (e.g. 
compounding and dispensing medication), to therapy-centered (e.g. education and 
counseling), and pharmacists are now on their way to a patient-centered focus (e.g. 
striving for concordance). More attention to the patient has been paid in the Dutch 
Charter of the pharmacist (in Dutch: ‘Handvest van de apotheker’), which describes 
three domains of knowledge relevant for the community pharmacists: 1) medicines, 
2) the human body, and 3) the human behavior.28 The last domain focuses on the 
patient him/herself, which is relatively new for this profession. 
In order to prepare pharmacists for their role as a communicator, the 
pharmaceutical curriculum contains programs focused on communication training. 
Furthermore, the majority of the pharmacies have a consulting room in which 
pharmacists and pharmacy technicians can talk privately with patients about their 
medication-taking behavior and any concomitant problems during counseling 
sessions29 (or pharmaceutical consultations, which are commonly performed only by 
pharmacists30). Community pharmacists are one of the designated healthcare 
providers to educate and counsel patients, because of several reasons. First of all, 
pharmacies are very accessible to visit. In addition, pharmacists and pharmacy 
technicians are the last provider whom patients have contact with when picking up 
their medications. Furthermore, pharmacists have insight into the patients 
medication-taking behavior through the dispensing history and they can use this 
information to identify patients who are non-adherent. 
However, little is known about the way pharmacists and technicians 
communicate with their patients, and whether pharmacists and pharmacy 
technicians differ in their communication. Differences in communication might exist 
between pharmacists and pharmacy technicians because of the differences in 
education, position and function in the pharmacy. Pharmacists have a managing role 
and can be the owner of the pharmacy, and pharmacy technicians have more 
frequent contacts with patients at the counter during dispensing of medications.  
 
Asthma and Chronic Obstructive Pulmonary Disease 
In this thesis, we focus on patients with asthma and/or Chronic Obstructive 
Pulmonary Disease (COPD) using inhaled corticosteroids. Asthma and COPD are 
chronic diseases affecting the airways (i.e. the bronchial tubes in the lungs). Asthma 
is a chronic inflammation of the airways, caused by genetic predisposition and 
environmental substances that evoke an allergic reaction or irritation in the airways 
when inhaled, like house dust mites, pollens, cigarette smoke and air pollution. 
Characteristics of asthma are ‘wheezing’, a high-pitched sound during breathing, 
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breathing difficulties, tightness in the chest, and/or coughing. Commonly, asthma 
develops during childhood, but people can also get asthma later on in life.31 
COPD has another epidemiology than asthma. COPD is an umbrella term for 
progressive pulmonary diseases, such as emphysema and chronic bronchitis. COPD 
is mostly caused by smoking (of cigarettes, pipes, cigars, etc.), but hereditary 
diseases, harmful pollutants (e.g. fumes), air pollution, and other pulmonary 
diseases (e.g. non-reversible asthma) can cause COPD as well. The disease is 
characterized by increased breathlessness, frequent coughing (with and without 
sputum), wheezing and/or tightness in the chest. The onset of COPD is usually later 
on in life (40 years or older).32,33  
In the Netherlands, around 610,000 people have asthma, and 600,000 people 
have COPD.33 
 
Inhaled corticosteroids 
Patients are treated with different sorts of medicines to control their asthma and/or 
COPD, which are short-acting reliever medication, long-acting reliever medication 
and preventer medication.34,35 It depends on the severity of the disease which 
(combinations of) medicines are used. Short-acting relievers act quickly to reverse 
bronchoconstriction and are only used when needed. Long-acting relievers are used 
on a daily basis to prevent and reverse bronchoconstriction, and work for a longer 
time than short-acting relievers (12 hours versus 5-45 minutes). Preventer 
medication has an anti-inflammatory effect in the lungs. To control the disease, it is 
important to take it daily and on the long-term, even when a patient experiences no 
symptoms. Inhaled corticosteroids (ICS) are the most effective preventer 
medications and are the cornerstone of the treatment of asthma. For patients with 
moderate to severe COPD, ICS are often part of the treatment, but they are less 
effective than in patients with asthma. ICS, as most of the reliever medications, are 
delivered by an inhaler. 
In the Netherlands, levels of non-adherence to ICS are around 36% in both 
patients with asthma36 and/or COPD.37 It appears that many patients using ICS have 
concerns about their medication and/or do not experience a high personal need to 
use ICS.38,39 Furthermore, 70% of the patients do not use their inhaler in a correct 
way.40 As a consequence, not all medication is absorbed by the lungs, causing a non-
optimal effect. This could, in turn, also negatively affect adherence, because the 
patient experiences no or less effect of the medication.  
Being the healthcare provider responsible for medication dispensing and 
educating patients in using their inhaler, the community pharmacist is the 
designated person to counsel and monitor patients using ICS in an effective way. 
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Aim and outline of this thesis 
Given the importance of optimal ICS use in asthma and the lack of insight into the 
extent to which healthcare providers communicate in a potentially adherence-
enhancing, patient-centered way at the community pharmacy, studies were initiated 
into patients’ and pharmacists’ beliefs and communication about ICS and 
adherence. The overall aim of this thesis is to explore patient-provider 
communication about ICS during counseling sessions at the community pharmacy 
and to take a closer look at factors that may relate to the patients’ adherence to ICS. 
 
Research questions 
Part one: The patient 
1. What is the relationship between medication beliefs, self-reported and 
 refill adherence, and asthma symptoms in patients using inhaled 
 corticosteroids? 
2. How do patients’ Big Five personality traits relate to medication 
 adherence? 
Part two: The healthcare provider 
3a. How do community pharmacists’ and pharmacy technicians’ perceptions 
 of patients’ ICS beliefs differ from those of patients with asthma? 
3b. How do ICS beliefs of community pharmacists, pharmacy technicians and 
 patients with asthma differ from each other?  
Part three: The communication 
4. What are the process and content of the communication during counseling 
 sessions about inhaled corticosteroids at the community pharmacy? 
5. How do pharmacists and pharmacy technicians respond to informational 
 and emotional cues expressed by patients with asthma about inhaled 
 corticosteroids and how are these responses related to patients’ 
medication beliefs and self-reported adherence? 
 
This thesis is divided into three parts. Part one, the patient, focuses on psychological 
patient-related factors. Chapter 2 describes the relationship between medication 
beliefs, self-reported and refill adherence, and symptoms in patients with asthma 
using inhaled corticosteroids. Chapter 3 reviews the existing literature on patients’ 
Big Five personality traits and medication adherence. 
In part two, the healthcare provider, we investigate some healthcare provider-
related factors in community pharmacy. In chapter 4, we compare pharmacists’ and 
pharmacy technicians’ perceptions of patients’ beliefs regarding ICS with the ICS 
beliefs of patients with asthma. In addition, the own ICS beliefs of pharmacists, 
pharmacy technicians and patients with asthma are compared.  
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Part three, the communication, pays attention to the communication in community 
pharmacy about ICS. Chapter 5 describes the process and content of the 
communication during counseling sessions about inhaled corticosteroids at the 
community pharmacy. Chapter 6 comprises the cue-responding behaviors during 
pharmacy counseling sessions with patients with asthma about inhaled 
corticosteroids and its relations with medication beliefs and self-reported 
adherence. 
Finally, in chapter 7 we summarize the results and discuss them in a broader 
context. In addition, we provide recommendations for future research and clinical 
practice. 
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Abstract 
 
Background 
Beliefs play a crucial role in medication adherence. Interestingly, the relationship 
between beliefs and adherence varies when different adherence measures are used. 
How adherence, in turn, is related to asthma symptoms is still unclear. Our aim was 
to investigate the relationship between beliefs (i.e. necessities and concerns) about 
inhaled corticosteroids (ICS) and subjectively as well as objectively measure 
adherence and the agreement between these measures. Further, the relationship 
between adherence and asthma symptoms was examined. 
 
Methods 
A total of 280 patients aged 18–80 years who filled at least two ICS prescriptions in 
the preceding year were recruited to complete a questionnaire. The questionnaire 
included the Beliefs about Medicines Questionnaire to assess necessity beliefs and 
concerns about ICS, four questions about ICS use to measure self-reported 
adherence, and the Asthma Control Questionnaire to assess asthma symptoms. 
Proportion of days covered was used to determine pharmacy refill adherence. 
 
Results 
Data from 93 patients with asthma were analyzed. Necessities were positively related 
to self-reported adherence (p=0.01). No other associations were found between 
beliefs and subjective or objective adherence. There was no correlation between 
self-reported and refill adherence. Participants were significantly (p<0.001) less 
adherent according to self-report data (24.4%) than according to pharmacy data 
(57.8%). No relationship was found between adherence and asthma symptoms. 
 
Conclusion 
Higher necessities are associated with higher self-reported adherence, suggesting that 
it could be more important to focus on necessities than on concerns in an attempt to 
improve adherence. Self-reported and refill adherence measurements cannot be 
used interchangeably. No relationship between adherence and asthma symptoms 
was found. 
 
Keywords: asthma, inhaled corticosteroids, adherence, medication beliefs, asthma 
symptoms 
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Introduction 
 
Asthma affects approximately 520,000 people in the Netherlands
1
 and is an increasing 
public health concern worldwide.
2
 The goal in treating asthma is achieving and 
maintaining symptom control with a minimum number of drugs. Inhaled corticosteroids 
(ICS) are the most effective anti-inflammatory medications in treating asthma, and are 
used as first-line therapy in its long-term or even lifelong treatment.
3–6
 
Unfortunately, ICS adherence, i.e. the degree to which patients take their ICS as 
prescribed by their care provider
7,8
 seems to be very poor (approximately 50%).
9,10 
There are several factors related to medication adherence,
11–14
 of which patients’ 
beliefs about medication are considered an important aspect in their motivation to 
take the medication as prescribed.
15
 Specific beliefs are related to thoughts about 
the patient’s own medication and appear to be more strongly associated with 
medication adherence than general beliefs about medication.
16
 Two specific 
medication beliefs can be distinguished according to the often used framework 
developed by Horne et al.,
17
 i.e. necessities and concerns. Patients can have specific 
thoughts related to the necessity of their medication in maintaining their health. On 
the other hand, patients can also have specific feelings (concerns) about the possible 
harmful long-term effects and dependence on their medication. 
Numerous types of measurement exist to assess adherence, i.e. direct, indirect, 
subjective, and objective methods.
18 
Menckeberg et al.
9
 have already demonstrated 
that beliefs about ICS correlate with both self-reported adherence and refill 
adherence. In a group of patients aged 18–45 years, higher concerns were 
correlated with lower self-reported adherence and higher necessities with higher refill 
adherence. Because of the great variance in measurements which can be applied to 
assess adherence, further characterization of the association between 
(non)adherence and medication beliefs remains relevant.
9,19
 Furthermore, we do not 
know whether these relationships can be replicated and whether they also exist in 
patients older than 45 years.
 
To some extent, studies have indicated a (noncausal) relationship between 
adherence with ICS and asthma symptoms, often using a self-reported scale to 
assess patient adherence.
20–23
 Given the subjectivity of self-report instruments, it is 
important to use objective methods as well to determine the relationship between 
adherence and asthma symptoms. Currently, this relationship has not been fully 
elucidated.
24,25
 
The aim of this study was to determine the relationship between medication 
beliefs (i.e. necessities and concerns) and adherence with ICS in an adult population 
aged 18–80 years. In addition, it aimed to examine the association between 
adherence and asthma symptoms. Finally, objective and subjective methods of 
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measuring adherence were compared which give insight into their agreement. 
 
 
Materials and methods 
 
Research design and setting 
This study is part of a larger research project investigating communication about 
ICS inhalers in pharmacies. The research proposal was assessed by the medical 
ethics committee of the University Medical Centre Utrecht. The medical ethics 
committee concluded that it was unnecessary to assess the proposal according to 
the law on medical scientific research involving human beings. 
This cross-sectional study was conducted between May and July 2011 in one 
pharmacy situated in the Netherlands. Participants were selected from the pharmacy 
system using ATC codes (unique codes for each medicine according to the 
Anatomical Therapeutic Chemical classification system) for ICS and combination 
products of β2-agonists and ICS.
26
  
Adult patients aged 18–80 years were invited to participate if they had used ICS 
for at least one year, and had filled at least two ICS prescriptions within the last year. 
Patients were excluded if they used a combination of medicines together with their 
ICS (e.g. ICS and tiotropium), which indicates chronic obstructive pulmonary disease 
(COPD) instead of asthma. 
 
Patients and procedure for data collection 
A total of 280 patients met the selection criteria and were invited to participate. 
The sample size was determined by the number of patients in this particular 
pharmacy who met the inclusion criteria. A questionnaire had to be completed by 
the participants, and pharmacy data were extracted from the year prior to the 
inclusion date. 
Participants were recruited by sending an information package with an 
information letter, an informed consent form, a questionnaire, and a return 
envelope. The front page of the questionnaire was marked with a sticker with the name 
of the ICS used by the patient. This made clear to patients that the questions were 
about their anti-inflammatory drugs (ICS) and not about other (inhaled) medicines. 
 
Measurement instruments 
The questionnaire included questions about sociodemographics (i.e. age, gender, 
and education). In addition, questions were asked about smoking and sport habits 
and the indication for ICS prescription (for asthma (symptoms), COPD or not known). 
Furthermore, two questions about ICS inhaler use (ICS use/day and puffs of 
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ICS/time) were included. 
ICS adherence was measured as self-reported adherence and as refill adherence. 
Self-reported adherence was measured using a scale with four dichotomous items 
comparable but not identical to the items from the Morisky scale.
27
 This scale was 
used to determine medication adherence in a subjective way and consists of four 
questions which can only be answered with yes (0 point) or no (1 point). An example 
of the questions is “Are you careless sometimes about taking your medicine?” 
Scores can be added up to generate a score range of 0–4. A score closer to four 
indicates higher adherence. Participants were divided into two groups, i.e. 
medication adherent (score of 4) and medication nonadherent (score <4).
28
 In 
addition, the scores were also used as continuous data. Pharmacy dispensing data 
for ICS were used to determine objectively measured refill adherence by calculating 
the proportion of days covered
29
 by dividing the total of one day’s supply by the 
total number of days evaluated, multiplied by 100%. The evaluation period for every 
person was about 365 days (one year). Episodes of medication use were truncated if 
the medication gap was ≥182 days (half a year). After calculation of refill adherence 
via pharmacy data, participants were divided into adherent users and nonadherent 
users. Patients were classified as nonadherent at the commonly used cutoff point of 
≤80%.
30–32
 
The validated Beliefs About Medicines Questionnaire (BMQ-specific) was used to 
assess specific ICS beliefs.
16
 The BMQ consists of a necessity scale and a concerns 
scale, each containing five 5-point Likert scaled items, ranging from “strongly 
disagree” to “strongly agree”. An example of a concerns item is “Having to take 
medicines worries me” and of a necessity item “My health in the future will depend 
on my medicines”. The scores were added up for both scales to produce a score 
ranging from 5 to 25. Higher scores indicate stronger beliefs. To determine which of 
the two scales was most important for the participants, a necessity-concerns 
differential was calculated by subtracting concerns scores from necessity ones, 
leading to a score range of -20 to 20. Lower scores indicate lower perceived 
necessity, which suggests more negative feelings towards using ICS medication.
9,33
 
To assess the association between medication beliefs and adherence from a more 
categorical perspective, four categories were created: patients with low necessities 
and high concerns, patients with low necessities and low concerns, patients with 
high necessities and high concerns, and patients with high necessities and low 
concerns. These groups can be classified as skeptical, indifferent, ambivalent, and 
accepting, respectively.
9,34
 To determine low/high necessity/concerns, the scale 
midpoint (indicated as 15) was used as the cutoff. 
The validated, six-item Asthma Control Questionnaire (ACQ) without Lung 
Function was used to assess asthma control,
35,36
 rated on a 7-point Likert scale from 
“no impairment” (0 points) to “maximum impairment” (6 points). An example of a 
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question is “On average, during the past week, how often were you woken by your 
asthma during the night?” All items are added up and divided by six; a score of 1.5 
or higher was regarded as not well controlled asthma.
36,37 
 
Data analysis 
Pharmacy and questionnaire data were manually transferred into a Statistical Package 
for the Social Sciences version 17.0 database (SPSS Inc, Chicago, IL, USA). A one-
sample test of proportions was used to determine whether patients were more or 
less adherent according to self-reported or refill adherence. A Pearson’s Chi-square 
test was used to determine associations between refill adherence and self-reported 
adherence, and between refill/self-reported adherence and BMQ attitudinal group. 
Multiple regression analyses were performed, all adjusting for age, gender, 
educational level, and exercise habits. Linear and logistic regression analyses of 
necessities and concerns on self-reported adherence were done. Logistic 
regression analyses were carried out to assess the relationship between medication 
beliefs and refill adherence, and the association between asthma control and self-
reported and refill adherence, respectively. 
 
 
Results 
 
Participants 
Questionnaires were returned by 142 of 280 patients (response rate 50.7%). 
Seven questionnaires were returned as “wrongly addressed” (net sent rate, 96.8%). 
Of the 142 respondents, 93 reported having asthma, 21 reported having COPD, and 
12 suffered from both asthma and COPD. Sixteen respondents reported their health 
problem as unknown or did not complete the question (missing). For the purpose of 
this study, only the questionnaires of patients with asthma without COPD (n=93) 
were analyzed. Three-quarters of the participants were highly educated. 
Approximately, half of the participants was aged 18–44 years and the other half was 
45 years or older (Table 2.1). 
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Table 2.1 Participant characteristics 
 Participants, n = 93 (100%) 
Gender  
Male 38 (40.9)  
Female 55 (59.1) 
Age, years  
Mean (years) ± SD (range) 43.7 ± 14.5 (18–77) 
Age group, years  
18–44 47 (50.5)  
≥45 46 (49.5) 
Education  
Low 10 (10.8)  
Intermediate 13 (14.0)  
High 70 (75.3) 
Living situation  
Living with parents/family 4 (4.3)  
Married/cohabiting 53 (57.0)  
Single with children 3 (3.2)  
Single without children 23 (24.7)  
Student house/residential community 10 (10.8) 
Smoking habits  
Nonsmoker 63 (67.7)  
Ex-smoker 22 (23.7)  
Smoker 8 (8.6) 
Exercise habitsa  
Low 14 (15.1)  
Intermediate 29 (31.2)  
High 50 (53.8) 
Type of ICS  
Budesonide 22 (23.7)  
Ciclesonide 10 (10.8)  
Fluticasone 48 (51.6)  
Beclomethasone 13 (14.0) 
Type of medication  
ICS alone 45 (48.4)  
ICS + long-acting β
2
-agonistb 48 (51.6) 
Frequency of administration (daily)  
1–1.5 12 (14.1)  
2 73 (85.9) 
Notes: aLow, 30 minutes of exercise less than 3 days a week; intermediate, 30 minutes of exercise 3–4 days a week; high, 
30 minutes of exercise ≥5 days a week. Country of origin is not taken into account, because only one respondent (1.08%) 
was non-western. bFixed-dose combination. 
Abbreviation: ICS, inhaled corticosteroids. 
 
Refill and self-reported adherence 
The mean refill adherence rate was 79.1% ± 17.2%, ranging from 38.4% to 100.0% 
(n=90). Table 2.2 illustrates the distribution of participants over the self-reported 
adherence scores (i.e. times answered “no” to a question). A higher score indicates a 
higher adherence rate. Almost a quarter of the patients (24.4%) answered “no” to all 
questions. However, none of the participants stopped using their medicine when 
they felt worse when taking it, so no participant did not answer “no” at all. Most 
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participants (65.6%) forgot their medicine at least once in the preceding month (data 
not shown). 
 
Table 2.2 Distribution for patient self-reported adherence scores using the self-reported 
 adherence scale 
Adherence scorea (%) 
0 0 (0.0%) 
1 18 (20.0%) 
2 25 (27.8%) 
3 25 (27.8%) 
4 22 (24.4%) 
Note: aScore <4, nonadherent with medication; score of 4, adherent with medication. 
 
A one-sample test of proportions showed that participants were significantly less 
adherent according to self-report (24.4% adherent) than according to pharmacy 
data (57.7% adherent) (p<0.001). Moreover, no association existed between self-
reported adherence and refill adherence (Table 2.3). Only 50% (15.9% + 34.1%) of 
the participants were classified in the same adherence category according to 
subjective and objective adherence measurements. The mean refill adherence rate in 
self-reported adherent participants did not differ significantly from self-reported 
nonadherent participants. 
 
Table 2.3 Participants classified as (non)adherent according to self-report or pharmacy data (n = 88, 
 five missing) 
Note: ap-value calculated by Pearson Chi-square test. 
 
Medication beliefs 
The internal consistency of the necessity scale of the BMQ was good (Cronbach’s 
α =0.81) and the consistency of the concerns scale was moderate (Cronbach’s 
α=0.65). More than one third of the participants (39.9%) had doubts about the 
necessity of using ICS (scores below scale midpoint). Approximately three-quarters 
(76.7%) indicated few concerns about using ICS (scores below scale midpoint). 
Participants scored higher on the necessity scale than on the concerns scale 
(necessity-concerns difference 3.77±4.37, ranging from -8 to 15), which indicates a 
positive evaluation towards use of ICS medication. 
  
 Self-reported adherence P-valuea 
 Adherent Nonadherent  
Refill adherence  
Nonadherent 8 (9.1%) 30 (34.1%) 0.46  
Adherent 14 (15.9%) 36 (40.9%)  
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Beliefs about ICS and adherence 
Figure 2.1 shows the distribution of participants over the four BMQ categories with 
percentage of adherent participants within each group. Most participants reported 
high necessities and low concerns (accepting, n=38; 43.7%), whereas the skeptical 
group (low necessities, high concerns) consisted of only five participants (5.7%). The 
percentage of adherent patients according to self-report was lowest in the indifferent 
group (13.3%) and skeptical group (0.0%) and highest in the accepting group (33.3%). 
According to refill adherence, the percentage of adherent patients was highest in 
the skeptical group (80.0%); however, the number of participants in this group is very 
low. Refill adherence is also high in the accepting group (63.2%), followed by the 
indifferent group (55.2%) and ambivalent group (40.0%). No associations between 
BMQ category and, on the one hand, self-reported adherence, and, on the other hand, 
refill adherence were found. 
 
Figure 2.1 Distribution of participants among the four Beliefs About Medicines Questionnaire 
categories and percentage of adherent participants  according to self-reported and refill 
adherence per category.  
a
Percentage of adherence participants according to self-reported adherence;  
bPercentage of adherence participants according to refill adherence. 
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Multiple linear regression analysis revealed a significant positive association (p=0.01) 
between necessities and self-reported adherence, adjusted for confounders (Table 
2.4). Multiple logistic regression analysis confirmed this association (p=0.02, data not 
shown). Table 2.5 illustrates that necessities are higher (p=0.01) in participants 
classified as self-reported adherent (17.1± 3.3) than in those classified as self-reported 
nonadherent (14.5±4.3). However, no association was found between necessities 
and refill adherence. The regressions of self-reported (linear) and refill adherence 
(logistic) regarding concerns did not show a significant relationship, so there was 
no association between concerns and adherence. 
 
Table 2.4 Association between necessities and self-reported adherence adjusting for age, gender, 
 education level, and exercise habits by multiple regression analysis 
 B-coefficient (SE) 95% CI 
Constant 0.98 (0.76) -0.54 to 2.49 
Necessities 0.06 (0.02)** 0.01 to 0.11 
Age 0.02 (0.008)* 0.0001 to 0.03 
Gender   
Femalea - - 
Male 0.25 (0.21) -0.18 to 0.67 
Education level   
Lowa - - 
Intermediate -1.26 (0.47)** -2.15 to -0.38  
High -0.37 (0.38) -1.12 to 0.38 
Exercise habits    
Lowa - - 
Intermediate 0.26 (0.34) -0.41 to 0.93 
High 0.28 (0.31) -0.33 to 0.89 
Notes: 
a
Reference category. *p<0.05; **p=0.01. 
Abbreviations: CI, confidence interval; SE, standard error. 
Table 2.5 Beliefs in refill/self-reported adherent and nonadherent participants 
Beliefs Self-reported adherence  Refill adherence 
 Nonadherent Adherent  Nonadherent Adherent 
 Mean ± SD Mean ± SD  Mean ± SD Mean ± SD 
Concerns 10.7 ± 3.4 (n = 68) 11.5 ± 3.7 (n = 22)  11.7 ± 4.0 (n = 38) 11.2 ± 3.4 (n = 52) 
Necessities 14.5 ± 4.3 (n = 68) 17.1 ± 3.3* (n = 22)  15.2 ± 3.9 (n = 38) 15.0 ± 4.5 (n = 52) 
Note: *p-value calculated by independent t-test, p<0.05. 
Abbreviation: SD, standard deviation. 
 
Adherence and asthma symptoms 
Internal consistency of the ACQ was good (Cronbach’s α=0.84). Most participants 
(84.6%) had well controlled asthma (ACQ <1.5). No significant associations were 
found between self-reported or refill adherence and asthma control. Furthermore, 
logistic regression analyses of necessities and concerns on asthma control did not 
reveal an association. 
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Discussion 
 
Relationship between beliefs about ICS and adherence 
According to the BMQ scores, participants’ beliefs regarding concerns and 
necessities were favorable with regard to the use of ICS because scores on the 
necessity scale were high and those on the concerns scale relatively low. 
According to these results, high adherence rates would be expected, because 
high needs and low concerns increase adherence.
9,13,38
 Nevertheless, this was not 
found in this study. Self-reported adherence was low, and although refill adherence 
was over two times higher than self-reported adherence, no association between 
beliefs and refill adherence was found. 
Menckeberg et al.
9
 showed that higher necessities were correlated with higher 
refill adherence and also showed a correlation between concerns and self-reported 
adherence. The present study only found a positive association between self-
reported adherence and necessities. This is consistent with findings in other studies, 
in which a stronger belief in the necessity of medication was also a predictor for 
higher adherence.
39,40
 
Most participants reported low concerns and high necessities, and were classified as 
“accepting” according to the four attitudinal types. In this group, the self-reported 
adherence level was the highest, although no significant differences in adherence 
rates were found between the four groups. No significant association between the 
attitudinal groups and adherence was seen either. 
Self-reported adherence levels were highest in the accepting and ambivalent group, 
which is similar to the findings of Menckeberg et al.
9
 In contrast, the present study 
shows the highest refill adherence rates in the accepting and skeptical group. 
However, adherence rates in the skeptical group are less reliable, since only five 
participants were classified in this group. 
 
Relationship between adherence and asthma symptoms 
Consistent with the findings of Menckeberg et al.,
9
 adherence with ICS was not 
associated with asthma control. This is in contrast with a study by Clatworthy et al.,
20
 
which showed an association between not well controlled asthma and low self-
reported adherence with ICS. A possible explanation for this is that only a small 
proportion of the participants did not have well controlled asthma (15.4%). 
Even though a positive relationship between adherence and asthma symptoms 
would be expected, well controlled asthma could also lead to less ICS use. Since 
patients could experience a low need for ICS when not suffering from clinically 
relevant symptoms, this could lead to nonadherence as well.
41,42 
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Relationship between self-reported and refill adherence 
This study showed no association between self-reported adherence and refill 
adherence (continuous as well as dichotomous self-reported adherence) to ICS. 
Only half of the participants were classified in the same group according to subjective 
and objective ICS adherence. Approximately two-thirds of the participants who were 
classified as adherent based on pharmacy data were classified as nonadherent 
according to self-report. This could be due to the relatively strict classification of 
adherent/nonadherent participants via self-report. Answering “yes” to the question 
“Do you ever forget to take your medicine?” on the self-reported adherence scale 
made a participant nonadherent. Classification as adherent/nonadherent according 
to pharmacy data is less strict; even if a participant misses up to 20% of their 
medication, the participant is still regarded as adherent. This allows participants to be 
classified as adherent even if they behave nonadherently in some way. Besides, even 
if a participant is adherent according to refill adherence, it is still questionable 
whether the medicine is actually taken. A prescription can be filled at the pharmacy, 
but it is unknown what happens thereafter. This problem is not present with self-
reported adherence. 
It is very important how the threshold in adherence/nonadherence is established, 
because this is the basis on which conclusions are drawn. This is why a post hoc 
analysis was performed in which the threshold of the self-reported adherence scale 
was changed from a score of 4 as adherent to a score of ≥3 as adherent, after which the 
classification in adherence changed. Another reason to perform this analysis is that 
mean refill adherence in self-reported adherent participants did not differ from self-
reported nonadherent participants. Self-reported adherence shifted from 22 adherent 
participants to 47 adherent participants (52.2%). Using this format, self-reported 
adherent participants had a mean refill adherence of 82.5% ± 15.9%, which is 
significantly higher (p=0.03) than the mean refill adherence of 74.7% ± 17.9% of the 
nonadherent participants according to self-report. This is an additional indication that 
the threshold of the self-reported adherence scale used divides people into 
nonadherent/adherent in a stricter manner than does refill adherence. 
To provide an easy method for filling in the questions on the self-reported 
adherence scale, the instruction of the questionnaire indicated that the statements 
that had to be completed were regarding the preceding month. The consequence of 
this is that it is more difficult to compare self-reported adherence with refill 
adherence, because the latter method covered adherence during the preceding 
year. However, if the statements referred to the preceding year, potentially even 
more participants would be classified as self-reported nonadherent. 
Refill adherence has more inherent difficulties. First of all, objective adherence 
measured with pharmacy data can be calculated in different ways.
43
 Second, many 
assumptions have to be made in order to calculate refill adherence. This is especially 
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the case for calculations which determine adherence with ICS. For example, 
sometimes dosage instructions were not clear (e.g. 1–2 puffs per day and usage 
known), and the researchers had to choose the most obvious instruction. In 
addition, assessment was done using treatment episodes. These introduce bias, 
because shorter periods (<30 days) result in higher adherence rate and longer 
periods (>180 days) result in lower adherence rates. In the present study, episodes 
were defined as ≤182 days (half a year). Self-reported adherence with ICS is not 
influenced by this problem because it does not depend on episodes. The 80% cutoff 
for determination of adherent participants is also an assumption. Shifting this cutoff 
provides a different classification of adherent participants. Altogether, this leads to 
refill adherence with ICS being a rough estimation. Using both self-reported and refill 
rates to indicate a person’s nonadherence probably offers the most valid estimation 
in daily practice. 
In this study, no association could be established between medication beliefs, 
adherence, and asthma symptoms. These relationships seem to operate in a 
complex manner, in which each element could influence another in a positive or 
contrary way. Adherence is expected to enhance asthma control, whereas asthma 
control could lead to nonadherence. Moreover, asthma symptoms can affect 
beliefs about medication, which in turn affect adherence with ICS, and 
consequently asthma symptoms themselves can change. Further research is needed 
to study these hypotheses. 
 
Limitations 
The study population had some unique characteristics, which restricts the ability 
to extrapolate its results to other populations. An important issue is the high 
educational level of the participants, in that 75.3% was highly educated, while in the 
general Dutch asthma population only 24.2% has been classified as highly 
educated.
44
 Higher education can lead to nonrepresentative adherence levels, 
because low levels of education have been associated with poorer adherence to 
ICS.
45 
Distinguishing between asthma and COPD in the pharmacy data was done on the 
basis of using comedication prescribed for COPD, which is not an ideal method. This 
was shown by a relatively large number of participants (14.8%) who described their 
health problem as COPD instead of asthma. An additional explanation for this large 
number could be that not all participants were aware of the exact nature of their 
health problem. It has been shown that not everybody with asthma actually knows 
that they have asthma.
3 
In addition, only data from one pharmacy were used in this study. This could also 
explain the higher educational level of the study participants, because the particular 
pharmacy is situated in a wealthier neighborhood in Utrecht, the Netherlands. 
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Implications for clinical practice 
This study showed that higher necessities were associated with higher self-reported 
adherence. Education about the need for ICS medication could potentially be 
beneficial in patients with lower perceived needs.
8
 In this study, 11.3% of 
respondents did not know the reason for their ICS prescription. This implies that 
more information should be provided by prescribers as well as pharmacists. This 
could lead to an improvement in understanding the disease and medication, and 
better awareness about the need for medication. Interventions by pharmacists which 
are intended to increase knowledge about medication and disease are indeed known 
to improve clinical outcomes and are therefore recommended.
46-48 
 
 
Conclusion 
 
We found that higher necessities are related to higher self-reported adherence. This 
suggests that in order to increase adherence it is more important to focus on 
strengthening needs than on diminishing concerns. The present study did not find 
an association between adherence and asthma symptoms. However, based on this 
study alone it cannot be ruled out that this association does not exist. Finally, there 
was no relationship between self-reported and refill adherence with ICS. This 
indicates that it cannot be simply assumed that self-reported adherence is a correct 
representation of refill adherence. Therefore, it is important to take both 
measurement methods into account in clinical practice as well as in further research. 
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Abstract 
 
Background 
Around 20% of patients with a chronic illness do not take their medication as 
prescribed. Personality traits could be related to this suboptimal adherence. This 
systematic review provides a summary of the performed research on personality 
traits and medication adherence and gives insight into which personality traits are 
associated with medication adherence. 
 
Materials and Methods 
A literature search was performed in PubMed, EMBASE, PsycINFO and CINAHL. The 
search included keywords related to adherence and the Big Five personality traits 
(i.e. neuroticism, extraversion, openness, agreeableness and conscientiousness).  
 
Results 
The search resulted in 1,679 unique records. A total of 23 studies (28 articles) were 
included in the systematic review. Several studies found a relationship between 
medication adherence and neuroticism as well as conscientiousness. Hardly any 
study found a significant relationship between extraversion, openness to experience 
and agreeableness on the one hand and medication adherence on the other hand.  
 
Conclusion 
There is no consistent evidence for a relationship between personality traits and 
medication adherence. However, there are some indications for an association with 
neuroticism and conscientiousness. More high quality research is needed to get 
more insight into possible relationships of neuroticism and conscientiousness with 
medication adherence.  
 
Keywords: Personality, Big five, medication adherence 
Big Five personality traits and medication adherence 39 
Introduction 
 
In developed countries, the degree of adherence to medication for chronic diseases, 
like diabetes, asthma and Chronic Obstructive Pulmonary Disease (COPD), is 
estimated to be around 20%.1 Apparently, many patients do not (always) follow the 
(agreed upon) prescribers’ instructions to take their medication. Such suboptimal 
adherence has negative consequences for patients as well as society. It may lead to 
poor health outcomes, reduced quality of life, higher healthcare costs and 
mortality.2,3 
 Several factors seem to be associated with medication adherence, including 
person-related factors such as knowledge, attitudes, beliefs, perceptions and 
expectations.2 As personality traits are expected to account for many of these 
factors,4 traits may also be related to adherence behavior. Traits are defined as 
“dimensions of individual differences in tendencies to show consistent patterns of 
thoughts, feelings and actions” (p. 23),5 and predict behavior.6,7 Several studies 
indeed found that some personality traits are associated with medication adherence 
(e.g. conscientiousness),8 health-related behaviors (e.g. wellness behaviors and 
substance-related risk taking),9-11 and personality is expected to play a central role in 
health and related mechanisms.12  
 There are numerous personality traits that each could potentially impact on 
adherence in a different way; a categorization system is needed to provide the 
necessary structure and cut down the number of traits to be investigated. The Five 
Factor Model (FFM) is a validated, commonly used model which describes 
personality in terms of five broad domains, i.e. the Big Five personality traits: 
neuroticism, extraversion, openness to experience, agreeableness, and 
conscientiousness (Table 3.1). Neuroticism denotes a person’s tendency to 
experience distress. Extraversion refers to the level of outgoingness and 
gregariousness. Openness to experience is characterized by creativity, intellectual 
interests, aesthetic sensitivity, need for variety and unconventional values. 
Agreeableness involves concepts as trust, altruism, and tender-mindedness. 
Conscientiousness refers to the level of self-discipline, responsibility, reliability, 
dutifulness, and perseverance.13,14 
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Table 3.1 Description of the Big Five Personality traits  
Trait Description 
Neuroticism Neuroticism denotes a person’s tendency to experience distress, 
which varies between emotional instability (high levels of 
neuroticism) to emotional stability (low levels of neuroticism). 
Persons high in neuroticism experience more negative emotional 
events, compared to individuals low in neuroticism. 
Extraversion Extraversion refers to the level of outgoingness and gregariousness. 
Extravert people experience higher levels of happiness and life 
satisfaction than individuals with lower levels of extraversion (i.e. 
introvert people). 
Openness to experience Openness to experience comprises a broad concept, which is 
characterized by creativity, intellectual interests, aesthetic 
sensitivity, need for variety and unconventional values. Persons 
high in openness are have broad interests and seek experiences. 
Agreeableness Agreeableness involves concepts as trust, altruism, and tender-
mindedness. Persons high in agreeableness are helpful, warm and 
emphatic, whereas persons low in agreeableness tend to be 
manipulative, pugnacious and untruthful. 
Conscientiousness Conscientiousness refers to the level of self-discipline, 
responsibility, reliability, dutifulness, and perseverance. Persons 
high in conscientiousness tend to be well-organized, goal-directed, 
and persistent, whereas people low in conscientiousness are more 
prone to be disorganized, careless and indecisive. 
 
To improve medication adherence, interventions may have to take into account the 
personality traits of patients and their reasons for suboptimal adherence.15 Getting 
insight into which personality traits are related to adherence could contribute to 
developing such tailored interventions. More knowledge about this might lead to 
being able to indicate which persons are more inclined to be suboptimal adherent 
and what intervention is most likely to be successful. 
Currently, many studies have been performed on the relationship between 
personality and medication adherence. However, the quality of empirical studies 
varies, questioning the reliability of the results. Furthermore, some relations 
between personality traits and adherence are contradictory and a recent summary 
is still missing. Therefore, the aim of this review is to give an overview of the 
performed research on personality traits (i.e. neuroticism, extraversion, openness to 
experience, agreeableness, and conscientiousness) and medication adherence and 
to give insight into which personality traits are associated with medication 
adherence. 
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Materials and Methods 
 
Data sources and searches 
PubMed, EMBASE, PsycINFO and CINAHL were searched for articles in April 2014. 
The search strategy consisted of the key words adherence and the Big Five 
personality traits neuroticism, extraversion, openness to experience, agreeableness 
and conscientiousness (See S1). Only empirical articles were included, without date 
restrictions. In addition, in November 2015 and February 2017 we performed an 
update of the search in the same four databases for the period April 2014 to 
November 2015 and November 2015 to February 2017. 
 
Study selection 
The selection of eligible articles was performed in two stages. First title and abstract 
were screened, then full text articles were assessed for eligibility. In the first 
selection stage, the following inclusion criteria were used: 1) the study contained an 
English abstract, 2) the study population consisted of patients of 18 years or older, 
3) both adherence and personality were measured at patient level, 4) the study 
focused on adherence to a treatment (such as medication, therapy, diet, lifestyle 
counseling, or appointment keeping) for patients with a diagnosed illness, 5) the 
study focused on personality in terms of (one of the) Big Five personality traits, 6) 
the relationship between adherence and personality was examined, 7) the study 
concerned an empirical study. To be included, a study had to meet all of the criteria. 
In addition, if it was unclear whether one or more of the criteria were fulfilled, the 
study was included in the first selection as well.  
One reviewer (JD) assessed all titles and abstracts and a second reviewer (SVD) 
screened about 25% of the records (n=421 in total). Agreement between the two 
reviewers was satisfactory (Cohen’s kappa=0.71). 
In the second stage, full-text articles of records that were included in the first 
stage were independently screened by two reviewers (JD and SVD). Previous stated 
inclusion criteria were maintained, except for criterion number 4. Because of the 
variety of treatments (e.g. medical treatments, lifestyle interventions, therapy), we 
decided to focus only on adherence to medication to be able to present coherent 
results and not to focus on adherence to other treatments as well. Therefore, the 
whole selection procedure of eligible articles (i.e. assessment of titles, abstracts and 
full-texts) in the search in November 2015 and February 2017 was only based on the 
criteria applied in this second stage.  
In addition, we agreed to exclude studies that assessed adherence using Serum 
Phosphorus levels, since Serum Phosphorus does not only indicate adherence to 
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medication as well as adherence to diet restrictions and dialysis attendance. 
Therefore it is not a reliable method for determining medication adherence only.16 
Disagreements on the eligibility of articles were resolved by discussion between 
the two reviewers (JD and SVD). 
 
Data extraction and quality assessment 
A predefined data extraction form was used to extract the data of each study 
regarding study design, statistics, measurements and results (see S2).  
An adapted version of the Quality Assessment Tool for Observational Cohort and 
Cross-Sectional Studies of the National Institutes of Health (NIH) was used to assess 
the methodological quality of the studies.17 We used the following criteria (i.e. 
questions): 1) Was the research question or objective in this paper clearly stated, 2) 
Was the study population clearly specified and defined, 3) Was the participation rate 
of eligible persons at least 50%, 4) Were all the subjects selected or recruited from 
the same or similar populations (including the same time period) and were inclusion 
and exclusion criteria for being in the study pre-specified and applied uniformly to 
all participants, 5) Were the exposure measures (independent variables) clearly 
defined, valid, reliable, and implemented consistently across all study participants, 
6) Were the outcome measures (dependent variables) clearly defined, valid, reliable, 
and implemented consistently across all study participants, 7) Was loss to follow-up 
after baseline 20% or less (in case of a longitudinal study)?  
The questions could be answered with ‘yes’, ‘no’, ‘cannot determine’, ‘not 
applicable’, and ‘not reported’. If criteria 5 or 6, about the reliability and validity of 
the independent and independent variables, were answered with ‘not reported’, 
this was indicated as a ‘no’.  
When all these questions were answered with a ‘yes’ the study was qualified as 
‘good’, when one or two questions were answered with a ‘no’ it was considered as 
‘fair’, and when three or more of these questions were answered with a ‘no’ it was 
judged as ‘poor’.  
Next to this, we looked more closely at the methods described in the article and 
determined whether the description of measurements, sample size and statistical 
analysis was sufficient to justify the results and conclusions. If these were not 
sufficient, the quality of the article was also judged as poor. Poor studies were 
excluded from the review.  
Two reviewers (JD and SVD) assessed the study quality of the included articles. 
Disagreements on study quality were resolved by discussion. When agreement 
could not be reached, the judgment of a third reviewer (PDS) was decisive.  
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Multiple publications from the same dataset 
To prevent bias, multiple articles based on the same dataset were identified and 
clustered, as in line with previous research.18,19 Bias could occur when these articles 
would be counted as separate studies and the datasets would affect the results of 
the review more strongly because the articles are not independent of each other.20 
In such cases, if possible, we referred to the first study, or described the results for 
the different articles but counting it as one study. 
 
 
Results 
 
Study characteristics 
The first search in April 2014 resulted in 2,034 records, of which 1,367 were unique 
records. The second search in November 2015 consisted of 324 records, of which 
169 were unique. The third search in February 2017 contained 283 records, of which 
143 were unique records. Of the 1,679 (1,367 + 169 + 143) unique records, 33 finally 
met the inclusion criteria. After quality assessment, five articles were qualified as 
poor and excluded from the review, resulting in a total of 28 included articles (Figure 
3.1). We indicated nine articles that belonged to four similar datasets, so the review 
contained 23 studies. Of these, twelve studies were qualified as high quality studies, 
and eleven studies were judged as fair (Table 3.2). 
   
  
Records screened on title and 
abstract 
n=1,679 (1,3671 + 3122) 
 
 
  
 
  
  
 
 
 
 
 
 
   
  
  
  
 
 
 
 
 
 
 
Figure 3.1  Flowchart of the study 
1Inclusion criteria applied in stage 1 of study selection 
2Inclusion criteria applied in stage 2 of study selection  
Search 1: until April 2014 , Search 2: April 2014 – November 2015, Search 3: November 2015 – February 2017 
Full-text articles meeting 
selection criteria2 
n=33 
 
Full-text articles 
excluded 
n=134 
 
 
 
Records excluded 
 
n=1,512 
 
- Did not (separately) measure adherence to 
medication (but (also) to exercise, diet, medical 
aids or other sorts of treatments): n=87 
- Did not measure adherence: n=23 
- Did not measure relation between personality 
and adherence: n=5 
- Personality was not measured, or was not 
defined or measured as predetermined: n=6 
- <18 years: n=6 
- No patients (but e.g. healthy subjects): n=4 
- No empirical study: n=3 
Full-text articles included 
 
n=28 
Poor study quality 
articles excluded 
n=5 
- Did not meet inclusion criteria: n=1,509  
(1,2041 + 3022) 
- Full-text not available: n=3 
Total records 
 
n=2,641 
 Double records 
removed 
n=962 
 
Full-text articles assessed for 
eligibility2 
n=167 
PubMed 
 
Search 1: n=561 
Search 2: n=95 
Search 3: n=79 
EMBASE 
 
Search 1: n=567 
Search 2: n=93 
Search 3: n=70 
PsycINFO 
 
Search 1: n=793 
Search 2: n=116 
Search 3: n=128 
CINAHL 
 
Search 1: n=113 
Search 2: n=20 
Search 3: n=6 
  
Table 3.2 Characteristics of included studies (n=23) 
No. First Author Year Country Participants’ 
medical condition 
Type of 
medication 
Sample size Age M (SD) 
[range] 
% Female Design Quality 
assessment 
1 Arnal, R.B.21 2012 Spain HIV-seropositive 
patients 
Antiretroviral 
medication 
66 33.9 (9.9) 
[26-65] 
 
48.5 Cross-
sectional 
Fair 
2 
 
Axelsson, M.22 2011 Sweden Chronic disease NR 749 53.59 (11.09) 57.0 Cross-
sectional 
Fair 
 
- Axelsson, M.23 2013 Sweden Diagnosed chronic 
disease 
Chronic 
medication 
786 53.7 (11.1) 57.0 Cross-
sectional 
Fair 
- Axelsson, M.24 2014 Sweden Asthma and/or 
allergic rhinitis 
Asthma 
medication 
Total: 180 
 
 57.8 Cross-
sectional 
Good 
      Men: 76 Men: 
50.3 (11.4) 
   
      Women: 
104 
Women: 
48.0 (10.2) 
   
3 Axelsson, M.25 2013 Sweden Asthma Asthma 
medication 
516 47.36 (15.6) 60.0 Cross-
sectional 
Fair 
- Axelsson, M.26 2016 Sweden Asthma Asthma 
medication 
104 49(14) 62 Cross-
sectional 
Good  
4 Broyles, L.M.27 2011 USA HIV-
seropositive/AIDS 
patients 
Antiretroviral 
medication 
308 Median: 44 31.8 RCT Good 
5 Bruce, J.M.28 2010 USA Multiple sclerosis Glatirames 
acetate 
55 43.36 (8.43) 89.1 Longitudinal 
(8 weeks) 
Fair 
6 Cheung, M.M.29 2014 Australia Asthma Asthma 
medication 
77 41.5 (16.2) 
[20-91] 
68.8 Cross-
sectional 
Good 
7 Cohen, N.L.30 2004 Canada Major depressive 
disorder 
Antidepressants 57 41.2 (10.8) 
[21.7-74.1] 
59.6 Longitudinal 
14 weeks 
Good 
8 Conrad, K.J.31 2004 USA HIV-seropositive 
patients 
Highly active 
antiretroviral 
treatment 
148 43.60 (8.29) 29.05 Cross-
sectional 
Good 
- table 3.2 continues -  
  
- table 3.2 continued - 
No. First Author Year Country Participants’ 
medical condition 
Type of 
medication 
Sample size Age M (SD)  
[range] 
% Female Design Quality 
assessment 
9 Dobbels, 
F.32 
2005 Belgium Heart, liver and 
lung transplant 
candidates 
Pretransplant 
medication 
Total: 174 
Lung: 69 
Heart: 33 
Liver: 72 
52.3 (11.2) 32.2 Cross-
sectional 
Fair 
- 
 
Dobbels, 
F.33 
2009 Belgium Heart, liver and 
lung transplant 
candidates 
Immuno 
suppressive 
medication 
141, Loss to 
follow-
up:11.3% 
52.4 (11.5) 33.3 Longitudinal 
(1 year) 
Fair 
10 Ediger, 
J.P.34 
2007 Canada Inflammatory 
bowel syndrome 
5-ASA, 
immuno 
suppressants 
326 41 (14.06) 
[18-80] 
60 Cross-
sectional 
Good 
11 Emilsson, 
M.35 
2011 Sweden Asthma Controller 
medication 
Total: 35 Total: 
52.85 (14.72) 
71.4 Cross-
sectional 
Good 
      Men: 10 Men: 56.70    
      Women: 25 Women: 51.25    
12 Evangelista, 
L.S.36 
2001 USA Patients with 
heart failure 
Heart failure 
medication 
82 54.14 (12.91) 
[22-90] 
37.8 Cross-
sectional 
Good 
- table 3.2 continues - 
 
 
 
  
  
- table 3.2 continued - 
No. First Author Year Country Participants’ 
medical 
condition 
Type of medication Sample size Age M (SD)  
[range] 
% Female Design Quality 
assessment 
13 Gomez-
Beldarrain, 
M.37 
2011 Spain Chronic migraine Analgesics and any 
combination of 
ergotamine, 
triptans, analgenics 
and/or opioids  
Total: 125, 
Loss to 
follow-up: 
4.8% 
  Longitudinal 
(1 year) 
Fair 
      Chronic 
migraine 
with drug 
overuse: 42 
 
Chronic migraine 
with drug overuse: 
41.21(8.2) 
Chronic 
migraine 
with drug 
overuse:  
92.9 
  
      Episodic 
migraine: 42 
 
Episodic migraine: 
36.19 (8.66) 
Episodic 
migraine:  
83.3 
  
      Controls: 41 
 
Controls:  
37.12 (8.59) 
Controls: 
73.2 
  
14 Gorevski, 
E.38 
2013 USA Kidney and liver 
transplant 
population 
Immunosuppressant 
therapy medication 
Total: 136    Cross-
sectional 
Good 
Kidney: 86 Kidney: 50.3(12.4) Kidney: 
33.0 
Liver:50 Liver: 57.9 (56.8) Liver:34.0 
15 Lin, E.H.B.39 1995 USA Depression 
 
Antidepressants 155 47.0 72.3 Longitudinal 
(4 months) 
Fair 
16 Nichols, 
L.M.W.40 
2004 USA Chronic health 
condition 
Medication on daily 
basis 
107 63.58 (14.179) 
[27-93] 
 
100 Longitudinal 
(6 weeks) 
Good 
- table 3.2 continues -
   
- table 3.2 continued - 
No. First Author Year Country Participants’ 
medical condition 
Type of 
medication 
Sample size Age M (SD)  
[range] 
% Female Design Quality 
assessment 
17 O’Cleirigh, 
C.41 
2007 USA HIV-seropositive 
patients 
Antiretroviral 
medication 
119 37.86 33 Longitudinal 
(1 year) 
Good 
- Ironson, 
G.H.42 
2008 USA HIV-seropositive 
patients 
Antiretroviral 
medication 
104 38 (8.48) 32 Longitudinal 
(4 years) 
Good 
18 Penedo, 
F.J.43 
2003 USA HIV-
seropositive/AIDS 
patients 
Highly active 
antiretroviral 
treatment 
116 39.2 (8.7) 45 Cross-
sectional 
Good 
19 Quine, L.44 2012 United 
Kingdom 
Hypertension Anti-
hypertensive 
medication 
934, Loss to 
follow-up: 
+/- 25% 
69.0 (11.7) 57.5 Longitudinal  
(8 weeks) 
Fair 
20 Sauceda, 
J.A.45 
2013 USA HIV-seropositive 
patients (Latino 
adult MSM) 
Highly active 
antiretroviral 
treatment 
140 42.2 (12.2) 0 Cross-
sectional 
Fair 
21 Stilley. C.S.46 2004 USA Adults with LDL 
serum cholesterol 
levels of 160mg/dl 
or higher 
Lovastatin 158 46.2 (8.7) 46.2 RCT  
(6 months) 
Good 
22 Wilson, 
S.T.47 
2003 USA Schizophrenia, 
schizoaffective 
disorder 
Antipsychotics 25, Loss to 
follow-up: 
20% 
31.12 (9.72) 44 Longitudinal 
(6 months) 
Fair 
23 Wouters, 
H.48 
2016 The 
Nether-
lands 
Patients using an 
antidepressant 
Antidepressants 137 51 (14) 76 Cross-
sectional 
Fair 
Abbreviations: HIV = Human immunodeficiency virus, AIDS = Acquired immune deficiency syndrome, MSM = men who have sex with men, LDL = low-density lipoprotein, NR = not reported, 
RCT = Randomized controlled trial 
  
 Big Five personality traits and medication adherence 49 
Regarding multiple articles based on the same dataset, three articles from Axelsson 
et al. were based on the same dataset.22-24 Two articles examined adherence in 
chronic patients,22,23 and one only analyzed a subgroup of the dataset (i.e. patients 
with asthma and/or allergic rhinitis) and performed separate analyses on the male 
sample and female sample instead of the entire sample.24 Two other articles from 
Axelsson et al. belonged to another same dataset. One article included the asthma 
patients who had completed the questions for that particular study (i.e. 
questionnaires on personality, medication beliefs and adherence), the other study 
included asthma patients who had reported that they had used asthma medication 
during the past twelve months. In addition, the articles from O’Cleirigh et al. and 
Ironson et al. were also based on the same dataset, but personality was measured 
using different versions of the NEO questionnaire (i.e. the NEO-FFI and the NEO-PI-
R) to measure persons’ Big Five personality traits.41,42 The article from O’Cleirigh et 
al. only examined the relation between conscientiousness and adherence. Two 
articles from Dobbels et al. were based on the same dataset.32,33 One of these was a 
longitudinal study, the other was cross-sectional. Table 3.2 gives an overview of the 
characteristics and quality of the 23 included studies (28 articles). 
The included studies were published between 1995 and 2016. Twelve studies 
were conducted in USA, three in Sweden, two in Canada, two in Spain, one in 
Australia, one in Belgium, one in the Netherlands, and one in the United Kingdom. 
Most studies examined medication adherence in terms of the extent to which 
patients followed the prescribed regimen, considering adherence as a continuous 
variable or dichotomous (non-adherent vs. adherent); some studies considered 
overuse or discontinuation. To assess adherence to medication, several instruments 
were used. All studies used an indirect method of measuring adherence. Seventeen 
studies used solely a self-report measure. Three studies used only an objective 
measure for assessing adherence, i.e. the Medication Event Monitoring System 
(MEMS). Drug dispensing data was used in one study. Personality factors were 
measured in twelve studies with the NEO-FFI(-3) (i.e. NEO Five-Factor Inventory(-3)), 
six used the NEO-PI-R (i.e. Revised NEO Personality Inventory), two studies assessed 
personality with the BFI (i.e. Big Five Inventory), whereas the IPIP (i.e. International 
Personality Item Pool), Zuckermann Kuhlmann III, EPQ (i.e. Eysenck Personality 
Questionnaire), and EPQ-R (i.e. Eysenck Personality Questionnaire (Revised)) were 
each used in one study.  
 
Neuroticism 
Neuroticism was studied in 20 studies.21-26,28-39,42,43,45-48 In fourteen studies using 
univariate analyses (i.e. ‘UV’ in Table 3.3), seven found a negative association 
between neuroticism and self-reported adherence.21-26,28,35,36,45 Of these, the study 
by Bruce et al. only found this association measured with ‘retrospective’ self-report 
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(i.e. adherence measured over the 8-week period prior to the study) and not 
regarding ‘prospective’ self-report (i.e. adherence measured during the 8-week 
period of the study), adherence diary or MEMS.28 The study by Sauceda used five 
different questions (i.e. methods) to measure adherence, four questions were about 
medication taken behavior during the past 30 days, and one question was about 
doses missed in the past seven days.45 Significant negative associations between 
neuroticism and adherence were found for the four methods regarding the past 30 
days and not regarding the past seven days. The study by Emilsson et al. did not find 
a significant association within the entire sample, but only in the subsample with 
male patients.35 One study by Axelsson et al. consisted of three articles. Two articles 
found an association for chronic patients.22,23 The third article by Axelsson et al. did 
not examine the entire sample of chronic patients, but investigated a male and 
female sample of patients with asthma and/or allergic rhinitis separately.24 In the 
male sample a univariate association was established, whereas none was found in 
the female sample. All found univariate associations were based on self-reported 
adherence measures. Three other studies that performed univariate analysis using 
(also) an objective measurement (i.e. MEMS) found no association.28,30,46 
In three of six studies that found a univariate negative significant 
association,22,26,36 this association was confirmed in a multivariate association (i.e. 
‘MV’ in Table 3.3), the other three did not perform a multivariate test. Of these 
three studies, Emilsson’s et al. study found this relationship again in the male 
sample, and not in the entire or female sample.35 Axelsson et al. performed a 
multivariate analysis only in one of the three articles based on the same dataset and 
found a relationship.22 In another study by Axelsson et al., consisting of two studies 
based on the same dataset, only one of the studies performed multivariate analysis 
and found a relationship.26 In four other studies, multivariate tests were performed 
without doing univariate tests first, and none of these four studies found any 
association.34,38,47,48 
One study looked at medication overuse in patients with migraine.37 At baseline, 
the authors found no difference in neuroticism scores between migraine patients 
with or without overuse and controls (i.e. healthy subjects). However, after one year 
they found that patients without overuse (i.e. patients with chronic headache that 
stopped medication overuse and patients with episodic headache without overuse) 
had lower neuroticism scores than patients with overuse (i.e. patients with chronic 
headache who persisted overusing medication and patients with episodic headache 
who converted into chronic migraine with medication overuse). 
Discontinuation of antidepressants (registered with a self-reported measure) was 
examined in one study, but no relation was found between neuroticism and 
discontinuation after 31 day or 91 days of medication use.39 
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Extraversion 
Sixteen studies examined the relationship between extraversion and medication 
adherence.21-26,28-35,38,42,43,46-48 In three out of twelve studies, a univariate association 
was found with adherence.21,30,46 A study by Cohen et al. found a negative 
association between extraversion and objective adherence measured with MEMS,30 
and Arnal et al. showed that self-reported non-adherent patients scored higher on 
extraversion than adherent patients.21 However, a study by Stilley et al. found a 
positive association between extraversion and MEMS adherence.46 This study only 
found this association in the sixteenth week of the study and not during the overall 
period or at other moments (i.e. first, eight and twenty-fourth week) at which 
adherence was assessed in this longitudinal study. 
Of these three studies, Cohen et al. performed a multivariate test, which found 
no significant relationship.30 Of five other studies in which (only) multivariate 
analyses were carried out, none found an association between extraversion and 
adherence.31,34,38,47,48 
 
Openness to experience 
Openness to experience was studied in fifteen studies.22-26,28-35,38,42,43,46-48 Eleven 
studies carried out a univariate analysis, two of which found a positive relationship 
between openness to experience and self-reported adherence.28,42 The study by 
Bruce et al. found an association with the retrospective self-report measure, but did 
not find an association with the prospective self-report measure, diary or MEMS.28 
These two studies did not perform multivariate analyses.  
Of four other studies that only performed multivariate analyses, two found a 
relation between openness and adherence.38,47 The study by Wilson et al. found a 
negative association between openness and self-reported adherence.47 Another 
study found a positive association between openness and self-reported adherence 
in kidney transplant patients.38 Kidney transplant patients with low openness scores 
were more likely to be non-adherers. This study also examined this relationship in 
liver transplant patients, in which no relation between openness and adherence was 
established. 
 
Agreeableness 
In sixteen studies agreeableness was studied.22-35,38,42,43,46-48 Two of eleven studies 
that performed univariate analyses showed a positive relationship between 
agreeableness and self-reported adherence.22-25 These two studies were both 
carried out by Axelsson et al. They showed in two articles (based on one study) a 
relationship in the entire sample of chronic patients.22,23 In a third article that 
belonged to the same study as the previous two, this relationship was found in 
male, but not in female patients with asthma and/or allergic rhinitis.24 In the second 
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study by Axelsson et al., the relationship was only established in one of the two 
articles.25  
One of Axelsson’s et al. articles about chronic patients confirmed this association 
with multivariate analysis, in other articles no multivariate tests had been executed 
(on agreeableness).22 Two other studies that only performed a multivariate analysis 
found also a positive association between agreeableness and adherence.34,48 Ediger 
et al. found a relationship with self-reported adherence in patients with 
inflammatory bowel disease.34 Wouters et al. found only a relationship of 
agreeableness with adherence measured with MEMS, but not with self-reported 
adherence or adherence determined with drug dispensing data. An association was 
only found in the third quartile of the agreeableness scores and not in the first, 
second and fourth quartiles.48 
In addition, a study by Broyles et al. looked also at medication overuse among 
HIV/AIDS patients, using MEMS.27 Agreeableness scores were higher in over-users 
(i.e. patients who used more than 100% of the prescribed medicines) than in 
patients that did not overuse their medication (i.e. patients who used less than 
100% of the prescribed medicines). 
 
Conscientiousness 
Conscientiousness was studied in 18 studies.22-35,38,40-44,46-48 In twelve of these 
studies, univariate analyses were performed, nine of which showed a significant 
positive relationship between conscientiousness and adherence.22-26,28,29,32,35,41,42,44,46 
In eight of these studies, the relationship was found with self-reported adherence,22-
26,28,29,32,35,41,42,44 and one study examined more objectively measured adherence (i.e. 
by using MEMS).46 The study by Bruce et al. only found associations between 
conscientiousness and medication adherence using self-report adherence measures 
and not with MEMS.28 In two articles the relationship with self-reported adherence 
was found in male, but not in female patients with asthma.24,35  
Of these nine studies, seven studies performed multivariate analysis, six of which 
established a multivariate relationship between conscientiousness and adherence. 
Five of these measured self-reported adherence,22,26,29,32,44 one measured 
adherence more objectively using MEMS.46 The study by Quine et al. only found an 
association between conscientiousness and self-reported adherence measured at 
baseline, but not at eight weeks follow-up.44 Cheung et al. only found an association 
in the entire sample and not in the women sample (no analyses were performed on 
the men sample).29 Stilley et al. only found a multivariate association with MEMS 
adherence measured over the entire study period (i.e. 6 months) and not for the 
separate measurements at week 1, 8, 16 and 24 of the study.46  
In two studies, univariate relations were not reported, but it was stated that 
variables (e.g. conscientiousness) in univariate or bivariate analysis with a p<0.10 
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were included in multivariate analysis and showed multivariate relationships 
between conscientiousness and adherence.27,33 In the study by Broyles et al. 
adherence was objectively measured,27 in the study by Dobbels et al. adherence was 
based on self-report.33 Five studies performed solely multivariate analyses.34,38,40,47,48 
Of these, only the study by Wouters et al. found a positive relationship between 
conscientiousness and self-reported adherence.48 An association was found in the 
third and fourth quartiles of the conscientiousness scores. No relationships were 
found for adherence measured with the MEMS and drug dispensing data.  
The study by Broyles et al. investigated also medication overuse among HIV/AIDS 
patients, using the MEMS.27 Conscientiousness scores were higher in over-users (i.e. 
patients who used more than 100% of the prescribed medicines) than in patients 
that did not overuse their medication (i.e. patients who used less than 100% of the 
prescribed medicines). 
   
Table 3.3 Outcomes of included studies (n=23) 
No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
1 Arnal, R.B.21 EPQ-R N, E Self-report: 
EAT 
Questionnaire 
Neuroticism Yes NT Mean (SD)  
Adherent patients: 
 5.71 (3.29) 
Non-adherent patients:  
8.30 (2.00) 
p=0.007 (t-test) 
     Extraversion Yes NT Mean (SD)   
        Adherent patients:  
6.43 (3.75) 
 
        Non-adherent patients: 
 8.90 (1.61) 
 
        p=0.002 (t-test)  
2 Axelsson, M.22 NEO-FFI N, E, O, A, C Self-report: 
MARS 
Neuroticism Yes Yes UV: r=-0.155, p=0.001 N, A, C 
MV: β=-0.028, p=0.035 
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness Yes Yes UV: r=0.129, p=0.044  
        MV: β=0.043, p=0.044  
     Conscientiousness Yes Yes UV: r= 0.162, p=0.001  
        MV: β=0.051, p=0.013  
- Axelsson, M.23 NEO-FFI N, E, O, A, C Self-report: 
MARS 
Neuroticism Yes NT r=-0.155, p<0.001  
Extraversion No NT - 
     Openness No NT -  
     Agreeableness Yes NT r=0.129, p<0.001  
     Conscientiousness Yes NT r=0.162, p<0.001  
 - table 3.3 continues -   
  
 
- table 3.3 continued - 
No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
- Axelsson, M.24 NEO-FFI N, E, O, A, C Self-report: 
MARS 
Sample men:     
Neuroticism Yes NT r=-0.358, p=0.01 
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness Yes NT r=0.285, p=0.05  
     Conscientiousness Yes NT r=0.312, p=0.01  
     Sample women:     
     All factors No NT -  
3 Axelsson, M.25 NEO-FFI N, E, O, A, C Self-report: 
MARS 
Neuroticism Yes NT sfl=-0.146, p<0.05  
Extraversion No NT - 
     Openness No NT -  
     Agreeableness Yes NT sfl=0.175, p<0.05   
     Conscientiousness Yes NT sfl=0.148, p<0.05  
- Axelsson,M.26 NEO-FFI N, E, O, A, C Self-report Neuroticism Yes Yes UV: r=0.321†, p=0.002 NR 
   MV: B=0.185†, β=0.242†, 
p=0.021 
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness Yes Yes UV: r=-0.313†, p=0.002  
        MV: B=-2.44†, β=-0.242†, 
p=0.021 
 
- table 3.3 continues - 
 
 
  
- table 3.3 continued - 
No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
4 Broyles, M.27 NEO-FFI A, C MEMS Analysis 1:    Analysis 1: Age, race, 
self-efficacy, AUDIT-
C-positive status 
Conscientiousness  NR Yes B=-0.47†, p=0.008 
     Analysis 2:    Analysis 2: Race,  
self-efficacy, AUDIT-
3-positive status 
Conscientiousness NR  Yes B=-0.45†, p=0.013 
     Analysis 3:   Adherence >100% vs. 
adherence <100% 
 
     Agreeableness Yes NT A higher if adherence > 100%, 
p=0.002 
 
     Conscientiousness Yes  NT C higher if adherence > 100%, 
p=0.005 
 
5 Bruce, J.M.28 NEO-FFI N, E, O, A, C Self-report:  
1. Adherence  
diary 
Retrospective self-
reported 
adherence: 
    
    2. % missed  Neuroticism Yes NT r=0.32†, p<0.05  
    doses Extraversion No NT -  
    3. MEMS Openness Yes NT r=0.36†, p<0.01  
     Agreeableness No NT -  
     Conscientiousness Yes NT r=-0.47†, p<0.01  
     Prospective self-
reported 
adherence: 
    
     Neuroticism No NT -  
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness Yes NT r=-0.31†, p<0.05  
- table 3.3 continues - 
  
 
- table 3.3 continued - 
No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
5 Bruce, J.M.28    Adherence diary:     
 (continued)    Neuroticism No NT -  
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness Yes NT r=-0.35†, p<0.01  
     MEMS:     
     Neuroticism No NT -  
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness No NT -  
6 Cheung, M.29 NEO-FFI-3 N, E, O, A, C Self-report: 
MARS 
Total sample:    Age, ACQ, PCAQ 
Neuroticism No NT - 
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness Yes Yes UV: r1=0.31, p=0.01  
        MV: β=0.24, p=0.03  
     Sample women:     
     All factors No NT -  
7 Cohen, N.L.30 NEO-PI-R N, E, O, A, C MEMS Neuroticism No No - Personality factors  
(N, E, O, A, C) Extraversion Yes No r=-0.323, p=0.024 
     Openness No No -  
     Agreeableness No No -  
     Conscientiousness No No -  
- table 3.3 continues - 
  
  
- table 3.3 continued - 
No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
8 Conrad, K.J.31 NEO-PI-R N, E, O, A, C Self-report: 
ACTG 
Neuroticism No No -  
    Extraversion No No -  
     Openness No No -  
     Agreeableness No No -  
     Conscientiousness No No -  
9 Dobbels, F.32 NEO-FFI N, E, O, A, C Self-report:  
1 question 
on 
medication 
taking 
Neuroticism No NT - Age, education, social 
support     Extraversion No NT - 
    Openness No NT -  
    Agreeableness No NT -  
    Conscientiousness Yes Yes UV: Mean (SD)  
        Adherent patients: 5.3 (2.1)  
        Non-adherent patients: 
4.2 (2.7), p=0.02 (t-test) 
 
        MV: logistic β= -0.23†, 
OR=0.49, 95% CI=0.26-0.91 
p=0.023 
 
- Dobbels, F.33 NEO-FFI N, E, O, A, C Self-report:  
2 questions 
on 
medication 
taking  
Neuroticism No NT - Transplant type, age, 
comorbidity, pre-
medication non-
adherence, level of 
education, social 
support 
    Extraversion No NT - 
    Openness No NT - 
    Agreeableness No NT - 
    Conscientiousness NR Yes Logistic β=-0.22†, p=0.014, 
95% CI=0.67-0.95 
- table 3.3 continues - 
  
  
 
- table 3.3 continued - 
No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
10 Ediger, P.34 NEO-FFI N, E, O, A, C Self-report: 
MARS 
Neuroticism NT No - Age, gender, 
employment, 
diagnosis, high and 
low N, high and low E, 
high and low O, high 
and low A, high and 
low C, gender x age, 
gender x diagnosis, 
gender x employment 
Extraversion NT No - 
Openness NT No - 
Agreeableness NT Yes OR=2.03, p<0.05 
Conscientiousness NT No - 
11 Emilsson, M.35 NEO-FFI N, E, O, A, C Self-report: 
MARS 
Total sample:    N, C 
    All factors No NT -  
     Sample men:     
     Neuroticism Yes Yes UV: r=-0.72, p=0.03  
        MV: B= -0.41, p<0.01  
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness Yes No MV: r=0.67, p=0.04  
     Sample women:     
     All factors No NT -  
12 Evangelista, 
L.S.36 
EPQ N Self-report: 
Modified 
version of the 
Compliance 
Questionnaire 
Neuroticism Yes Yes UV: r=-0.321, p<0.01 Age 
MV: B: NR, p=0.006 
         
- table 3.3 continues - 
 
 
 
  
- table 3.3 continued - 
No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
13 Gomez-
Beldarrain, M.37 
Zuckermann-
Kuhlmann III 
N Determined 
according to 
criteria of the 
International 
Headache 
society 
Time 1:     
Neuroticism No NT - 
Time 2:   - 
Neuroticism Yes NT No overuse vs. overuse 
Median (range)  
No overuse: 8 (0-16) 
Overuse: 11.5 (1-19) 
p=0.038 (t-test) 
14 Gorevski, E.38 NEO-FFI N, E, O, A, C Self-report: 
ITAS 
Kidney:    Sociodemographical 
variables, personality 
traits (N, E, O, A ,C), 
quality of life, 
depression categories 
    Neuroticism NT No - 
     Extraversion NT No - 
     Openness NT Yes OR=0.09, 95% CI= 0.01-
0.51, p<0.02 
     Agreeableness NT No -  
     Conscientiousness NT No -  
     Liver:     
     All factors NT No -  
- table 3.3 continues - 
  
  
 
- table 3.3 continued - 
No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
15 Lin, E.H.B.39 NEO-FFI N Self-report Early adherence  
(> 31 days): 
   Age, sex, education, 
severity of depression 
and anxiety (IDS 
score), dysthymia or 
recurrent depressive, 
days pt curtailed 
activities, chronic 
physical disease 
indicator, taken similar 
Rx previously, 
antidepressant Rx 
fluoxetine, number of 
severe side effects 
experienced, patient 
education and 
behavioral discussions, 
agreement with 
treatment 
     Neuroticism NT No - 
     Late adherence 
(91 days): 
   
     Neuroticism NT No - 
16 Nichols, 
L.M.W.40 
NEO-FFI C Self-report: 
RAQ 
Time 1:    Depressive 
symptomatology, 
perceived social 
support, autonomous 
motivation, perceived 
autonomy 
supportiveness of 
provider-patient 
relationship, perceived 
competence 
   Conscientiousness NT No - 
     Time 2:    
     Conscientiousness NT No - 
- table 3.3 continues - 
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No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
17 O’Cleirigh, C.41 NEO-FFI C Self-report: 
AACTG 
Conscientiousness Yes NT r=0.37, p<0.01  
-  Ironson, G.H.42 NEO-PI-R N, E, O, A, C Self-report: 
AACTG 
Neuroticism No NT -  
    Extraversion No NT -  
     Openness Yes NT r=-0.24†, p<0.05   
     Agreeableness No NT -  
     Conscientiousness Yes NT r=-0.20†, p<0.05  
18 Penedo, F.J.43 NEO-PI-R N, E, O, A, C Self-report: 
ACTG 
Neuroticism No NT -  
    Extraversion No NT -  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness No NT -  
19 Quine, L.44 IPIP C Self-report: 
Augmented 
version of 
Morisky scale 
Time 1:    Gender, age, marital 
status, car ownership, 
health status, years on 
medication, daily 
dosage, perceived side 
effects, medical risk 
factors, family risk 
factors, hypertensive 
identity, knowledge, 
attitude, subjective 
norm, PBC, intention, 
intention certainty, 
intention x certainty 
    Conscientiousness Yes Yes UV: r=0.18, p<0.001 
       MV: β=0.10, p<0.01 
    Time 2 (8 weeks):    
    Conscientiousness Yes No UV: r=0.11, p<0.01 
- table 3.3 continues - 
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No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
20 Sauceda, J.A.45 BFI-N N Self-report:      
    1. Frequency of 
doses taken 
Neuroticism Yes NT r=-0.31, p<0.01  
    2. Ability to 
take al HIV 
medications 
Neuroticism Yes NT r=-0.27, p<0.01  
    3. Doses missed 
in past 30 days 
Neuroticism Yes NT r=0.25, p<0.01  
    4. Visual analog 
scale: % of 
doses taken in 
past 30 days 
Neuroticism Yes NT r=-0.25, p<0.05  
    5. Doses missed 
in past 7 days 
Neuroticism No NT -  
21 Stilley. C.S.46 NEO-PI-R N, E, O, A, C MEMS Entire study 
period: 
   Psychological distress, 
IQ, mental 
flexibility/perceptual 
organization, IQ x C 
     Neuroticism No NT - 
     Extraversion No NT - 
     Openness No NT - 
     Agreeableness No NT -  
     Conscientiousness Yes Yes UV: β=0.24, p<0.01  
        MV: β=0.232, p<0.01  
- table 3.3 continues - 
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No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
21 Stilley. C.S.46    Week 1:     
 (continued)    Neuroticism No NT -  
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness No NT -  
     Week 8:     
     Neuroticism No NT -  
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness Yes NT UV: β=0.18, p<0.05  
     Week 16:     
     Neuroticism No NT -  
     Extraversion Yes NT UV: β=0.19, p<0.05  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness Yes NT UV: β=0.17, p<0.05  
     Week 24:     
     Neuroticism No NT -  
     Extraversion No NT -  
     Openness No NT -  
     Agreeableness No NT -  
     Conscientiousness Yes NT UV: β=0.24, p<0.01  
- table 3.3 continues -  
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No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
22 Wilson, S.T.47 NEO-PI-R N, E, O, A, C Self-report: TCI Neuroticism NT No - E, C 
Extraversion NT No - 
     Openness NT Yes Logistic B=-0.13, 
OR=0.88, p<0.05 
 
     Agreeableness NT No -  
     Conscientiousness NT No -  
23 Wouters, H.48 BFI N, E, O, A, C 1. Self-report: 
MARS 
MARS:    Education 
Neuroticism NT No - 
    2. MEMS Extraversion NT No -  
    3. Drug 
dispensing 
data 
Openness NT No -  
Agreeableness NT No - 
Conscientiousness NT Yes Third quartile: OR=3.63, 
95% CI = 1.34-9.86, 
p≤0.05 
        Fourth quartile: OR=2.97, 
95% CI = 1.09-8.08 , 
p≤0.05 
 
     MEMS, Days 
missed, ≤ 10%: 
    
     Neuroticism NT No -  
     Extraversion NT No -  
     Openness NT No -  
     Agreeableness NT No -  
     Conscientiousness NT No -  
- table 3.3 continues - 
  
  
- table 3.3 continued - 
No. First author Measurements Association 
  Personality 
measure 
Personality 
factors 
Medication 
adherence 
measure 
 UV MV Strength of association 
personality factor and 
adherence 
Covariates/predictors 
23 Wouters, H.48 
(continued) 
   MEMS, Days missed, 
<4 consecutive days: 
    
     Neuroticism NT No -  
     Extraversion NT No -  
     Openness NT No -  
     Agreeableness NT Yes Third quartile: 
OR=4.34, 95% CI = 
1.38-13.66, p≤ 0.05 
 
     Conscientiousness NT No -  
     Drug dispensing 
data: 
    
     Neuroticism NT No -  
     Extraversion NT No -  
     Openness NT No -  
     Agreeableness NT No -  
     Conscientiousness NT No -  
Abbreviations: N = neuroticism, E = extraversion, O = openness to experience, A = agreeableness, C = conscientiousness, UV = univariate analysis, MV = multivariate analysis, NR = not reported, 
NT = not tested, † = association is measured in relation to the degree of non-adherence; direction of effect should therefore be reversed, r1 = Spearman’s rank coefficient, SFL = Standardized 
factor loadings (corresponds with standardized correlation coefficient), OR = odds ratio, CI = Confidence interval, B = Unstandardized regression coefficient, β = Standardized regression 
coefficient, BFI(-N) = Big Five Inventory(-Neuroticism subscale), EPQ(-R) = Eysenck Personality Questionnaire (Revised), NEO-FFI(-3) = NEO Five-Factor Inventory(-3)), NEO-PI-R = Revised NEO 
Personality Inventory, IPIP = International Personality Item Pool, PBC= Perceived, behavioral control, ACQ = Asthma Control Questionnaire, PCAQ = Perceived control of asthma, MARS = 
Medication adherence report scale, (A)ACTG = AIDS Clinical Group Adherence Measure, ITAS = Immunosuppressive therapy adherence scale, RAQ = adaptation of the Brief Medication 
Questionnaire, TCI = Treatment Compliance Interview, MEMS = Medication Event Monitoring System. 
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Discussion 
 
The current review shows that there is no consistent evidence that personality traits 
are related to medication adherence. Of all personality traits, neuroticism and 
conscientiousness showed most indications for a relationship with medication 
adherence, but the results are inconclusive. 
 
Neuroticism 
A negative relationship between neuroticism and adherence was found in a number 
of studies. Because the evidence is not conclusive, it is not possible to draw 
conclusions on whether a negative relationship exists between neuroticism and 
adherence; more research is needed.  
However, it is likely that more studies will confirm a negative relationship 
between neuroticism and adherence, because people with a high level of 
neuroticism are more likely to be anxious and emotionally distressed, and therefore 
be easily more concerned about their illness or medication than people with a low 
level of neuroticism. Concerns about medication are often found to relate to 
reduced medication adherence.49,50 These concerns could be about side effects, fear 
for dependency, and long term consequences of the medication. On the other hand, 
a positive relation could also be reasonable between neuroticism and adherence. 
Being anxious about the negative consequences of a disease might just increase 
patient’s adherence. However, no study in this review found a significant positive 
association between neuroticism and adherence. 
Two studies in this review considered the effect of concerns as well. Emilsson et 
al. found in the male sample of their study not only an association between 
neuroticism and adherence, but also a positive relationship between neuroticism 
and concerns in the male sample.35 However, the authors did not analyze whether 
concerns were a confounder or a mediator in the relationship between neuroticism 
and adherence. In addition, Axelsson et al. looked more closely at the mediating 
effect of medication beliefs on the relationship between personality traits and 
adherence in patients with asthma.25 They found a positive association between 
neuroticism and concerns, and that concerns partially mediated the relationship of 
neuroticism with adherence amongst others. More research is required to get more 
insight into this. 
 
Conscientiousness 
Conscientiousness was positively related to medication adherence in the majority of 
studies, but this evidence is not conclusive, as other studies found no relationship. 
However, it might be expected that an association between conscientiousness and 
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adherence exists, as people who are more conscientious tend to be more punctual, 
disciplined, goal-directed, and persevering.13,14 These characteristics are likely to be 
important in remembering to take the medicine and to plan when and what dose to 
take, and actual medication taking behavior.  
Axelsson et al. looked in one of their articles also at the relationship between 
conscientiousness and concerns. Conscientiousness had a significant negative 
correlation with concerns, and Axelsson et al. identified that concern is a mediator 
in the relation between conscientiousness and adherence.25  
Furthermore, a meta-analysis by Molloy et al. found a small association between 
conscientiousness and medication adherence (r=0.15).8 Although we have included 
for the most part the same studies, because of differences in search key words, 
inclusion criteria, and date of review, our review and the meta-analysis by Molloy et 
al. also included other studies. 
 
Extraversion, Openness to experience and Agreeableness 
Most studies found no evidence for a relationship of extraversion, openness to 
experience, and agreeableness with medication adherence. We consider it unlikely 
that new studies would show a real relationship between these traits and 
adherence.  
 
Sample size of studies  
The inconclusive results we found regarding the relation of neuroticism and 
conscientiousness with adherence might be related to the sample size of the 
included studies. Some studies had a large sample size (e.g. more than 500 
participants) and others had smaller sample sizes (e.g. less than 60 participants). 
Although we determined whether the sample size of the studies were sufficient to 
justify the results and conclusions, estimations performed in large sample sizes are 
more reliable than in small samples.  
Of the thirteen studies studying neuroticism with a sample size larger than 100 
participants,22-26,31-34,37-39,42,43,45,46,48 only four studies found an association between 
neuroticism and adherence.22-26,37,45 Of the eight studies with sample sizes below 
100 participants,21,28-30,35,36,38,47 four found an association between neuroticism and 
adherence.21,28,35,36 This makes the interpretation of the results even more complex, 
and underlines the importance of future research with good study quality and large 
sample sizes.  
Regarding conscientiousness, eight22-27,32,33,41,42,44,46,48 of twelve studies with a 
sample size larger than 100 participants established an association.22-27,31-34,40-44,46,48 
Three28,29,35 out of the six studies with a sample size below 100 found an 
association.28,29,30,35,38,47 This suggests that a relationship between conscientiousness 
and adherence is more likely than not. 
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Possible mediating factors 
Apart from concerns, a few other possible mediating factors may be relevant. First 
of all, two studies looked at the role of gender in the relationship between 
personality traits and adherence. The study by Emilsson et al. showed an association 
of neuroticism (univariate and multivariate) and conscientiousness (univariate, but 
not multivariate) with adherence to asthma (i.e. controller medication) in the male 
sample, but not in the female sample.35 This association was again established by a 
study by Axelsson et al.24 On the basis of these two studies it is not possible to draw 
conclusions about whether possible relationships between personality traits and 
adherence work different in men and women and further research is recommended. 
Second, however not previously examined, coping could play a mediating role. 
Personality factors seem to relate to several coping styles,51,52 and coping is in turn 
related to adherence.53 Extraversion and conscientiousness are positively associated 
with more engagement coping, which is aimed at dealing with the distress by, for 
instance, looking for support, acceptance, and regulating emotions. Conversely, 
neuroticism is positively related to disengagement coping, which is about avoiding 
and escaping from distress.51,52 In future research coping could be to be taken into 
account. At last, self-efficacy could play a mediating role as well.23 
 
Adherence measures 
All included studies used indirect methods for assessing medication adherence that 
do not register actual medication-taking behavior. Direct measurements were not 
used, such as measuring drug concentrations or detecting biologic markers (which 
have been added to the drug). Most studies (n=18) used a self-report measure like 
questionnaires and dairies, and only five studies used a more objective measure. 
Self-report measures can be expected to be less reliable in measuring adherence 
than medication event monitoring systems (MEMS). They might overestimate 
patients’ adherence, because answers can be distorted by patients.54 For instance, 
patients might not correctly recall their medication use or might give social desired 
answers. 
MEMS might be a more reliable method to measure adherence. It daily monitors 
the time of opening of the bottle, dispensing of drops or activating an inhaler device 
(depending on the type of drug). Although it is an indirect method - because it does 
not register whether a patient really has taken the medication - it gives detailed 
information about the patient’s medication-taking behavior. Therefore, MEMS is 
considered to be a reliable and accurate adherence measure, and relatively easy to 
utilize in research and therapeutic settings.54,55 However, DiMatteo showed in his 
review that it cannot be concluded whether subjective or objective measurements 
are more reliable.1  
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In our review, five studies used MEMS,27,28,30,46,48 four of which found a positive 
association between (one or more) personality factors and adherence measured 
with MEMS.27,30,46,48 Only the study by Bruce et al. and the study by Wouters et al. 
used both methods and found solely a relationship between adherence and 
conscientiousness with self-report methods but not with MEMS.28,48 More research 
is needed to draw conclusions about relations between personality and subjectively 
and objectively measured adherence, and future studies should especially use more 
than one adherence measurement (i.e. direct, indirect, subjective or objective). 
 
Intentional versus unintentional non-adherence 
According to the literature, two types of non-adherence can be distinguished, 
intentional and unintentional. In general, intentional non-adherence refers to 
patients’ reasoned choice to do not take medication as prescribed, whereas 
unintentional non-adherence results from forgetfulness, carelessness, or reasons 
beyond patients’ control (e.g. health literacy or manual dexterity). Overlaps between 
the types are possible.56-58 
In our review, only two studies distinguished between intentional and 
unintentional adherence. Quine et al. found that conscientiousness was significantly 
and negatively related to carelessness, but not to forgetfulness, and intentional non-
adherence factors.44 In addition, Axelsson et al. found only in the male study 
population a negative relationship between neuroticism and ‘intentional 
adherence’, and positive associations of agreeableness and conscientiousness with 
‘intentional adherence’.24 There was a positive relation between conscientiousness 
and ‘unintentional adherence’ in the male population as well. As traits could be 
related to intentional and unintentional non-adherence in different ways, it is 
important to distinguish these two types when investigating the relationship 
between personality and adherence. 
 
Discontinuation and overuse 
Most of the studies examined non-adherence in terms of taking less medication 
than prescribed. Few studies looked specifically at discontinuation and overuse of 
medication. Therefore, this review gives only insight into adherence behavior of 
patients who do follow the medication regimen and patients who take less than the 
prescribed regimen (measured on a continuum or dichotomously). Although these 
non-adherers could also include patients who discontinued, these studies did not 
make this a distinction between taking less medication and stopping with the 
medication. 
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Implications 
Although the results are inconclusive, there are indications that neuroticism and 
conscientiousness might be related to medication adherence. Therefore, patients’ 
level of neuroticism and conscientiousness might need to be taken into account to 
improve patients’ adherence. Because the included studies only measured 
associations, we cannot draw conclusions about any causality of the possible 
relationships. However, personality traits are expected to be fairly stable in persons 
above the age of 30 years.59 This has two implications; first it implies that personality 
should affect adherence (instead of the other way around). In addition, it suggests 
that it is not possible to intervene on the traits themselves to change them in order 
to improve adherence. Therefore, we need to intervene on other factors. As 
described before, patients with high levels of neuroticism are inclined to be anxious 
and they might have more concerns about their medications, and patients with low 
level of conscientiousness are prone to be less organized and show less goal-
directed behavior. Therefore, reducing anxiety and concerns might be a solution in 
patients high in neuroticism to improve medication adherence. In addition, offering 
patients with low levels of conscientiousness a more simple drug regimen or an 
improvement in patients’ goalsetting skills might improve their medication 
adherence. Interventions should therefore be tailored to these specific traits and 
their effects on adherence. For instance, supporting patients high in neuroticism in 
coping with their disease and diminishing their concerns by being emphatic and 
giving reassurance, might be important. If relevant, future research should 
concentrate as well on how patients’ personality traits in light of their medication 
adherence behavior could be assessed and whether health care providers could play 
an important role in educating and counseling patients. Only assessing personality 
traits would not be sufficient.  
 
Limitations 
This review is not without limitations. The search strategy could have missed 
relevant articles. The term ‘personality’ was not included in the search strategy, 
because it gave too much noise in the data. Therefore we have chosen to use only 
the (related) terms of the Big Five and the five personality traits to capture as many 
relevant articles as possible.  
Furthermore, some researchers are critical of the Five Factor Model because of 
some limitations, such as the lack of a theoretical approach, relying on factor 
analysis as an adequate method in understanding and explaining personality, no 
consideration of new, essential developments in personality assessments, and 
reluctance to accept evidence that there are more fundamental factors than the Big 
Five traits. However, using just one framework, like the FFM, has the benefit to find 
easier clear results because of using homogeneous personality constructs and 
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concepts. In addition, although not based on a theory, the FFM has often been 
proven to be a valid model.  
 
 
Conclusion 
 
Our review shows that there is no consistent evidence for a relationship between 
personality traits and medication adherence in general. However, there are some 
indications that an association of neuroticism and conscientiousness with 
medication adherence exists. More high quality research is needed to get more 
insight into this. Large sample size studies and using multiple adherence measures 
are recommended. 
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Supplementary materials 
 
S1. PubMed search strategy 
 
(extraversion[Mesh] OR introversion[Mesh] OR "five factor model"[tiab] OR 
FFM[tiab] OR "5 factor model"[tiab] OR "big five"[tiab] OR "big 5"[tiab] OR 
extravert[tiab] OR extraversion[tiab] OR extrovert[tiab] OR extroversion[tiab] OR 
introvert[tiab] OR introversion[tiab] OR agreeableness[tiab] OR agreeable[tiab] OR 
conscientiousness[tiab] OR conscientious[tiab] OR “emotional stability”[tiab] OR 
“emotionally stable”[tiab] OR "emotional stable"[tiab] OR neuroticism[tiab] OR 
openness[tiab]) 
 
AND  
 
("Patient compliance"[Mesh] OR "Medication adherence"[Mesh] OR “patient 
dropouts”[Mesh] OR Adhere*[tiab] OR Nonadhere*[tiab] OR Complian*[tiab] OR 
Noncomplian*[tiab] OR Persisten*[tiab] OR Nonpersisten*[tiab] OR 
Concordance[tiab] OR Concordant[tiab] OR Concordancy[tiab] OR 
Concordantly[tiab] OR "no show"[tiab] OR "no shows"[tiab] OR "treatment 
dropout"[tiab] OR "treatment dropouts"[tiab] OR “treatment termination”[tiab] OR 
"appointment keeping"[tiab] OR Adherance[tiab] OR Adherant[tiab] OR 
Nonadherance[tiab] OR Nonadherant[tiab] OR Persistance[tiab] OR Persistant[tiab] 
OR Nonpersistance[tiab] OR Nonpersistant[tiab] OR Persistancy[tiab] OR “patient 
dropout”[tiab] OR “patient dropouts”[tiab]) 
 
NOT  
 
(Editorial[PT] OR Letter[PT] OR Comment[PT] OR “Newspaper article”[PT] OR 
Interview[PT]) 
  
 Big Five personality traits and medication adherence 77 
S2. Data extraction form 
 
Study: 
REF ID no.:______________________________________ 
First author:______________________________________ 
Setting: 
Country:_________________________________________ 
Other information:_________________________________ 
Participants:  
Medical condition:__________________________________ 
Type of medication:_________________________________ 
Sample size (n):____________________________________ 
Longitudinal studies: % loss to follow-up:_______% 
Age, [Mean (SD)]:__________________________________ 
% Female:_______________________________________% 
? Disease duration:__________________________________ 
Design:___________________________________________ 
Measurements: 
Personality measure:_________________________________ 
Personality factors: ☐1. Extraversion / Introversion* 
   ☐2. Neuroticism / Emotional stability* 
   ☐3. Agreeableness 
   ☐4. Conscientiousness 
   ☐5. Openness to experience 
Medication adherence measure: 
☐ Self-report: Name of scale (if reported):________________ 
☐ Objective measure:_________________________________ 
 
Significant association present between personality and adherence: 
☐ Univariate:  Yes / No / not tested / not reported*  
☐ Multivariate: Yes / No / not tested / not reported *  
 
Covariates:-
____________________________________________________________________ 
 
Number domains bias free (see other form):________________ 
 
* Strike out what does not apply 
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S2. (continued) 
 
REF ID no.:______________________________________ 
 
1. Extraversion / Introversion* 
Significant association present between personality and adherence: 
☐ Univariate:  Yes / No / not tested / not reported*  
 Strength of association:_______ 
 P value:___________ 
☐ Multivariate: Yes / No / not tested / not reported *  
 Strength of association:  
Unstandardized B / standardized β / Odds ratio / logistic regression 
coefficient*:_______ 
 P value:___________ 
   
2. Neuroticism / Emotional stability* 
Significant association present between personality and adherence: 
☐ Univariate:  Yes / No / not tested / not reported*  
 Strength of association: _______ 
 P value:___________ 
☐ Multivariate: Yes / No / not tested / not reported *  
 Strength of association:  
Unstandardized B / standardized β / Odds ratio / logistic regression 
coefficient*:_______ 
 P value:___________ 
 
3. Agreeableness 
Significant association present between personality and adherence: 
☐ Univariate:  Yes / No / not tested / not reported*  
 Strength of association:_______ 
 P value:___________ 
☐ Multivariate: Yes / No / not tested / not reported *  
 Strength of association:  
Unstandardized B / standardized β / Odds ratio / logistic regression 
coefficient*:_______ 
 P value:___________ 
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S2. (continued) 
 
4. Conscientiousness 
Significant association present between personality and adherence: 
☐ Univariate:  Yes / No / not tested / not reported*  
 Strength of association:_______ 
 P value:___________ 
☐ Multivariate: Yes / No / not tested / not reported *  
 Strength of association:  
Unstandardized B / standardized β / Odds ratio / logistic regression 
coefficient*:_______ 
 P value:___________ 
  
5. Openness to experience 
Significant association present between personality and adherence: 
☐ Univariate:  Yes / No / not tested / not reported*  
 Strength of association:_______ 
 P value:___________ 
☐ Multivariate: Yes / No / not tested / not reported *  
 Strength of association:  
Unstandardized B / standardized β / Odds ratio / logistic regression 
coefficient*:_______ 
 P value:___________ 
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Abstract 
 
Objectives 
To compare pharmacists’ and pharmacy technicians’ perceptions of patients’ beliefs 
regarding inhaled corticosteroids (ICS) with those of patients and to compare the ICS 
beliefs of pharmacists and technicians with those of patients with asthma.  
 
Methods 
1269 community pharmacies were approached to fill out an online questionnaire; 
1952 patients were sent a questionnaire by post. Beliefs (i.e. necessity and 
concerns) regarding ICS were measured using (an adapted version of) the Beliefs 
about Medicines Questionnaire (BMQ-specific). Pharmacists and technicians were 
instructed to fill out the BMQ for themselves, and to fill it out in the way they 
thought most of their patients would complete it. 
 
Results 
136 pharmacists, 90 pharmacy technicians and 161 patients with asthma completed 
the questionnaire. Pharmacists and technicians thought patients had more concerns 
about ICS than patients themselves reported (p<0.0001). They also thought that 
patients had stronger beliefs in their personal need for ICS than patients reported 
(p<0.01). Pharmacists reported lower levels of concerns than patients (p<0.05) and 
both providers attributed a higher level of necessity to ICS than patients did 
(p<0.0001).  
 
Conclusion 
Pharmacists and technicians overestimate the personal need for treatment as well 
as the concerns patients with asthma have regarding ICS. They also have, to some 
extent, stronger positive beliefs about ICS than patients. If pharmacists and 
technicians expect that patients share their positive views about ICS, they might be 
less likely to elicit and address patients’ doubts and concerns about ICS, which might 
be relevant for effective ICS treatment and subsequent patient outcomes. 
 
Keywords: Beliefs about medicines, perceptions of patients’ beliefs, patient-
pharmacist communication, adherence, patient-centered communication 
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Introduction 
 
Worldwide, an estimated 334 million people are affected by asthma.
1
 Patients’ self-
management skills, such as acquiring knowledge about asthma, self-monitoring of 
symptoms, psychological coping and adhering to medication recommendations, are 
important in asthma treatment.
2 
Despite the importance of using inhaled 
corticosteroids (ICS) regularly and of continuously controlling asthma symptoms, 
about 40% of patients fail to take ICS as prescribed by their healthcare provider.
3,4
 
This suboptimal adherence is associated with reduced quality of life, poor asthma 
outcomes, morbidity, mortality, and high healthcare use and costs.
3,5-7
 Therefore, 
suboptimal ICS adherence is a significant problem and it is important to find out how 
to improve adherence, which is essential for effective self-management and positive 
patient outcomes. 
Suboptimal adherence is related to beliefs about medicines, and, in particular to 
how patients judge their personal need for treatment (necessity beliefs) compared 
to their concerns about potential negative effects. Addressing these beliefs could 
therefore contribute to better adherence.
8-11
 Horne and colleagues distinguish 
between general and specific medication beliefs.
12
 General medication beliefs 
include patients’ thoughts about the harmfulness of medicines, overprescribing by 
doctors, and benefits of medication in general. Specific medication beliefs refer to 
perceptions of personal need for the treatment (necessity beliefs) and concerns 
regarding medicines for a particular disease. Studies indicate that about 30–43% of 
patients with asthma have concerns about ICS, relating to side effects, fear of long-
term adverse effects and drug dependency.
8,11
 One study found a smaller number of 
patients with high concern rates than other studies have reported (23%), but showed 
that more than one third of the patients doubted the necessity of ICS.
13 
To facilitate informed choice, optimal adherence to appropriately prescribed 
treatment, and self-management, healthcare providers should take patients’ 
medication beliefs into account. In their interactions with patients, they can 
accomplish this by being alert, empathic and responsive to patients’ concerns, 
feelings, and ideas regarding their medication use. Such a patient-centered 
approach, ‘in which the patient’s point of view is actively sought’
14
, is considered to 
enhance patient satisfaction, medication adherence, and health outcomes, although 
literature studies yield inconsistent findings.
15,16 
The level to which healthcare providers communicate in a patient-centered way 
and are able to achieve concordance - i.e. a shared responsibility by providers and 
patients in treatment and therapeutic decisions, whereby patients’ beliefs and 
preferences are taken into account
8,17
- might be reflected in an accurate perception 
of patients’ medication beliefs. Such perceptions are built during providers’ 
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interactions with patients. In turn, if healthcare providers’ perceptions of patients’ 
medication beliefs correspond with patients’ actual beliefs, this might enhance their 
responsiveness (i.e. being attentive and sensitive) to patients’ concerns and doubts 
about the need for ICS. No previous research has examined providers’ perceptions of 
patients’ beliefs. Therefore, it is interesting to get insight into providers’ perceptions 
of patients’ beliefs and to compare these with patients’ actual beliefs. 
Additionally, healthcare providers’ own beliefs are likely to influence the degree 
of patient-centered communication and the concordance that can be achieved. If 
providers and patients hold the same medication beliefs, the providers might be 
expected to be more responsive to their patients’ doubts and concerns about ICS and 
elicit them. However, if providers have a more positive view of ICS than patients, they 
might be more inclined to assume that patients have similar beliefs, and therefore fail 
to extensively explore patients’ thoughts. Few studies have examined these issues 
but there is some evidence that healthcare providers have more positive views about 
medicines in general than patients do.
18,19
 In addition, Rämstrom and colleagues 
showed that pharmacists have more positive medication beliefs than patients do, 
and therefore they emphasized that it is important that pharmacists elicit patients’ 
views, experiences and concerns; pharmacists must not assume that patients are as 
positive about medication as they are themselves.
20 
In this study we concentrate on specific medication beliefs, in particular 
perceptions of the necessity of ICS and concerns, as held by patients with asthma, 
community pharmacists, and pharmacy technicians. Regarding adherence to ICS, 
specific medication beliefs are likely to be most salient, in particular perceptions of 
the necessity of ICS and concerns.
10
 We focus on the setting of the community 
pharmacy because patient counseling has become a pivotal task of community 
pharmacists.
21 
To gain more insight into differences in ICS beliefs between patients with asthma 
and providers, the objectives of this study are: 1) to compare pharmacists’ and 
pharmacy technicians’ perceptions of patients’ ICS beliefs with the ICS beliefs of the 
patients themselves, and 2) to compare the ICS beliefs of patients with asthma with 
the beliefs of pharmacists and pharmacy technicians. Pharmacists’ and pharmacy 
technicians’ beliefs will be examined separately as several studies found differences 
in their communication and beliefs.
19,22,23 
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Methods 
 
Setting 
This cross-sectional study is part of a larger research project investigating the 
communication of community pharmacists and pharmacy technicians with patients 
with asthma and/or Chronic Obstructive Pulmonary Disease (COPD) about their ICS 
use. 
Data for this study were obtained in two different ways. Patients’ data were 
obtained in 12 community pharmacies between September 2011 and February 
2012; the methods used are described in the “Patient part.” Pharmacists’ and 
pharmacy technicians’ data were obtained between January 2014 and March 2014; 
the methods for this are described in the “Pharmacy part.” 
 
Ethics 
The research proposal was assessed by the Medical Ethics Committee (METC) of the 
University Medical Center Utrecht (UMCU). The METC concluded that it did not fall 
within the remit of the Law on Medical Scientific Research involving Human Beings. 
 
Patient part (September 2011 – February 2012) 
Participants 
Eligible patients were 18 years of age or older, had been using ICS for at least one 
year, and had filled two or more ICS prescriptions in the preceding year; the latter 
criterion was to include only daily ICS users. Patients who were living in an 
institution (e.g. a nursing home or assisted living facility) were excluded. For the 
purpose of the present study, data were used only of patients who reported having 
asthma (symptoms) without COPD. 
 
Procedure 
Patients were recruited in twelve community pharmacies; these pharmacies had 
participated in a previous study in cooperation with the Utrecht Pharmacy Practice 
Network for Education and Research (UPPER).
24
 A total of 1952 eligible patients were 
sent an information package, consisting of an invitation letter, a questionnaire, and 
an informed consent form, by their pharmacists. To participate in the study, patients 
had to return the completed questionnaire and a signed informed consent form. 
  
86 Chapter 4 
Pharmacy part (January 2014 – March 2014) 
Participants 
All 1269 community pharmacists belonging to the UPPER network were eligible to 
participate; no further inclusion or exclusion criteria were applied. Pharmacy 
technicians were eligible if they were experienced in instructing patients in inhaler 
techniques, as determined by the pharmacists. 
 
Procedure 
To recruit pharmacists, UPPER sent an e-mail to the community pharmacists 
belonging to the UPPER network. The e-mail contained information about the study 
and a secure web link to an online questionnaire. To reach more pharmacists and to 
recruit pharmacy technicians, pharmacists were requested to send this e-mail to 
other pharmacists and pharmacy technicians at their pharmacy. The pharmacists and 
pharmacy technicians from the 12 pharmacies who had already participated in the 
initial study (n = 24) were invited to participate again in this study via e-mail, and the 
secure web link was also sent to them. 
 
Questionnaires and measures 
The questionnaire for both patients and pharmacists/pharmacy technicians included 
questions on sociodemographic characteristics. Patients were asked about the 
indication for ICS prescription (asthma (symptoms), COPD, or not known). Data on 
pharmacists’ and technicians’ experience in education and counseling patients about 
ICS was collected as well. 
In addition, the validated Beliefs about Medicines Questionnaire (BMQ-specific) 
was used to measure specific beliefs about ICS. This questionnaire had been 
developed initially for patients.
12
 The BMQ-specific contains a ‘necessity’ scale and a 
‘concerns’ scale. An example of a ‘necessity’ item is: ‘Without these medicines, I 
would be very ill’, and of a ‘concerns’ item: ‘These medicines disrupt my life’. Each 
scale consisted of five items originally, but a sixth item, i.e. ‘ICS give me unpleasant side 
effects’, can be added to the ‘concerns’ scale, depending on the reliability of the 
scale. All eleven items were included in this study. 
Patients filled out the original version of the BMQ-specific, whereas pharmacists 
and pharmacy technicians completed two versions of the BMQ-specific. First, the 
BMQ-specific was adapted to assess pharmacists’ and pharmacy technicians’ own ICS 
beliefs; these changes were approved by the developer of the BMQ-specific.
25
 Items 
were rephrased so that pharmacists and pharmacy technicians could answer them 
from their own perspective. Examples are: ‘These medicines disrupt the life of my 
patients’ and ‘Without these medicines, my patients would be very ill’. Second, to 
assess pharmacists’ and pharmacy technicians’ perceptions of patients’ ICS beliefs, 
they had to complete the original, unadapted, BMQ-specific. This time they had to 
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complete it from the perspective of their patients. The instruction was to fill it out in 
the way they thought most of their patients with asthma would complete it. 
BMQ items were rated on a 5-point Likert scale ranging from ‘strongly disagree’ 
to ‘strongly agree’. The scores were added up for each scale, where higher scores 
indicate stronger beliefs. The ‘necessity’ scale sum scores were divided by 5, 
resulting in a scale score ranging from 1 to 5 (midpoint: 3). The internal consistency of 
the ‘necessity’ scales was sufficient to good (range of Cronbach’s α: 0.70–0.84). To 
reach an acceptable internal consistency for all versions of the ‘concerns’ scale, the 
sum score was calculated on the basis of four items instead of five (or six) items 
(range of Cronbach’s α: 0.60– 0.77). The item ‘I have insufficient knowledge about the 
effects of ICS’ was excluded. Sum scores of the ‘concerns’ scale were divided by 4, 
resulting in a scale score ranging from 1 to 5 (midpoint: 3). ‘Necessity’ and 
‘concerns’ scores below the scale midpoint (<3) were considered to be ‘low’, and 
scores from midpoint and above (≥3) were considered to be ‘high’. 
 
Statistical analysis 
Data were analyzed using Stata version 13. Descriptive statistics were used to 
describe the characteristics of the study participants. Two-sample t-tests and a 
Pearson’s chi-squared test were performed to compare the characteristics of 
pharmacists and pharmacy technicians who did not fill out the questionnaire 
entirely (i.e. non-completers) with the characteristics of those who did complete it. 
Data for non-responding patients was not available. Two-sample t-tests were also 
performed to compare the mean values of the patient BMQ scores, with the 
pharmacists’ and pharmacy technicians’ BMQ scores. 
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Results 
 
Study sample 
A total of 429 patients (22.0%) responded, of whom 169 patients reported having 
asthma (symptoms) without COPD. Of these, 161 completed the BMQ-specific 
sufficiently for calculations of scale scores and were therefore included in this 
study. The mean age was 56.2 years (SD=16.8), and the majority of the patients were 
female (67.3%). 
Of the 1269 pharmacies approached, 1257 pharmacists received the invitation 
(there were 12 e-mail delivery errors). The link to the questionnaire was opened by 
174 pharmacists and 106 pharmacy technicians, and completed by 136 pharmacists 
and 90 pharmacy technicians. Non-completers (n=54) did not differ from 
completers in age, gender, and own medication beliefs (these parts were filled in 
by all pharmacists and pharmacy technicians who opened the link). Of the 
completers, a small majority of the pharmacists were female (56.6%) whereas 
almost all pharmacy technicians were female (98.9%). The mean age of the 
pharmacists was 41.5 years (SD=11.8), and that of the pharmacy technicians was 
41.4 years (SD= 11.2). 
In everyday practice, approximately one third of the responding pharmacists and 
a quarter of the responding pharmacy technicians reported that they did not provide 
counseling sessions (i.e. consultations in which patients’ experiences with medication 
use is discussed to monitor patients’ health and/or medication use) for ICS at their 
pharmacy.  
 
Table 4.1 Patient, pharmacist and pharmacy technician characteristics 
- table 4.1 continues - 
 
  
Patient characteristics n=161 
Femalea 107(67.3%) 
Age in yearsa  
Mean (SD)  56.2(16.8) 
(range) (20-87) 
Age group, yearsa  
18-44 42(26.1%) 
45-64 64(39.8%) 
65 or over 53(32.9%) 
Educational levela  
Low 46(28.6%) 
Intermediate 37(23.0%) 
High 76(47.2%) 
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- Table 4.1 continued - 
Notes: 
a
2 missing values, 
b
4 missing values. 
 
Beliefs about ICS 
Table 4.2 shows the percentages of patients, pharmacists and pharmacy technicians 
who had high scores on the ‘necessity’ and ‘concerns’ scales. The majority of the 
patients with asthma (65.2%) had high scores on the ‘necessity’ scale, and about 
one-third (34.8%) had low ‘necessity’ scores. Most patients (78.9%) had low scores 
on the ‘concerns’ scale. Regarding the perceptions of patients’ beliefs, most 
pharmacists (89.7%) and pharmacy technicians (87.8%) assessed patients as having 
high ‘necessity’ scores and around 80% of them believed patients to have concerns. 
The majority of pharmacists (95.6%) and pharmacy technicians (92.2%) had high ICS 
‘necessity’ scores, and low ‘concern’ scores themselves (86.8% and 80.0%, 
respectively). 
 
Table 4.2 Percentages of patients, pharmacists and pharmacy technicians giving a high score on the 
 ‘necessity’ and ‘concerns’ scales 
 Patients Pharmacists: 
perceptions of 
patients’ beliefs 
Pharmacists 
 
Pharmacy 
technicians: 
perceptions of 
patients’ beliefs 
Pharmacy 
technicians 
High score on 
‘necessity’ 
scale 
65.2% 89.7% 95.6% 87.8% 92.2% 
High score on 
‘concerns’ 
scale 
21.1% 78.7% 13.2% 84.4% 20.0% 
Patient characteristics n=161 
Ethnicityb  
Dutch 124(77.0%) 
Western background 21(13.0%) 
Non-Western background 12(7.5%) 
Pharmacist and pharmacy technician 
characteristics 
Pharmacists  
n=136 
Pharmacy technicians  
n=90 
Female  77(56.6%) 89(98.9%) 
Age in years   
Mean (SD) 41.5(11.8) 41.4(11.2) 
(range) (25-76) (20-63) 
Experience with dispensing of first and second 
ICS prescriptions (DP) and counseling sessions 
(CS) with patients about ICS  
 
DP 
 
CS 
 
DP 
 
CS 
No 0 31(22.8%) 0 24(26.7%) 
Yes, usually at the counter 40(29.4%) 59(43.4%) 12(13.3%) 41(45.6%) 
Yes, usually in private room 96(70.6%) 46(33.8%) 78(86.7%) 25(27.8%) 
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Table 4.3 presents the individual items in the BMQ and the patients’, pharmacists’ 
and pharmacy technicians’ mean scores to illustrate the results. The mean scores of 
the ‘necessity’ items were high for all groups except the item ‘Without ICS I would be 
very ill’, which was given a mean score below the scale midpoint by the patients. 
Regarding the personal beliefs of patients, pharmacists and pharmacy technicians, 
the mean scores of the ‘concerns’ items were low, except for the item ‘ICS give my 
patients unpleasant side effects’, which had a high score in the pharmacy technicians 
group. On the other hand, all the mean scores of items about pharmacists’ and 
pharmacy technicians’ perceptions of patients’ beliefs were high, except the item ‘ICS 
disrupt my life’. 
 Table 4.3 Mean scores for all original and adapted items of the BMQ-Specific 
 Patients Pharmacists: 
perceptions of 
patients’ beliefs 
Pharmacists Pharmacy technicians: 
perceptions of patients’ 
beliefs 
Pharmacy  
technicians 
 M (SD) M (SD) M (SD) M (SD) M (SD) 
Necessity items      
1My health, at present, depends on ICS 3.2 (1.1) 3.5 (0.8) - 3.6 (0.9) - 
2My patients’ health, at present, depends on ICS - - 3.6 (0.8) - 3.4 (0.8) 
1My life would be impossible without ICS 3.3 (1.0) 3.5 (0.8) - 3.7 (0.7) - 
2My patients’ life would be impossible without ICS - - 3.9 (0.7) - 3.7 (0.7) 
1Without ICS I would be very ill 2.8 (1.2) 3.4 (0.8) - 3.6 (0.8) - 
2Without ICS my patients would be very ill - - 3.5 (0.8) - 3.5 (0.8) 
1My health in the future will depend on ICS 3.3 (0.9) 3.4 (0.7) - 3.4 (0.8) - 
2The future health of my patients will depend on ICS - - 3.7 (0.7) - 3.5 (0.7) 
1ICS protect me from becoming worse 3.5(0.9) 3.7 (0.6) - 3.7 (0.6) - 
2These medicines protect my patients from becoming worse - - 4.1 (0.6) - 4.0 (0.5) 
Concern items      
1Having to take ICS worries me 2.2 (1.0) 3.6 (0.8) - 3.5 (0.8) - 
2It worries me that my patients have to take ICS - - 2.0 (0.8) - 2.3 (0.7) 
1&2I sometimes worry about long-term effects of ICS 2.9 (1.3) 3.8 (0.7) 2.4 (0.9) 3.7 (0.8) 2.9 (0.8) 
1&2I have insufficient knowledge about the effects of ICS* 2.5 (1.1)a 3.2 (0.9) 2.2 (1.2) 3.1 (0.9) 2.6 (1.2) 
1ICS disrupt my life 1.6 (0.8) 2.5 (0.7) - 2.7 (0.9) - 
2ICS disrupt the life of my patients - - 1.9 (0.8) - 2.2 (0.6) 
1I sometimes worry about becoming too dependent on ICS 2.3(1.1) 3.2 (0.8) - 3.5 (0.9) - 
2I sometimes worry that my patients are becoming too dependent 
on ICS 
- - 2.1 (1.0) - 2.4 (0.7) 
1ICS give me unpleasant side effects* 2.3 (1.1)b 3.4 (0.7) - 3.4 (0.7) - 
2ICS give my patients unpleasant side effects* - - 2.8 (0.9) - 3.1 (0.8) 
Notes: BMQ-Specific, ©Professor Robert Horne, University of Brighton 
Mean BMQ-scores range between 1-5. Higher scores refer to stronger beliefs. 
a
2 missing values 
b1 missing value 
1Original BMQ-item 
2Adapted BMQ-item 
*Not included for calculation of sum score of ‘concerns’ scale
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Differences between patients, pharmacists and pharmacy technicians in assessing 
necessity beliefs 
Two-sample t-tests revealed that patients on the one hand and pharmacists and 
pharmacy technicians on the other hand, differ in the (perceived) degree of 
necessity of ICS (Table 4.4). Patients’ ‘necessity’ scores (mean=3.2 ± SD=0.8) were 
lower on average than pharmacists’ and pharmacy technicians’ perceptions of 
patients’ necessity beliefs (pharmacists: 3.5±0.5, p<0.01; pharmacy technicians: 
3.6±0.6, p<0.001). In addition, the patients’ mean ICS necessity score was significantly 
lower than the pharmacists’ own mean score (3.7± 0.5, p<0.0001) and the pharmacy 
technicians’ own mean score (3.6±0.5, p<0.0001). No significant differences were 
found between the pharmacists’ ‘necessity’ scores and the pharmacy technicians’ 
scores, or between the two groups’ perceptions of patients’ necessity beliefs. 
 
Table 4.4 Results of two-sample t-tests of differences in the ICS necessity beliefs of patients with 
asthma, pharmacists and pharmacy technicians, and of pharmacists’ and pharmacy 
technicians’ perceptions of patients’ necessity beliefs 
 
 
 
 
 
 
Pharmacists: 
perceptions 
of patients’ 
necessity 
beliefs 
Pharmacists  Pharmacy 
technicians: 
perceptions of 
patients’  
necessity beliefs 
Pharmacy 
technicians  
 M(SD) 3.5(0.5) 3.7(0.5) 3.6(0.6) 3.6(0.5) 
Patients 3.2(0.8) p<0.01 p<0.0001 p<0.001 p<0.0001 
Pharmacists: perception 
of patients’ necessity 
beliefs 
3.5(0.5) - - ns - 
Pharmacists  3.7(0.5) - - - ns 
Notes: ns = not significant 
 
Differences between patients, pharmacists and pharmacy technicians in assessing 
concerns 
Pharmacists and pharmacy technicians thought that patients’ ‘concerns’ scores were 
higher than the actual patients’ ‘concerns’ scores (patients: 2.3±0.8; pharmacists: 
3.3±0.5, p<0.0001; pharmacy technicians: 3.3±0.6, p<0.0001) (Table 4.5). Patients 
had a significantly higher mean ‘concerns’ score than pharmacists (2.1±0.7, p<0.05), 
but no difference was found with pharmacy technicians’ own concerns. 
Pharmacists’ mean ‘concerns’ score was significantly lower than pharmacy 
technicians’ mean ‘concerns’ score (2.1±0.7 vs. 2.4±0.5, p<0.0001), but their 
perceptions of patients’ concerns did not differ. 
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Table 4.5 Results of two-sample t-tests of differences in the ICS concerns of patients with asthma, 
pharmacists, and pharmacy technicians, and of pharmacists’ and pharmacy technicians’ 
perceptions of patients’ concerns  
 
 
 
 
 
 
 
Pharmacists: 
perceptions of 
patients’ 
concerns 
Pharmacists Pharmacy 
technicians: 
perceptions of 
patients’ 
concerns 
Pharmacy 
technicians 
 M(SD) 3.3(0.5) 2.1(0.7) 3.3(0.6) 2.4(0.5) 
Patients 2.3(0.8) p<0.0001 p<0.05 p<0.0001 ns 
Pharmacists: 
perceptions of 
patients’ concerns 
3.3(0.5) - - ns - 
Pharmacists  2.1(0.7) - - - p<0.0001 
Notes: ns = not significant 
 
 
Discussion 
 
Our findings show that there are differences in ICS beliefs between patients with 
asthma, community pharmacists and pharmacy technicians, and between patients’ 
beliefs and pharmacists’ and pharmacy technicians’ perception of patients’ beliefs. 
Pharmacists and pharmacy technicians overestimate the extent to which patients 
consider ICS to be a necessity, but they also overestimate the extent of the concern 
beliefs. Their perceptions of patients’ concern beliefs are different from their own 
beliefs. Pharmacists, and to some extent pharmacy technicians, hold more positive 
beliefs about ICS than patients with asthma. 
First, pharmacists and pharmacy technicians thought patients would rate their 
personal need for ICS much higher than they actually did. Their overestimation of 
patients’ ICS necessity beliefs might suggest that pharmacists and pharmacy 
technicians are not yet paying enough attention to patients’ necessity beliefs. 
However, it seems important to emphasize the need for ICS in the enhancement of 
adherence since a positive relationship between necessity beliefs and ICS adherence 
has been found.
10,11,13
 Our results also show that about one-third of the patients 
doubted the necessity of ICS, so the necessity beliefs of ICS could be strengthened in 
this large group. That patients doubt the necessity of ICS might be due to the 
perception that ICS are not associated with the immediate relief of the symptoms of 
airways constriction in the same way that bronchodilators are.
10
 The inflammatory 
effect of ICS can be seen only in the long term, so the effect is not as noticeable as 
the effect of bronchodilators. Providing more information and increasing knowledge 
about ICS might therefore be of importance.
26
 
In contrast, pharmacist and pharmacy technicians expected that patients would 
experience more concerns about ICS than patients actually did. Although 
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pharmacists themselves are less concerned, they imagine that patients can be 
concerned. It has to be noted that in this study fewer patients (21.1%) had concerns 
than in previous studies, in which more than one third of patients with asthma were 
reported to have concerns.
8,11 
 In the light of the results of these earlier studies, the 
perceptions of patients’ ICS concerns by pharmacists and pharmacy technicians might 
be not as much of an overestimate as is suggested in our study. 
Furthermore, regarding pharmacists’ and pharmacy technicians’ own beliefs, we 
found that both categories of provider have higher ICS necessity beliefs than patients 
do. Pharmacists have fewer concerns about ICS than patients. So pharmacists have 
more positive beliefs about ICS than patients do (because pharmacists gave higher 
scores for the necessity of ICS and lower scores for concerns), and pharmacy 
technicians are more positive in terms of ICS necessity. These discrepancies in ICS 
beliefs between providers and patients could hinder providers in achieving patient-
centered communication and alignment. If providers have few concerns about 
potential adverse effects, they might assume that their patients share a similar 
positive view of the treatment and therefore be less inclined to elicit specific 
concerns (e.g. side effects, long-term effects, fear of dependency) that might be of 
importance to the patient and even act as a barrier to adherence and persistence. 
To prevent possible negative influences of discrepancies in communication, more 
attention should be paid to patients’ beliefs about medication and how these are 
related to medication adherence. George and colleagues have explored the themes 
that are discussed during contacts between patients with asthma and their primary 
care provider. They found that providers initiate a talk about modifiable ICS beliefs 
only when they have prior knowledge of patients’ negative ICS beliefs.
27
 Also, 
healthcare providers’ medication beliefs and their perceptions of patients’ beliefs 
should be taken into account. Being aware of providers’ own thoughts, possible 
discrepancies, and (unconscious) processes in behavior and communication could 
make communication more patient-centered. Besides, just communicating in a 
more patient-centered way could change providers’ perceptions of patients’ beliefs. 
Using more patient-centered communication enables the healthcare provider to 
learn about patients’ thoughts and concerns and could change their incongruent 
perceptions. The results might indicate that pharmacists and pharmacy technicians 
need to improve their affective and responsive communication skills (e.g. through 
training and educational courses) to become more patient-centered and to explore 
and elicit the actual beliefs of patients more thoroughly. 
Findings from this study indicate that pharmacists and pharmacy technicians differ 
in their concerns about ICS. Pharmacy technicians are somewhat more concerned 
than pharmacists, but they have a similar assessment of the necessity of ICS. The 
result is in line with a previous study that showed that pharmacy technicians held 
slightly more negative general beliefs about medication than pharmacists; to some 
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extent, pharmacy technicians thought medicines to be more harmful, whereas 
pharmacists believed medicines to be slightly more beneficial.
19
 Pharmacy 
technicians and patients do not differ in their own degree of ICS concerns. A possible 
explanation for this similarity is that technicians have more frequently contact with 
patients than pharmacists,
28 
which might influence the pharmacy technicians’ beliefs. 
We showed that pharmacists’ and pharmacy technicians’ perceptions of patients’ 
beliefs and their own beliefs differ from those of patients with asthma, which might 
have clinical implications. More research is needed to study whether this 
incongruence affects patient-provider communication, ICS adherence and 
consequently self-management and patient outcomes, such as quality of life and 
asthma control. 
We suggest that it is important to make pharmacists and pharmacy technicians 
aware of the fact that patients’ beliefs in the necessity of ICS are not as strong as they 
expect. A topic for future research is the question of whether making providers aware 
of their patients’ perceptions is sufficient for them to act in a more patient-centered 
way or whether their own ICS beliefs are more dominant in influencing their 
communicative behavior. The relationship between the agreement between providers’ 
beliefs and patients’ beliefs on the one hand and achieving concordance on the other 
is also a new subject to  investigate. 
 
Limitations 
To our knowledge, this is the first study comparing patients’ ICS beliefs with the 
beliefs of pharmacists and pharmacy technicians. In addition, no previous research 
also took healthcare providers’ perceptions of patients’ beliefs into account, which is 
a valuable addition to the research on provider-related characteristics and 
communication. 
However, there are some limitations. We were not able to make pairwise 
comparisons between pharmacies and their own patients and therefore we could 
not investigate the actual discrepancies between patients’ beliefs and their 
providers’ beliefs and perceptions. Instead, the measured providers’ perceptions 
about patients’ beliefs are, in a way, ‘generalizations’. A more robust methodology 
for this type of study would be a one-to-one comparison where the patient fills out 
the BMQ and the pharmacists or technician fills out the BMQ for that specific 
patient. 
Furthermore, the BMQ was originally developed to measure patients’ medication 
beliefs. In our study, we also used the BMQ to assess the ICS beliefs of pharmacists 
and technicians and their perceptions of patients’ ICS beliefs. As reported in this 
article, the internal consistency of the different ‘concerns’ scales was not high, and 
therefore not all the original items were included in this scale. Because the BMQ was 
not developed and validated for use in this way, the outcomes should be interpreted 
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carefully. In future research, the development and validation of comparable tools is of 
importance in order to measure healthcare providers’ beliefs and their perceptions 
of patients’ beliefs in a sound way. 
Another limitation is that the selection of our sample of patients with asthma 
(symptoms) was based on self-report. Such self-reported diagnostics are not entirely 
reliable because of their subjectivity, and this might have consequences for the 
representativeness of our sample and the implications that follow from our results. 
It is possible that we have included patients with Chronic Obstructive Pulmonary 
Disease (COPD). Because of the differences in the nature and implications of these 
diseases, patients with COPD might have different experiences with and beliefs 
about ICS than patients with asthma. However, suboptimal ICS adherence is a 
problem in patients with COPD as well.
29,30
 Also, it has been found that beliefs (e.g. 
concerns about medication) are related to suboptimal medication adherence in 
patients with COPD.
31,32
 Therefore, the two different patient groups are not likely to 
differ greatly in their ICS beliefs. 
Also, selection bias could have occurred, which can limit the generalizability of 
our results. Participating pharmacists, pharmacy technicians and patients could have 
different characteristics to non-participants because they could be more engaged in 
this topic of research, and therefore could have non-representative beliefs about 
asthma and ICS. The occurrence of selection bias could be an explanation for 
different findings compared to other studies regarding the level of patients’ 
concerns. In addition, the average age of the patients in our study sample was 56.2 
years, which is higher than the average age of the general population of patients 
with asthma in the Netherlands and therefore limits the representativeness of our 
sample.
33 
Finally, the data were obtained in two different periods, in 2011–2012 and in the 
beginning of 2014. This difference might have influenced our outcomes, as 
significant information on ICS might have been published between these two periods, 
making the two periods less comparable. However, there were no new 
developments regarding ICS between the two measurements. 
 
Conclusion 
 
Pharmacists and technicians seem to judge patients to have stronger necessity 
beliefs than is actually the case. When pharmacists and technicians were asked to 
report the views of a ‘typical patient’, they reported patients as being more 
convinced of their need for daily ICS than reflected in the mean ratings for ICS necessity 
beliefs reported by patients. Pharmacists and pharmacy technicians generally hold 
more positive beliefs about ICS than patients with asthma. If pharmacists and 
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technicians assume that patients share their positive views about ICS, this might mean 
that they will be less likely to elicit patients’ ICS doubts and concerns and therefore 
will be less likely to address the beliefs that act as barriers to adherence and 
persistence to essential medication for asthma. 
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Abstract 
 
Background 
Pharmaceutical care is one of the major tasks of pharmacists, which aims to improve 
patient outcomes. Counseling patients with asthma or chronic obstructive 
pulmonary disease about their use of inhaled corticosteroids (ICS) might enhance 
medication adherence and symptom control. Therefore, effective pharmacist–patient 
communication is very important. In this regard, both affective communication, for 
handling emotions, and instrumental communication, for exchanging biomedical 
and lifestyle information, are relevant. Until now, only few studies have explored 
pharmacist–patient communication, and further insight is needed in this regard. The 
aim of this study is to investigate how pharmacists and pharmacy technicians 
communicate about ICS with patients with asthma and/or chronic obstructive 
pulmonary disease, what topics are discussed by them, and whether pharmacists and 
pharmacy technicians differ in their communication during counseling sessions. 
 
Methods 
Patients aged ≥18 years who had used ICS for at least 1 year and filled at least two 
ICS prescriptions in the preceding year were recruited through 12 pharmacies. 
Participants had one counseling session with a pharmacist or a pharmacy technician, 
which was video-recorded. The process and content of the provider–patient 
communication were analyzed using the Roter interaction analysis system, adapted 
to the pharmaceutical setting. 
 
Results 
A total of 169 sessions were recorded and analyzed. The communication appeared 
largely instrumental. Lifestyle, psychosocial issues, and ICS adherence were not 
discussed in detail. The pharmacists had longer conversations and more affective 
talk than the pharmacy technicians. 
 
Conclusion 
Pharmacists and pharmacy technicians may need to pay more attention to ICS 
adherence, lifestyle, and psychosocial topics. They differed in their communication; 
the pharmacists exhibited more affective behavior and discussed medical and 
therapeutic issues more extensively compared to the pharmacy technicians. 
Educational courses for pharmacists and pharmacy technicians could focus more on 
the discussion of adherence, lifestyle, and psychosocial topics with patients. 
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Introduction 
 
According to the Pharmaceutical Care Network Europe definition, “Pharmaceutical 
care is the pharmacist’s contribution to the care of individuals in order to optimize 
medicines use and improve health outcomes”.
1 
The community pharmacist’s role has 
recently been extended from just dispensing to providing guidance in pharmaceutical 
care. Several pharmaceutical care programs and activities have been developed 
to educate and counsel patients with (chronic) medication use, showing some 
promising results in improving outcomes such as disease control and medication 
adherence.
2-5 
Patients with asthma and chronic obstructive pulmonary disease (COPD) could 
especially benefit from these activities. Around 40% of them fail to take their inhaled 
corticosteroids (ICS) as prescribed.
6 
Regular ICS treatment reduces symptoms and 
the frequency of exacerbations and enhances lung function and quality of life.
7,8 
Taking less medication than prescribed (suboptimal adherence) leads to poor 
disease control, morbidity, mortality, and high health care costs.
6
 Many patients with 
asthma (17%–57%) do indeed have poor disease control,
9
 as shown by the high rates 
of emergency room visits and hospital admissions.
10 
Sufficient and correct knowledge about the disease and medication is needed 
to achieve better adherence to antiasthma drugs and have better asthma control.
11,12 
But the knowledge among patients with asthma appears suboptimal.
13 
Many patients 
report taking their medication only when they think they should or when they 
experience shortness of breath.
14 
In addition, 70% of patients using ICS apply 
incorrect inhaler techniques that disenable total absorption of the medication in the 
lungs.
15 
Improving inhaler technique is likely to improve symptom control.
16 
Clearly, educating patients with asthma and COPD about their disease, medication 
use, and inhalation technique is of great importance in enhancing ICS adherence and 
symptom control. This is even more so as patients’ potentially modifiable 
medication beliefs are related to ICS adherence.
17-19 
Patients who have many 
concerns and misconceptions about ICS (e.g. about side effects and drug 
dependency) are more inclined to be nonadherent. Therefore, health care providers 
should try to diminish patients’ concerns and strengthen their ICS necessity beliefs,
17,19
 
by showing empathy and providing reassurance and information about ICS use and 
adherence. However, medication adherence is hardly addressed at all in clinical 
encounters,
20,21
 even though Zolnierek and Dimatteo
22
 showed that the odds of 
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patient adherence are 2.16 times higher when a physician communicates effectively. 
To perform their new role as communicators, pharmacists and pharmacy 
technicians receive training in patient education and communication in 
undergraduate and postgraduate courses.
23 
However, so far, little is known about 
the extent to which they actually apply these skills in counseling sessions.
24 
Recent 
research indicates that pharmacists focus mainly on biomedical issues and pay little 
attention to psychosocial issues.
25,26 
In counseling sessions, pharmacists or technicians can discuss patients’ 
experiences with (chronic) medication, usually in a private consulting room at the 
community pharmacy. Although some pharmacies do offer counseling sessions to 
patients about their ICS use, these sessions are not common practice in the 
Netherlands yet.
23,27 
Furthermore, it is unknown whether pharmacists and technicians are equally able 
to conduct these sessions. For instance, there are differences in the undergraduate 
and postgraduate courses for pharmacists and technicians. As technicians have 
more frequent contacts with patients than pharmacists,
28
 they might be more 
experienced in patient communication. A study of patients’ perceived barriers in 
communication with their health care provider revealed that patients experience 
fewer barriers to participation in a visit with a nurse than with a physician.
29 
This 
might also apply to pharmacists and technicians, with fewer barriers in talks with 
technicians. However, pharmacists might have a more persuasive communication 
style by virtue of their position, as they are the managers and often owners of the 
pharmacy. Getting insight into the differences in the communication content and 
process might have relevance for session and patient outcomes and might indicate who 
is most capable of performing these counseling sessions and who might need 
additional communication training. 
The aim of this study was therefore to explore 1) how pharmacists and pharmacy 
technicians communicate with patients with asthma and/or COPD about ICS during 
a counseling session (communication process); 2) what topics are discussed during 
these sessions (communication content); and 3) to what extent pharmacists and 
technicians differ in their communication. Based on practice guidelines about 
asthma and COPD, we thereby focus especially on the following communicative 
aspects:
30-32
 affective communication (e.g. showing empathy and giving 
reassurance), providing information about asthma/COPD and ICS, discussing 
adherence, inhalation technique, side effects, concerns, and necessity beliefs about 
ICS, and lifestyle topics (e.g. smoking and exercise). 
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Materials and methods 
 
Setting 
This observational study is part of a larger research project examining the 
communication of community pharmacists and technicians with patients with 
asthma and/or COPD, which was performed between September 2011 and February 
2012. Data were collected with the help of pharmacists belonging to the Utrecht 
Pharmacy Practice Network for Education and Research (UPPER), and the work 
was conducted in compliance with the requirements of the UPPER institutional 
review board of the Department of Pharmacoepidemiology and Clinical 
Pharmacology. A total of 130 community pharmacies were approached via email by 
UPPER and invited to participate, with 12 pharmacies actually participating. No 
selection criteria were applied for pharmacies’ participation. 
Per pharmacy, recruited patients were randomly assigned to an intervention 
group or a control group. Randomization was performed using a statistical 
program (Stata Version 12.1), which generated lists consisting of a random series of 
0s and 1s. We generated a separate list for each pharmacy. A “0” referred to 
assignment to the control group, and a “1” referred to assignment to the 
intervention group. By following the order of the numbers on the list, patients were 
assigned to the two groups in the sequence of their registration for participation. 
Patients in the intervention group had a counseling session at the community 
pharmacy; patients in the control group had no session and only completed 
questionnaires. For the purpose of this study, only data from patients who had a 
counseling session were used. 
At each participating pharmacy, one pharmacist and one pharmacy technician 
performed individual counseling sessions with patients with asthma and/or COPD. 
Each pharmacist selected a pharmacy technician from his/her own team, so 12 
pharmacists and 12 technicians held sessions. Each patient had one session with 
either a pharmacist or a pharmacy technician. The number of counseling sessions 
depended on the number of participating patients in that particular pharmacy and 
on an agreed maximum number of participants per pharmacy. 
To get an authentic impression of pharmacists’ and technicians’ communication 
styles, only general instructions were provided about the counseling sessions, that is, 
“discuss the patient’s experience with ICS use, the effectiveness and (possible) side-
effects of ICS, and whether the patient uses ICS in an appropriate way”. 
 
Ethical approval 
The Medical Ethics Committee of the University Medical Center Utrecht assessed the 
research proposal and concluded that ethical approval was not required because the 
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study did not fall within the remit of the Law on Medical Scientific Research involving 
Human Beings. 
 
Participants 
Patient recruitment took place through the participating pharmacies. Anatomical 
Therapeutic Chemical classification system codes for ICS and combination 
products of β2-agonists and ICS were used to determine in the pharmacy system to 
which patients’ ICS had been dispensed. Patients were eligible if they were aged 18 
years or older, had been diagnosed with asthma or COPD (based on self-report), had 
been using ICS for at least 1 year, and had filled two or more ICS prescriptions in the 
preceding year. Patients living in an institution were excluded because they might 
receive other or additional care and counseling, which might influence the 
generalizability of the study results. Patients did not receive a reimbursement for 
participation. 
 
Procedure 
At each pharmacy, all eligible patients were invited to participate in the study, up to a 
maximum of 200 patients per pharmacy. If there were >200 eligible patients, a random 
subset of 200 patients were selected. An information pack was sent by post to 1,952 
potentially eligible patients by their pharmacist, containing an invitation letter, a 
questionnaire, and an informed consent form. Patients were informed about the 
procedure and the videotaping of the consultations, and they had the opportunity to 
ask questions about the study and the videotaping of the session before consenting to 
participation. The completed questionnaire and a signed informed consent form had 
to be returned for study participation. A researcher contacted the participants by 
phone to make an appointment for a counseling session with a pharmacist or 
technician within 2 months after inclusion. The schedules for pharmacists and 
technicians had been determined beforehand. Depending on patients’ preferences 
for a date or time for an appointment, the consultation was scheduled. These sessions 
were performed in Dutch, took place in a private room, and were recorded by an 
unmanned camera, which was directed at the pharmacist or technician. 
 
 
Materials and measurements 
 
Questionnaire 
The questionnaire consisted of questions about sociodemographics, the medical 
indication for the ICS prescription (asthma/asthma symptoms and/or COPD or 
unknown), and other questions related to the patient’s medical condition and ICS 
use. 
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Communication measurements 
Analyses of the video-recorded sessions were performed using an extended version 
of the Roter interaction analysis system (RIAS). RIAS is a validated instrument for 
coding both provider and patient communication, applicable to the pharmacy 
setting.
33-35
 Each small meaningful unit of speech (an utterance) is coded. 
RIAS distinguishes two categories of communication: 1) affective or 
socioemotional communication and 2) instrumental communication, further divided 
into task- and process-oriented communication. Affective communication includes 
expressions of empathy, concern, optimism, and understanding, which contribute to a 
therapeutically effective provider–patient relationship.
36
 Instrumental 
communication focuses on the exchange of medical and psychosocial information 
and advice (task-oriented communication) and process-oriented utterances that 
guide the process of the conversation, like giving instructions (i.e. “orientations”). 
The four main task-oriented RIAS categories are 1) medical, 2) therapeutic, 3) 
lifestyle/social, and 4) psychosocial. For the purpose of this study, the task-oriented 
categories were further divided into 36 content categories, including asthma- and 
COPD-specific items derived from existing communication literature and guidelines 
for asthma and COPD,
31
 from the consumer quality index asthma/COPD,
30 
and from 
the Dutch pharmacy COPD guideline.
32 
This literature was used to indicate topics 
that are relevant for patients with asthma and/or COPD and that could be discussed 
during counseling sessions. Examples of specific medical and therapeutic content 
categories are medical history, current health status, ICS side effects, and ICS 
adherence. Each main category furthermore had one “residual category” for utterances 
that belonged to that particular main category but did not fit into any of the specified 
categories (i.e. “medical, other”, “ICS, other”, “lifestyle, other”, and “psychosocial 
ICS, other”). Utterances about the study or comments about the recording were 
labeled as “other”. For each task-oriented utterance, it was established whether it 
concerned a question (“question”), the provision of information (“giving 
information”), or an advice for the patient to change behavior (“counseling”) (Table 
S1). 
Furthermore, the proportion of utterances made by the pharmacists, pharmacy 
technicians, and patients was determined as a global indicator of conversational 
contribution. The videotapes were coded by three coders from the research team. 
Observer XT7 software was used to code the communication directly from the 
videotapes.
37 
 
Interrater reliability 
Interrater reliability was tested using the intraclass correlation coefficient (ICC) and 
calculated for all main categories with a mean frequency >2%, except for the “other” 
categories.
38 
One coder recoded a random 10% of the two main coders’ 
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consultations. ICC reliability averaged 0.85 (range 0.37–0.98) for pharmacist and 
technician categories and 0.89 (0.70–0.97) for patient categories, which indicates 
moderate to good reliability, except for the category “orientations”, which had an ICC 
of 0.37. Given the low ICC of the orientations category, no results are reported for this 
category. 
 
Statistical analysis 
Multilevel analysis was carried out to allow for the clustering of patients in 
pharmacies. Weighted mean and standard errors of all communication categories 
were calculated for pharmacists and technicians separately and have been 
reported. To control for visit length, weighted mean per category was divided by the 
total number of utterances and multiplied by 100%. 
Furthermore, we calculated the number of sessions in which a particular content 
category was mentioned by the pharmacist or the technician once only, more than once, 
or not at all, whether as a question, piece of advice, or information. Analyses were 
performed using MLwiN Version 2.25. To determine whether patients’ 
sociodemographic characteristics differed between the pharmacists’ sample and 
those of pharmacy technicians, two-sample proportion tests and Student’s t-tests 
were performed using Stata Version 12.1. Descriptive statistics were calculated using 
Stata Version 12.1. 
 
 
Results 
 
Study sample 
A total of 429 patients returned a completed consent form and questionnaire. One 
hundred and ninety-nine patients were assigned to the intervention group, of whom 
30 patients (15.1%) dropped out for one of the following reasons: they could not be 
reached by phone/email, involuntary withdrawal (e.g. due to poor health), were no 
longer using ICS, had recently had a session about ICS or asthma, or did not want to 
participate after all. One hundred and sixty-nine patients received a counseling 
session at their pharmacy. Of these, 93 patients (55.0%) were female and 76 (45.0%) 
male. The mean age was 63.1 years (SD=13.9). Half of the 12 pharmacists were male 
and all the 12 technicians were female. The mean age of the pharmacists was 36.7 
years (SD=11.5), and the mean age for technicians was 35.4 years (SD=11.9) (Table 
5.1). The pharmacists performed 7.2 sessions on average (range: 3–11 sessions) and 
pharmacy technicians 6.9 sessions (range: 3–10 sessions). The sociodemographic 
characteristics of patients in the pharmacists’ sample did not differ significantly from 
those in the pharmacy technicians’ sample. 
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Counseling sessions 
Pharmacists’ counseling sessions lasted significantly longer than those of pharmacy 
technicians (mean ± standard error: 16.46±0.80 minutes and 11.34±0.80 minutes, 
respectively; p<0.001). Both categories of professionals talked more than patients in 
terms of the percentage of utterances (pharmacists accounted for 55.0% of the 
utterances in their sessions, technicians 53.2%), and most of the communication 
consisted of instrumental talk (Table 5.1). 
 
Table 5.1 Patient, pharmacist, and pharmacy technician characteristics and summary of pharmacist–
 patient and technician–patient communication 
 
 
Patient characteristics 
Pharmacist–
patient sessions 
n=86 
Technician–patient 
sessions 
n=83 
Total n=169 
Female 47 (54.7%) 46 (55.4%) 93 (55.0%) 
Age, years 
Mean (years) ± SD (range) 63.7±13.4 (26–88) 62.5±14.5 (28–87) 63.1±13.9 (26–88) 
Age group, years 
18–44 8 (9.3%) 12 (14.5%) 20 (11.8%) 
45–64 32 (37.2%) 29 (34.9%) 61 (36.1%) 
>64 46 (53.5%) 42 (50.6%) 88 (52.1%) 
Educational levela,b 
Low 33 (38.4%) 37 (44.6%) 70 (41.4%) 
Intermediate 17 (19.8%) 16 (19.3%) 33 (19.5%) 
High 35 (40.7%) 29 (34.9%) 64 (37.9%) 
Diagnosisc 
Asthma 34 (39.5%) 34 (41.0%) 68 (40.2%) 
COPD 21 (24.4%) 21 (25.3%) 42 (24.9%) 
Asthma and COPD 17 (19.8%) 16 (19.3%) 33 (19.5%) 
Unknown 14 (16.3%) 12 (14.5%) 26 (15.4%) 
Pharmacist and pharmacy 
technician characteristics 
Pharmacists 
n=12 
Pharmacy technicians 
n=12 
 
Age group, years    
Mean (years) ± SD (range) 36.7±11.5 (24–57) 35.4±11.9 (23–53)  
Female 6 (50%) 12 (100%)  
Number of years since graduating 
Mean (years) ± SD (range) 11.1±10.4 (0–32) 14.4±11.8 (2–34)  
 - Table 5.1 continues -  
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Pharmacist–patient and pharmacy technician–patient communication  
 Pharmacist Patient Technician Patient 
Total communicationd 55.0% 45.0% 53.2% 46.8% 
Affective communication 20.2% 16.7% 19.4% 16.3% 
Instrumental communication 34.8% 28.3% 33.8% 30.5% 
Session length 
Meane (minutes) ± SE(range) 16.46±0.80 (5.42–33.30) 11.34±0.80 (4.23–26.73) 
Notes: aTwo missing. bLow: no education, primary school, prevocational secondary education (VMBO), lower vocational 
secondary education (LBO), junior general secondary education (MULO/MAVO); intermediate: upper vocational 
secondary education (MBO), senior general secondary education (HAVO), preuniversity education (VWO); high: 
university of applied sciences (HBO), university (WO). cDiagnosis based on self-report. dPercentages are based on 
weighted mean. eWeighted mean. Abbreviations: COPD, chronic obstructive pulmonary disease; SE, standard error. 
 
 
Affective and process-oriented communication 
Table 5.2 shows the weighted mean of the affective and process-oriented 
communication behaviors per counseling session. Pharmacists and technicians 
mainly exhibited social behavior, expressed approval and agreement, and gave 
verbal attention and reassurance to patients. Patients showed similar behaviors and 
also expressed concerns or worries. With respect to process-oriented 
communication, pharmacists and technicians paraphrased and checked for 
understanding and asked the patient for an opinion at least once per session. 
Patients mainly paraphrased and checked for understanding. 
 
Table 5.2 Weighted mean (SE) of affective behaviors and process-oriented behaviors of pharmacists, 
 technicians, and patients in counseling sessions 
 Pharmacists’ and technicians’ 
behavior 
Patients’ behavior 
 Pharmacists Technicians Pharmacists’ 
sessions 
Technicians’ 
sessions 
Affective parta 89.02 (5.48)* 63.72 (5.53)* 73.55 (5.06)** 53.66 (5.12)** 
Social behavior 10.55 (1.68)** 4.86 (1.70)** 10.47 (2.01) 6.52 (2.04) 
Approval 6.91 (0.56)* 3.68 (0.56)* 1.70 (0.24) 1.45 (0.24) 
Agreements 59.95 (4.91)** 48.50 (4.94)** 54.54 (3.67)* 39.61 (3.71)* 
Verbal attention 3.91 (0.56)** 2.00 (0.57)** 0.12 (0.04) 0.06 (0.04) 
Shows concern or worry 0.44 (0.09)*** 0.15 (0.10)*** 1.95 (0.37) 1.37 (0.38) 
Reassurance 7.77 (0.62)* 5.16 (0.63)* 3.82 (0.42) 3.40 (0.43) 
Disagree 0.24 (0.05)** 0.05 (0.05)** 0.95 (0.57) 1.39 (0.57) 
- Table 5.2 continues -  
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 Pharmacists’ and technicians’ behavior Patients’ behavior 
 Pharmacists Technicians Pharmacists’ 
sessions 
Technicians’ 
sessions 
Instrumental part 
Process-orienteda 28.63 (2.15)* 21.45 (2.16)* 4.69 (0.62) 4.08 (0.62) 
 Orientationsb 8.26 (0.98)* 4.15 (0.98)* 0.28 (0.07) 0.14 (0.07) 
 Paraphrase/check for 
 understanding 
17.91 (1.70)*** 15.25 (1.70)*** 4.19 (0.57) 3.73 (0.57) 
 Bid for repetition 0.04 (0.02) 0.05 (0.02) 0.14 (0.05) 0.14 (0.05) 
 Ask for understanding 0.56 (0.13) 0.44 (0.13) 0.06 (0.03) 0.07 (0.03) 
 Ask for opinion 1.89 (0.26) 1.58 (0.26) 0.00 (0.01) 0.01 (0.01) 
 Request for services  
 (patient category) 
– – 0.04 (0.02) 0.00 (0.02) 
Notes: aTotals have been calculated using the model and can be different from the total of individual categories. bDue to 
a low intraclass correlation coefficient (ICC), no results have been reported in this article for this category. *Significant at 
p<0.001. **Significant at p<0.01. ***Significant at p<0.05. 
Abbreviation: SE, standard error. 
 
Task-oriented communication 
Several medical and therapeutic topics were discussed during the counseling sessions 
(Tables 5.3 and 5.4). In the following paragraphs, we describe the topics on which on 
average at least one utterance per session was made by pharmacists, technicians, or 
patients. 
 
Medical and therapeutic communication 
Pharmacists and technicians made at least one utterance per session about each of 
the following topics: “medical, other”, inhaler and inhalation technique, non-ICS 
treatment (other medication used by the patient), ICS medicinal effects, side 
effects, dosage and time of inhalation of ICS, current health status, adherence to 
ICS, reason for use, and “ICS, other”. In contrast to technicians, pharmacists also 
asked at least once about patients’ current health status and medical effects, and 
gave information about explanation about asthma/COPD more than once. 
Patients made at least one utterance per session about the following issues: 
inhaler and inhalation technique, non-ICS medication, “medical, other”, dosage and 
time of inhalation, current health status, medical history, side effects, contact with 
health care providers about asthma/COPD, “ICS, other”, ICS medicinal effects, ICS 
adherence, lung function test, contact with other health care providers about ICS, 
and reason for use. 
 
 
Table 5.3 Weighted mean (SE) of task-oriented behaviors of pharmacists and pharmacy technicians during counseling sessions 
Task-oriented communication Question Giving information Counseling 
Pharmacists Technicians Pharmacists Technicians Pharmacists Technicians 
Medicala 3.42 (0.43)* 1.86 (0.43)* 9.25 (1.35)* 3.60 (1.36)* 0.50 (0.19) 0.44 (0.19) 
Prevalence 0 0 0.06 (0.04) 0.00 (0.04) 0 0 
Prognosis 0 0 0.02 (0.01) 0.00 (0.01) 0 0 
Exacerbations  0.06 (0.02) 0.00 (0.02) 0.06 (0.04) 0.04 (0.04) 0 0 
Current health status  1.31 (0.19)* 0.62 (0.19)* 1.87 (0.28) 1.31 (0.28) 0.00 (0.01) 0.01 (0.01) 
Medical history 0.37 (0.10) 0.20 (0.10) 0.31 (0.08) 0.22 (0.08) 0 0 
Heredity 0.00 (0.05)** 0.09 (0.05)** 0.03 (0.05) 0.09 (0.05) 0 0 
Contact other health care 
providers about asthma/COPD 
0.49 (0.10) 0.54 (0.10) 0.53 (0.14) 0.37 (0.14) 0.15 (0.11) 0.39 (0.11) 
Lung function test 0.32 (0.10) 0.08 (0.10) 0.96 (0.32)** 0.13 (0.32)** 0.19 (0.08) 0.00 (0.08) 
Explanation about asthma/COPD 0.01 (0.01) 0.00 (0.01) 2.65 (0.62)* 0.06 (0.63)* 0 0 
Medical, other  0.85 (0.21)*** 0.33 (0.21)*** 2.74 (0.58) 1.47 (0.59) 0.15 (0.04) 0.05 (0.05) 
Therapeutic: ICS treatmenta 10.97 (0.87) 10.57 (0.87) 46.53 (3.17)* 33.42 (3.20)* 11.25 (1.45) 11.12 (1.46) 
Reason for use/need 0.45 (0.10)** 0.20 (0.10)** 1.03 (0.14)*** 0.54 (0.14)*** 0.05 (0.03) 0.05 (0.03) 
Dosage 1.27 (0.16) 0.95 (0.16) 3.30 (0.35)* 1.27 (0.35)* 0.86 (0.17) 0.53 (0.17) 
Adherence 0.42 (0.10) 0.45 (0.10) 1.38 (0.26) 1.21 (0.26) 0.17 (0.14)*** 0.49 (0.14)*** 
Medicinal effects 1.11 (0.23) 0.83 (0.23) 7.36 (0.75)* 3.30 (0.76)* 0.02 (0.01) 0.00 (0.01) 
Side effects 1.36 (0.29)** 1.90 (0.29)** 3.87 (0.56) 3.84 (0.57) 0.13 (0.04) 0.05 (0.04) 
Inhaler/inhalation  5.05 (0.48) 4.76 (0.48) 25.29 (2.24)*** 19.50 (2.26)*** 9.41 (1.41) 9.49 (1.42) 
Contact other health care 
providers about ICS 
0.40 (0.10) 0.55 (0.10) 0.39 (0.10) 0.48 (0.10) 0.50 (0.12) 0.47 (0.12) 
Self-management 0.05 (0.02)*** 0.00 (0.02)*** 0.17 (0.07) 0.07 (0.07) 0.01 (0.01) 0.00 (0.01) 
Facilitators 0.07 (0.06) 0.14 (0.06) 0.88 (0.20) 0.84 (0.20) 0.01 (0.01) 0.00 (0.01) 
Barriers 0.06 (0.03) 0.04 (0.03) 0.52 (0.12) 0.36 (0.12) 0 0 
ICS, other 0.69 (0.12) 0.71 (0.13) 2.23 (0.47) 1.99 (0.47) 0.06 (0.03) 0.06 (0.03) 
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Task-oriented communication Question Giving information Counseling 
Pharmacists Technicians Pharmacists Technicians Pharmacists Technicians 
Therapeutic: non-ICStreatmenta 2.31 (0.27)*** 1.61 (0.27)*** 12.34 (1.32)** 7.46 (1.34)** 1.21 (0.31) 1.33 (0.32) 
Lifestyle/sociala 0.74 (0.18)*** 0.40 (0.18)*** 3.31 (0.56)** 1.43 (0.57)** 0.17 (0.07) 0.08 (0.07) 
Smoking 0.22 (0.10) 0.19 (0.10) 0.38 (0.14) 0.18 (0.14) 0.03 (0.02) 0.00 (0.02) 
Exercise 0.05 (0.03) 0.04 (0.03) 0.43 (0.14) 0.12 (0.14) 0.08 (0.05) 0.05 (0.05) 
Weight 0 0 0 0 0 0 
Nutrition 0.02 (0.01) 0.00 (0.01) 0.11 (0.06) 0.02 (0.06) 0.01 (0.01) 0.00 (0.01) 
Stress 0 0 0.00 (0.01) 0.02 (0.01) 0 0 
Drugs 0.02 (0.02) 0.00 (0.02) 0.05 (0.03) 0.00 (0.03) 0 0 
Influenza vaccine 0.02 (0.01) 0.00 (0.01) 0.00 (0.03) 0.04 (0.03) 0 0 
Living environment 0.15 (0.07) 0.14 (0.07) 0.89 (0.27) 0.41 (0.27) 0.01 (0.01) 0.00 (0.01) 
Social context 0.07 (0.02) 0.02 (0.02) 1.20 (0.28)*** 0.52 (0.28)*** 0.01 (0.02) 0.04 (0.02) 
Lifestyle, other 0.19 (0.07)*** 0.01 (0.07)*** 0.30 (0.09) 0.17 (0.09) 0.02 (0.01) 0.00 (0.01) 
Psychosocial/feelingsa 0.32 (0.08) 0.25 (0.08) 1.18 (0.26) 1.09 (0.26) 0.03 (0.02) 0.00 (0.02) 
ICS concerns 0.01 (0.01) 0.00 (0.01) 0.14 (0.04)*** 0.01 (0.04)*** 0 0 
ICS necessities 0 0 0.08 (0.04) 0.10 (0.04) 0 0 
Psychosocial ICS, other 0.30 (0.07) 0.20 (0.07) 0.66 (0.15) 0.59 (0.15) 0.03 (0.02) 0.00 (0.02) 
Non-ICS 0.01 (0.03) 0.05 (0.03) 0.29 (0.13) 0.39 (0.13) 0 0 
Other 0.41 (0.08)* 0.04 (0.08)* 20.72 (1.52)** 15.09 (1.54)** 0.01 (0.01) 0.00 (0.01) 
Totala 18.15 (1.22)* 14.70 (1.22)* 93.31 (5.57)* 61.87 (5.61)* 13.13 (1.57) 12.90 (1.58) 
Notes: aTotals have been calculated using the model and can be different from the total of individual categories. *Significant at p<0.001. **Significant at p<0.01. ***Significant at p<0.05. 
Abbreviations: SE, standard error; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids. 
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Table 5.4 Weighted mean (SE) of task-oriented behaviors of patients in sessions with 
 pharmacists and pharmacy technicians 
Task-oriented communication Question Giving information 
 Pharmacists’ 
sessions 
Technicians’ 
sessions 
Pharmacists’ 
sessions 
Technicians’ 
sessions 
Medicala 0.33 (0.07)* 0.12 (0.07)* 22.94 (2.20)* 17.01 (2.24)* 
Prevalence 0.01 (0.01) 0.00 (0.01) 0 0 
Prognosis 0 0 0 0 
Exacerbations  0 0 0.21 (0.10) 0.15 (0.10) 
Current health status  0.06 (0.03) 0.06 (0.03) 5.52 (0.53) 4.31 (0.53) 
Medical history 0.03 (0.02) 0.01 (0.02) 5.01 (0.66)** 2.24 (0.68)** 
Heredity 0 0 0.11 (0.12) 0.30 (0.12) 
Contact other health care 
providers about asthma/COPD 
0.02 (0.01) 0.01 (0.01) 2.83 (0.41) 2.46 (0.42) 
Lung function test 0.08 (0.06) 0.02 (0.06) 1.86 (0.35) 0.99 (0.36) 
Explanation about 
asthma/COPD 
0.07 (0.03) 0.00 (0.03) 0.15 (0.05) 0.06 (0.05) 
Medical, other  0.06 (0.02) 0.02 (0.02) 7.33 (1.47) 6.62 (1.49) 
Therapeutic: ICStreatmenta 2.62 (0.35) 2.28 (0.36) 44.19 (3.08) 40.72 (3.10) 
Reason for use/need 0.06 (0.05) 0.07 (0.05) 1.19 (0.18) 1.00 (0.18) 
Dosage 0.36 (0.10)* 0.08 (0.10)* 5.67 
(0.49)*** 
3.92 (0.49)*** 
Adherence 0.04 (0.02) 0.01 (0.02) 1.95 (0.31) 1.43 (0.31) 
Medicinal effects  0.15 (0.04) 0.05 (0.04) 2.44 (0.38) 1.82 (0.39) 
Side-effects  0.24 (0.08) 0.23 (0.08) 3.86 (0.57) 3.91 (0.58) 
Inhaler/inhalation  1.52 (0.26) 1.64 (0.26) 22.76 (2.11) 22.64 (2.12) 
Contact other health care 
providers about ICS 
0.08 (0.02) 0.02 (0.02) 1.62 (0.30) 2.11 (0.30) 
Self-management  0 0 0.16 (0.09) 0.29 (0.09) 
Facilitators  0.01 (0.01) 0.01 (0.01) 0.51 (0.15) 0.56 (0.15) 
Barriers  0.02 (0.02) 0.02 (0.02) 0.92 (0.19)* 0.34 (0.19)* 
ICS, other  0.14 (0.04) 0.13 (0.04) 2.81 (0.29) 2.47 (0.29) 
Therapeutic: Non-
ICStreatmenta 
0.74 (0.15) 0.59 (0.15) 15.21 (1.49) 12.40 (1.52) 
Lifestyle/sociala 0.17 (0.05)** 0.00 (0.05)** 9.29 (1.43)* 5.74 (1.45)* 
Smoking 0 0 0.99 (0.31) 0.62 (0.31) 
Exercise 0.05 (0.02) 0.00 (0.02) 1.99 (0.34)* 1.01 (0.35)* 
Weight 0 0 0.00 (0.09) 0.18 (0.09) 
Nutrition 0 0 0.30 (0.19) 0.33 (0.19) 
Stress 0 0 0.01 (0.03) 0.04 (0.03) 
Drugs 0 0 0.16 (0.08) 0.00 (0.08) 
Influenza vaccine 0 0 0.04 (0.06) 0.18 (0.06) 
(Living) environment 0.07 (0.04) 0.00 (0.04) 1.52 (0.25)** 0.70 (0.25)** 
Social context 0.05 (0.02)* 0.00 (0.02)* 2.75 (0.67) 1.60 (0.68) 
Lifestyle, other 0.01 (0.01) 0.00 (0.01) 1.43 (0.37) 0.96 (0.37) 
Psychosocial/feelingsa 0.09 (0.04) 0.05 (0.04) 5.84 (0.78) 5.37 (0.79) 
ICS concerns 0.05 (0.02) 0.02 (0.02) 0.98 (0.21)* 0.45 (0.21)* 
ICS necessities 0.02 (0.01) 0.00 (0.01) 0.51 (0.13) 0.44 (0.13) 
Psychosocial ICS, other 0.02 (0.01) 0.01 (0.01) 2.14 (0.37) 2.05 (0.37) 
Non-ICS 0.00 (0.01) 0.01 (0.01) 2.15 (0.55) 2.39 (0.56) 
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Task-oriented 
communication 
Question Giving information 
 Pharmacists’ 
sessions 
Technicians’ 
sessions 
Pharmacists’ 
sessions 
Technicians’ 
sessions 
Other 0.44 (0.09) 0.21 (0.09) 17.92 (1.31)** 11.89 (1.34)** 
Totala 4.38 (0.49) 3.22 (0.50) 115.40 (6.28)*** 92.77 (6.36)*** 
Notes: aTotals have been calculated in the model and can be different from the total of individual categories. 
*Significant at p<0.05. **Significant at p<0.01. ***Significant at p<0.001. 
Abbreviations: SE, standard error; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids. 
 
 
Lifestyle and social context communication 
Pharmacists gave some social context information, but other lifestyle and social 
context topics were not mentioned more than once. Patients gave information 
about physical activity, social context, the (living) environment, and “lifestyle, 
other”. 
 
Psychosocial/feelings communication 
Concerning psychosocial information, patients gave information about how they felt 
about non-ICS medication and “ICS, other”. Pharmacists and technicians addressed 
almost no psychosocial topics. 
 
Differences in communication between pharmacists and pharmacy technicians in 
their sessions 
Below, we describe the differences between pharmacists and pharmacy 
technicians in communication during the counseling sessions. Only significant 
differences (p<0.05) are reported. 
Pharmacists used more affective utterances per session on average than 
technicians. Patients did not differ in the number of affective utterances in their 
communication with pharmacists or technicians, except for giving agreements. 
Patients agreed more frequently in sessions with pharmacists than with technicians. 
With respect to process-oriented communication, pharmacists and technicians 
differed in the number of utterances paraphrasing/checking for understanding. 
Patients had the same number of process-oriented utterances during sessions with 
pharmacists and technicians. 
 
Medical and therapeutic information 
The pharmacists were more likely to ask questions about the following topics than 
the technicians: patients’ current health status, reason for ICS use, and other 
medication. Questions about side effects were asked more often by technicians 
than by pharmacists. Patients were more likely to ask questions about dosage and 
time of inhalation of ICS during sessions with pharmacists than with technicians. 
116 Chapter 5 
Pharmacists were more likely to give information about a lung function test, 
asthma/COPD, reason for ICS use, dosage and time of inhalation, ICS effects, inhaler 
and inhalation technique, and other medication. Patients were more likely to 
provide information to pharmacists than technicians about the following topics: 
medical history, dosage and time of inhalation, and barriers. Technicians were more 
likely to give advice about ICS adherence than pharmacists. 
 
Lifestyle and social context information 
Pharmacists gave information about the social context more often than technicians. 
Patients gave information to pharmacists more often than to technicians about 
physical activity and the (living) environment. 
 
Psychosocial information/feelings 
Pharmacists and technicians differed in giving information regarding concerns about 
ICS, which was mentioned on average less than once a session. Patients also differed 
in giving information about this topic; they talked more often about ICS concerns 
in sessions with pharmacists than in sessions with technicians. 
 
Number of sessions in which topics were discussed 
Several clinically relevant topics were not discussed during many of the counseling 
sessions (Table S2). The comparison between pharmacists and technicians revealed 
that questions about current health status were asked more often by pharmacists 
than by technicians, in 26 versus eleven sessions, respectively. Pharmacists gave an 
explanation about asthma more than once in 22 sessions; technicians did so in three 
sessions. Pharmacists paid attention more than once to the reason for ICS use in 26 
sessions and to dosage in 55 sessions, whereas technicians only did so in 12 and 25 
sessions, respectively. Technicians asked more than once about side effects in 42 
sessions, whereas pharmacists did so in 29 sessions. Lifestyle/social categories were 
hardly mentioned. Smoking, the (living) environment, and the social context were 
discussed in a couple of sessions. In addition, psychosocial aspects or feelings were 
seldom discussed. 
 
Outcomes controlled for visit length 
As stated before, pharmacists’ sessions lasted longer than those of technicians. After 
controlling for visit length, most of the differences between pharmacists and 
technicians in communication behaviors remained significant. This was also the case for 
the differences found in patient communication during sessions with pharmacists 
and technicians after controlling for visit length (Table S3). 
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After controlling for visit length, differences between pharmacists’ and technicians’ 
communication remained significant for the following affective categories: social 
behavior, approval, verbal attention, showing concerns/worry, and disagreeing. The 
differences in the number of questions about current health status, heredity, “medical, 
other”, side effects, “lifestyle, other”, and “other” also remained significant. In 
addition, differences in paraphrasing/checking for understanding and giving 
information about the lung function test, explanation about asthma/COPD, dosage, 
medicinal effects, and ICS concerns were still significant after controlling for visit 
length, as well as counseling about adherence. 
For patient utterances, the number of questions about dosage, giving 
information about medical history, the (living) environment, and ICS concerns still 
differed between sessions with pharmacists and technicians after controlling for visit 
length. 
 
 
Discussion 
 
Many important issues were addressed during the counseling sessions. However, 
pharmacists and technicians could pay more attention to some topics. Some 
differences in communication have been found between pharmacists and pharmacy 
technicians. 
The counseling sessions consisted largely of instrumental talk. Medical and 
therapeutic topics were frequently discussed, such as current health status, inhaler 
and inhalation technique, side effects, dosage and time of inhalation, and ICS 
medicinal effects. Pharmacists and pharmacy technicians discussed adherence to a 
limited degree only. In this respect, counseling sessions reflect those of other health 
care providers: this topic is often avoided during patient–provider interactions.
21,31 
 
Lifestyle and psychosocial issues were hardly addressed by pharmacists and 
technicians, while patients did mention these topics. As concerns have relevance for 
adherence to medication,
18,39 
there might be room for improvement in discussing 
patients’ concerns about ICS and why it is necessary to use them. Pharmacists and 
technicians could also pay more attention to lifestyle topics, such as smoking habits 
and exercise. 
Pharmacists and technicians talked with the patients extensively about the inhaler 
and inhalation technique, clearly the main aim of the session. In addition, medication 
other than ICS (the category “non-ICS treatment”) was often discussed, such as 
bronchodilators (relievers). Because bronchodilators are often used in combination 
with ICS, pharmacists and technicians probably discuss these to check the inhalation 
technique as well as the effectiveness of the medication. 
Remarkably, patients raised very few questions. On average, they only asked 
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questions about the inhaler and inhalation technique more than once per session. This 
suggests either that they did not have much to ask or that there was not enough 
opportunity to pose questions. Pharmacists and technicians could invite patients 
more explicitly to ask questions. 
An important aspect concerning pharmacist–patient communication is the way 
patients view the pharmacists’ role (i.e. tasks and responsibilities). A few studies 
have shown that some groups of patients have positive views about pharmacists’ 
enhanced role in disease management and medication advice.
40,41 
However, other 
studies have found that patients do not perceive pharmacists as having a significant 
role in patient counseling, medication management, or monitoring; patients believe 
this to be primarily the task of physicians.
42-44 
These findings could be a reason for 
patients’ possible reticence in posing questions and discussing medical, lifestyle, and 
psychosocial issues. 
When comparing pharmacists’ and technicians’ sessions, pharmacists showed 
more affective behavior than technicians, and they also discussed some task-
oriented topics more extensively. Although pharmacists’ sessions lasted 1.5 times 
longer than those of technicians, these differences could not be fully explained by 
the longer visit length of the pharmacists’ sessions. In contrast to pharmacists and 
technicians, patients did not differ in their affective and process-oriented 
communications when being counseled by one or the other professional. 
Pharmacist and pharmacy technicians spoke more than patients (55.0% and 
53.2% of the utterances, respectively). Although this indicates that the providers 
made a greater conversational contribution than patients, we think the share of 
provider–patient communication is fairly balanced because the percentages are close 
to the middle (i.e. 50%). 
We can compare our findings with only a few studies. Because of dissimilarities 
in study setting and health care providers, these findings are difficult to compare. 
When comparing our findings with general practitioner–patient communication, no 
remarkable differences were found. Pharmacists and technicians in our study 
showed ~5% more affective behavior than general practitioners, which could be 
explained to a large extent by the many agreements that pharmacists and 
technicians expressed.
20 
General practitioners did not discuss lifestyle/social and 
psychosocial topics in much depth; however, pharmacists and technicians discussed 
them even less. Our findings also confirm the results of a simulated patient study of 
Chong et al.
25 
about antidepressants, which showed that pharmacists’ 
communication is merely focused on biomedical topics and that lifestyle and 
psychosocial topics are underexposed. 
To our knowledge, this is the first study about communication during counseling 
sessions about ICS in the pharmacy. For future research, it would be interesting to 
study the relationship between the communication process and content on the one 
Communication during counseling sessions 119 
hand and outcomes on the other hand, such as patients’ medication adherence, 
satisfaction, and symptom control. In addition, the experiences of patients and 
health care providers with the communication could be taken into account, to get 
insight into which communication styles enhance medication optimization, 
according to them. 
 
Strengths and limitations 
This study has several strengths. First, exploring the content of counseling sessions at 
the pharmacy has never been done before in such an extensive way, resulting in rich 
information about these sessions and an objective and quantitative presentation of 
the content of the verbal communication. In addition, this study did not only take 
pharmacists’ communication into account but also looked at technicians’ 
communication and compared the content of the sessions of these two categories of 
professionals. 
However, there are some limitations. Selection bias could have occurred during 
pharmacy and patient recruitment. Participating pharmacies could be more engaged 
in patient counseling than the nonparticipating pharmacies, and participating 
patients might be more willing to communicate about ICS use, related problems, 
and feelings. In the Netherlands, counseling sessions are not yet routine activities in 
pharmacies,
23 
which implies that, in general, pharmacists and technicians are not 
very experienced in conducting counseling sessions about ICS. Therefore, the 
participating pharmacists and technicians might have better counseling skills than 
their nonparticipating colleagues. Hence, the generalizability of the findings is 
limited. 
In addition, the pharmacists sent the invitation letter to patients. This might have 
resulted in bias as patients might feel obligated to participate in the study. However, 
it was stated clearly in the letter that participation was voluntary. 
Finally, because counseling sessions are not performed very frequently, we 
provided general instructions to the pharmacists and technicians about which 
themes could be discussed during the sessions. Although these instructions were 
very broad, they might have influenced our results. 
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Conclusion 
 
Both pharmacists and pharmacy technicians addressed many important medical and 
therapeutic topics in counseling sessions with patients with asthma and/or 
COPD, but they could pay more attention to ICS adherence and to lifestyle and 
psychosocial topics. The two categories of professionals differed in their 
communication: pharmacists exhibited more affective behavior than technicians 
and also discussed medical and therapeutic topics in particular more extensively. 
 
Practice implications 
Educational courses for pharmacists and pharmacy technicians could draw attention 
to the discussion of ICS adherence, lifestyle, and psychosocial topics in patient 
communication. Pharmacy technicians in particular could be encouraged to attend 
to other factors than purely the technical aspects of using ICS. 
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Supplementary materials 
 
Table S1 Examples of statements for RIAS categories 
RIAS category Examples of statements 
Affective part 
Social behavior At the beginning of the session: Pharmacist: “How are you?” 
Approval (Patient shows inhaler technique) Pharmacist: “That looks very good!” 
Agreements “Hmm, hmm” “Okay” 
Verbal attention Pharmacist: “I understand how you must be feeling” 
Shows concern or worry Patient: “I hope it’s nothing serious” 
(Ask for) reassurance Patient: “My asthma is much better” 
Disagree Patient: “That’s impossible!” 
Instrumental part 
Process-oriented 
 Orientations Pharmacist: “Can you show me how you use your inhaler, please?” 
 Paraphrase/check for 
 understanding 
(Pharmacist: “You have to hold your breath for ten seconds”) 
Patient: “Ten seconds?” 
 Bid for repetition Patient: “What did you say?” 
 Ask for understanding Pharmacist: “Do you follow?” 
 Ask for opinion Pharmacist: “Any questions?” 
 Request for services 
 (patient category) 
Patient: “Could you contact the doctor for this, please?”  
Task-oriented communication 
 Medical Pharmacist: “Do you have asthma?” 
 Therapeutic Patient: “I take two puffs per day” 
 Lifestyle/social Pharmacist: “Do you smoke?” 
Psychosocial/feelings Patient: “I’m worried about the long-term effects of ICS” 
Other Patient: “Where can I fill in the questionnaire?” 
Abbreviations: RIAS, Roter interaction analysis system; ICS, inhaled corticosteroids. 
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Table S2 The number of sessions in which a topic is discussed zero times, once, or more than once 
 (divided into questions, giving information, and counseling) 
 Question Giving information Counseling 
 0 1 >1 0 1 >1 0 1 >1 
Medical 
Prevalence 
 Pharmacists 86 0 0 85 0 1 86 0 0 
 Technicians 83 0 0 83 0 0 83 0 0 
Prognosis 
 Pharmacists 86 0 0 84 2 0 86 0 0 
 Technicians 83 0 0 83 0 0 83 0 0 
Exacerbations 
 Pharmacists 82 3 1 83 2 1 86 0 0 
 Technicians 83 0 0 82 0 1 83 0 0 
Current health status 
 Pharmacists 40 17 29 35 22 29 86 0 0 
 Technicians 49 23 11 41 20 22 82 1 0 
Medical history 
 Pharmacists 65 13 8 69 10 7 86 0 0 
 Technicians 69 10 4 72 8 3 83 0 0 
Heredity 
 Pharmacists 86 0 0 84 1 1 86 0 0 
 Technicians 77 4 2 79 2 2 83 0 0 
Contact other health care providers about asthma/COPD 
 Pharmacists 60 15 11 64 12 10 78 4 4 
 Technicians 56 16 11 69 7 7 70 7 6 
Lung function test 
 Pharmacists 72 8 6 62 10 14 81 1 4 
 Technicians 78 4 1 74 5 4 83 0 0 
Explanation about asthma/COPD 
 Pharmacists 85 1 0 59 5 22 86 0 0 
 Technicians 83 0 0 79 1 3 83 0 0 
Medical, other 
 Pharmacists 56 10 20 45 10 31 77 6 3 
 Technicians 69 6 8 55 9 19 80 2 1 
Therapeutic: ICS treatment 
Reason for use/need 
 Pharmacists 54 25 7 45 15 26 82 4 0 
 Technicians 64 18 1 59 12 12 81 1 1 
Dosage/inhalation 
 Pharmacists 31 22 33 18 13 55 59 11 16 
 Technicians 32 29 22 36 22 25 62 13 8 
Adherence 
 Pharmacists 60 19 7 45 16 25 76 8 2 
 Technicians 55 21 7 49 12 22 67 8 8 
Medicinal effects 
 Pharmacists 40 25 21 10 8 68 84 2 0 
 Technicians 43 22 18 13 16 54 83 0 0 
Side effects 
 Pharmacists 30 27 29 26 10 50 78 5 3 
 Technicians 16 25 42 18 9 56 81 1 1 
- Table S2 continues - 
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- Table S2 continued - 
 Question Giving information Counseling 
 0 1 >1 0 1 >1 0 1 >1 
Therapeutic: ICS treatment (continued) 
Inhaler/inhalation 
 Pharmacists 5 8 73 2 3 81 13 4 69 
 Technicians 5 4 74 0 1 82 7 7 69 
Contact other health care providers about ICS 
 Pharmacists 62 17 7 68 8 10 65 7 14 
 Technicians 57 15 11 60 14 9 62 12 9 
Self-management 
 Pharmacists 82 4 0 79 3 4 85 1 0 
 Technicians 83 0 0 81 0 2 83 0 0 
Facilitators 
 Pharmacists 83 1 2 61 6 19 85 1 0 
 Technicians 74 7 2 59 11 13 83 0 0 
Barriers 
 Pharmacists 83 2 1 66 6 14 86 0 0 
 Technicians 80 3 0 71 3 9 83 0 0 
ICS, other 
 Pharmacists 49 22 15 28 18 40 82 3 1 
 Technicians 44 29 10 38 14 31 78 5 0 
Therapeutic: non-ICS treatment 
 Pharmacists 22 18 46 14 6 66 56 13 17 
 Technicians 31 16 36 14 9 60 55 11 17 
Lifestyle/social 
Smoking 
 Pharmacists 72 8 6 74 6 6 83 3 0 
 Technicians 73 6 4 78 3 2 83 0 0 
Exercise 
 Pharmacists 83 2 1 71 11 4 82 2 2 
 Technicians 80 3 0 79 2 2 82 0 1 
Weight 
 Pharmacists 86 0 0 86 0 0 86 0 0 
 Technicians 83 0 0 83 0 0 83 0 0 
Nutrition 
 Pharmacists 85 1 0 83 2 1 85 1 0 
 Technicians 83 0 0 81 2 0 83 0 0 
Stress 
 Pharmacists 86 0 0 86 0 0 86 0 0 
 Technicians 83 0 0 81 2 0 83 0 0 
Drugs 
 Pharmacists 85 0 1 85 0 1 86 0 0 
 Technicians 83 0 0 83 0 0 83 0 0 
Influenza vaccine 
 Pharmacists 84 2 0 86 0 0 86 0 0 
 Technicians 83 0 0 82 0 1 83 0 0 
(Living) environment 
 Pharmacists 77 6 3 62 9 15 85 1 0 
 Technicians 75 5 3 66 7 10 83 0 0 
- Table S2 continues - 
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- Table S2 continued - 
 Question Giving information Counseling 
 0 1 >1 0 1 >1 0 1 >1 
Therapeutic: non-ICS treatment (continued) 
Social context 
Pharmacists 80 6 0 63 5 18 85 1 0 
Technicians 81 2 0 66 4 13 81 1 1 
Lifestyle, other 
Pharmacists 78 5 3 73 7 6 84 2 0 
Technicians 82 1 0 73 7 3 83 0 0 
Psychosocial/feelings 
ICS concerns 
Pharmacists 85 1 0 79 4 3 86 0 0 
Technicians 83 0 0 82 1 0 83 0 0 
ICS necessities 
Pharmacists 86 0 0 82 1 3 86 0 0 
Technicians 83 0 0 77 5 1 83 0 0 
Psychosocial ICS, other 
Pharmacists 65 17 4 65 8 13 84 1 1 
Technicians 71 8 4 54 18 11 83 0 0 
Non-ICS 
Pharmacists 85 1 0 75 5 6 86 0 0 
Technicians 81 1 1 72 6 5 83 0 0 
Other 
Pharmacists 66 11 9 0 0 86 85 1 0 
Technicians 79 4 0 0 0 83 83 0 0 
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids.  
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Table S3 Weighted mean (SE) of behaviors of pharmacists, pharmacy technicians, and patients, 
 controlled for visit length 
 Pharmacists’ and technicians’ 
behavior 
Patients’ behavior 
 Pharmacists Technicians Pharmacists’ 
sessions 
Technicians’ 
sessions 
Affective part 
Social behavior 2.11 (0.29)* 1.22 (0.29)* – – 
Approval 1.69 (0.17)** 1.29 (0.67)** – – 
Agreements 13.86 (1.02) 14.36 (1.02) 12.07 (0.54) 12.36 (0.55) 
Verbal attention 0.87 (0.11)*** 0.47 (0.11)*** – – 
Shows concern or worry 0.09 (0.02)* 0.03 (0.02)* – – 
Reassurance 1.79 (0.15) 1.76 (0.15) – – 
Instrumental part 
Process-oriented 
 Paraphrase/check for 
 understan-ding 
4.06 (0.35)* 4.76 (0.35)* – – 
Task-oriented 
Question 
 Medical 
 Current health status 0.30 (0.05)* 0.18 (0.05)* – – 
 Heredity −0.00 (0.02)** 0.03 (0.02)** – – 
 Medical, other 0.21 (0.05)* 0.09 (0.05)* – – 
ICS treatment 
 Reason for use/need 0.12 (0.03) 0.08 (0.03) – – 
 Dosage – – 0.08 (0.02)* 0.02 (0.02)* 
 Side-effects 0.35 (0.09)*** 0.69 (0.09)*** – – 
 Self-management 0.01 (0.01) 0.00 (0.01) – – 
 Non-ICStreatment 0.54 (0.09) 0.54 (0.09) – – 
 Lifestyle/social 
 Social context – – 0.01 (0.00) 0.00 (0.00) 
 Lifestyle, other 0.03 (0.01)* 0.00 (0.01)* – – 
 Other 0.10 (0.02)*** 0.02 (0.02)*** – – 
Give information 
Medical 
 Medical history – – 1.00 (0.12)* 0.63 (0.13)* 
 Lung function test 0.22 (0.08)* 0.03 (0.08)* – – 
 Explanation about 
 asthma/COPD 
0.49 (0.10)*** 0.02 (0.10)*** – – 
- Table S3 continues -
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- Table S3 continued - 
 Pharmacists’ and technicians’ 
behavior 
Patients’ behavior 
 Pharmacists Technicians Pharmacists’ 
sessions 
Technicians’ 
sessions 
Task-oriented (vervolg) 
ICStreatment 
 Reason for use/need 0.24 (0.04) 0.16 (0.04) – – 
 Dosage 0.76 (0.09)*** 0.39 (0.09)*** 1.38 (0.14) 1.30 (0.14) 
 Medicinal effects 1.67 (0.15)** 1.07 (0.15)** – – 
 Inhaler/inhalation 6.02 (0.55) 6.09 (0.55) – – 
 Barriers – – 0.19 (0.04) 0.09 (0.04) 
Non-ICStreatment 2.63 (0.30) 2.09 (0.31) – – 
Lifestyle/social 
 (Living) environment – – 0.35 (0.06)* 0.22 (0.06)* 
 Social context 0.25 (0.06) 0.16 (0.06) – – 
Psychosocial/feelings 
 ICSConcerns 0.03 (0.01)* 0.00 (0.01)* 0.23 (0.05)* 0.11 (0.05)* 
Other 4.79 (0.40) 4.82 (0.40) 4.10 (0.32) 3.68 (0.32) 
Counsel 
ICStreatment 
 Adherence 0.05 (0.04)* 0.13 (0.04)* – – 
Notes: *Significant at p<0.05. **Significant at p<0.01. ***Significant at p<0.001. 
Abbreviations: SE, standard error; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids 
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Abstract 
 
The aim of this study was to examine cue-responding behavior at the pharmacy 
while counseling about inhaled corticosteroids (ICS) in relation to medication 
adherence and medication beliefs. Patients with asthma aged ≥18 years using ICS 
were recruited from 12 pharmacies. Counseling sessions were video-recorded. 
Patients’ emotional and informational cues and pharmacists’ and pharmacy 
technicians’ cue-responding behaviors were coded using an expanded version of the 
Medical Interview Aural Rating Scale. The Beliefs about Medicines Questionnaire 
assessed patients’ ICS concern and necessity beliefs. Self-reported ICS adherence 
was measured by four questions. During the 86 sessions, patients expressed on 
average 2.3, mostly informational, cues (70.8%). In 26.7% of the sessions, no cues 
were expressed. Pharmacists’ and technicians’ responses to emotional cues (59.3%) 
were mostly inadequate, and to informational cues mostly appropriate (63.6%). 
Providing inappropriate information (20.3%) was related to higher concerns post 
session (p<0.05), and cue exploration to higher self-reported adherence at 3 
months (p<0.05). Apparently, providers’ responses to patients’ cues might have 
therapeutic value. In addition, patients might need to be encouraged to ask 
questions and express their concerns. 
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Background 
 
Asthma is a growing health burden. Approximately 300 million people suffer from 
asthma worldwide, with mortality rates of 250,000 deaths per year.
1
 Inhaled 
corticosteroids (ICS) are frequently used in the management of asthma and have to 
be taken on a long-term and regular basis.
2
 However, about 40% of asthma patients 
do not take ICS as prescribed.
3
 This suboptimal adherence leads to poor asthma 
control, increased risk of asthma events, and high health care costs.
3,4
 
Patients’ insufficient knowledge, misconceptions, and beliefs about ICS are related 
to suboptimal adherence.
5-8
 Some patients think that ICS are ineffective;
6
 others 
only use ICS when experiencing symptoms, rather than regularly.
9
 Horne et al. 
examined patients’ ICS beliefs in relation to medication adherence.
10
 They 
distinguished two kinds of beliefs, namely, concern and necessity beliefs. Concern 
beliefs refer to worries about, for instance, side effects and drug dependency. 
Necessity beliefs refer to the conviction that medication is needed for maintaining 
health. Higher concerns and lower necessity beliefs have shown to be associated 
with lower adherence. Many patients report having concerns about using ICS, 
especially about potential addiction to ICS and side effects, like reduced bone 
density, weight gain, and unknown long-term.
5-7,11
 
To improve ICS adherence, health care providers have to assist patients to 
increase their knowledge, change their misconceptions, and diminish their concerns 
about ICS. They should attend to patients’ needs and respond to these in an 
adequate or supportive way.
12
 Several studies found a positive association between 
such patient-centered communication and medication adherence, but the results 
are, as yet, inconclusive.
13,14
 
According to Engel’s biopsychosocial model, patients have “a need to know and 
to understand” and “a need to feel known and understood”.
15,16
 The first refers to 
informational needs about medical issues. The second denotes that patients have 
emotional needs, such as a need for support, acceptance, and respect. Bensing and 
colleagues transformed Engel’s model into the “stress-coping model” that indicates 
that health care providers have to take these two different needs into account, and 
that each need requires another approach or response from the health care 
provider.
17
 To fulfill patients’ informational needs, the exchange of appropriate 
medical information about the treatment, illness, and medication is important. This 
type of exchange is called “instrumental communication.” To meet patients’ 
emotional needs, attention has to be paid to patients’ feelings, concerns, and 
psychosocial issues. Such “affective communication” includes behaviors such as 
listening to patients’ concerns, showing empathy, and reassuring patients.
15
 
Instrumental and affective communication are expected to enhance a patient’s 
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problem-oriented and emotional coping behaviors, respectively. 
A prerequisite for such communication is that patients voice their needs clearly. 
However, many patients only give implicit “cues”.
18
 Many patients with asthma do 
not discuss their worries about ICS with their health care provider or mention less 
than one psychosocial concern about ICS during counseling sessions at the 
pharmacy.
11,19
 Clearly, there is a need for health care providers to identify and 
explore implicitly expressed cues,
18
 and, in line with the stress-coping model, to 
respond to these in an appropriate way. 
The present study focuses on the community pharmacy. Since the emphasis of 
pharmacists’ role has shifted from a logistic dispensing role to a more patient-
centered guiding role, pharmacists are more engaged in patient education and 
counseling.
20
 In the Netherlands, many pharmacies annually conduct counseling 
sessions to monitor patients’ chronic medication use, but these are not yet common 
practice everywhere.
21
 
So far, there is a lack of knowledge of the way patients with asthma express their 
informational and emotional needs and how pharmacists respond to them during 
counseling sessions. In this study, we focus especially on cues as an expression of 
patients’ needs. Differences may exist between pharmacists and pharmacy 
technicians in their cue-responding behaviors and patients’ expressions of cues 
during these sessions, as shown in other research about instrumental and affective 
communication.
19
 
Therefore, the aims of this study are (1) to examine asthmatic patients’ 
informational and emotional cues during counseling sessions about ICS and their 
relationship with medication beliefs and self-reported adherence, (2) to investigate 
pharmacists’ and pharmacy technicians’ cue-responding behaviors and their 
relationship with these outcomes, and (3) to explore the differences in expressions 
of cues and responses between pharmacists and pharmacy technicians. 
 
 
Method 
 
Setting 
This observational study is part of a larger project investigating the communication 
of community pharmacists and pharmacy technicians with patients with asthma and 
chronic obstructive pulmonary disease (COPD) about their ICS use. The research 
proposal was assessed by the Medical Ethics Committee (METC) of the University 
Medical Centre Utrecht (UMCU). The METC concluded that this study did not fall 
within the remit of the Law on Medical Scientific Research involving Human Beings. 
In total, 130 community pharmacies were invited by the Utrecht Pharmacy 
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Practice Network for Education and Research (UPPER) to join the study, of which 12 
community pharmacies were willing to participate. At each participating pharmacy, 
one pharmacist and one pharmacy technician had several counseling sessions with 
patients, depending on the number of participating patients of the particular 
pharmacy, and on an agreed maximum number of participants per pharmacy. 
The purpose of a counseling session was to talk individually with a patient about 
his or her medication use. Several issues could be discussed, like inhalation 
technique, ICS dose, reason for use, adherence to ICS, the degree of asthma control, 
and so on. To get as the best possible authentic impression of providers’ 
communication styles, only general instructions were provided about the counseling 
sessions, that is, “discuss patients’ experiences with ICS use, the effectiveness and 
(possible) side effects of ICS, and whether the patient uses ICS in an appropriate 
way.” Pharmacists and pharmacy technicians were unaware of the specific aims of 
the study. 
 
Participants 
Patients were recruited from the participating pharmacies and were eligible for the 
study when they were 18 years of age or older, were diagnosed with asthma or 
COPD (based on self-report), had been using ICS for at least 1 year, and had filled 
two or more ICS prescriptions in the preceding year. Patients living in an institution 
were excluded. For the purpose of this study, only data of patients with self-
reported asthma (symptoms) were used. 
 
Procedure 
In total, 1,952 potentially eligible patients received an information package from 
their pharmacists, with an invitational letter, a questionnaire, and an informed 
consent form, by post. This baseline questionnaire assessed, among other things, 
patients’ sociodemographic characteristics and asthma control (Asthma Control 
Questionnaire).
22,23
 To participate in the study, patients had to return the completed 
baseline questionnaire and a signed informed consent form. To protect patients’ 
privacy, these had to be returned separately. Participants were randomly allocated 
to the intervention group, which received a planned counseling session, or the 
control group, without a planned counseling visit. In this study, we only consider the 
data of patients with asthma who had a counseling session. Within 2 months after 
inclusion, participants had one planned counseling session in the consulting room at 
the pharmacy. These sessions were videotaped using an unmanned camera, 
directed at the pharmacist or pharmacy technician. Patients filled in a questionnaire 
directly after the counseling session. Three months after baseline, participants again 
received a questionnaire by post. 
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Measurements 
An expanded version of the Medical Interview Aural Rating Scale (MIARS) was used 
to analyze the video recordings and to identify the number of patients’ emotional 
cues and how pharmacists and pharmacy technicians responded to emotional 
cues.
24,25
 The coding scheme was expanded to capture also informational cues and 
responses to these.
26,27
 This version of the MIARS corresponds with the elements of 
the stress-coping model and enables measurement of the two types of patient-
provider communication (i.e. detecting patients’ emotional and informational cues 
and the subsequent affective or instrumental response provided by the pharmacist 
or pharmacy technician). 
A cue is defined as a verbal or nonverbal hint or expression (word or sentence) of 
a patient that indicates that the issue is important to the patient or that the issue 
would need clarification from a health care provider, or that indicates a need for 
information, or a worry or concern. “Turns” were used as units of observation and 
analysis. A turn is the period a patient, pharmacist, or pharmacy technician is talking 
before the next speaker takes over. Responses of a pharmacist and pharmacy 
technician were coded in the first turn after the patient’s cue (i.e. lag 1). 
Observers coded the cues and responses directly from the videotapes with 
Observer XT7 software,
28
 which enables observation of verbal as well as nonverbal 
aspects, like emotional tone of voice. Each recording was coded by one observer. 
The times of cues and responses were registered in order to provide sequential 
data. 
 
Emotional cues and responses 
The MIARS distinguishes three levels of emotional cues, based on their degree of 
intensity: (1) hints of worry or concern, (2) mention of worry or concern, and (3) 
clear expression of worry or concern. These cues can be followed by one of these 
types of responses: (1) exploration (by eliciting, clarification, or educated guess), (2) 
acknowledgment (by an emphatic statement, reflection, checking, or minimal 
encouragement [i.e. backchannel responses, as “mmmh” and “aha,” and 
agreements, as “right” and “okay”]), (3) factual clarification (by giving/questioning 
about clinical relevant information, without responding to the emotion), (4) 
distancing (by switching focus or giving premature reassurance or inappropriate 
advice), or (5) overt blocking (Table 6.1). According to the MIARS, exploration and 
acknowledgment are considered adequate responses to emotional cues, whereas 
factual clarification, distancing, and overt blocking are inadequate responses. 
  
Table 6.1 Examples of patients’ cues and pharmacists’ and pharmacy technicians’ responses 
Patients’ cues Examples of cues Responses by pharmacists and 
pharmacy technicians 
Examples of responses 
Emotional cues    
Level 1 (hints) ‘I am against prednisone and antibiotics. When I 
am short of breath, I get these medicines, but I 
never want them.’ 
Factual clarification ‘But sometimes these medicines help for a 
while.’ 
  Overt blocking No response. Pharmacist or pharmacy 
technician ignores the cue. 
  Distancing ‘You have to discuss that with your doctor.’ 
 ‘I am so sensitive for all those side effects…’ Acknowledgement ‘Yes, that must be annoying.’ 
Level 2 (mention) ‘I worry about the long-term effects of my 
medication.’ 
Exploration 
 
‘Can you tell me what you are worried about?’ 
Level 3 (clear expression) ‘I am terrified.’ 
[No level 3 cues have been expressed.] 
  
Patients’ informational cues    
Medical ICS/ inhaler use ‘I always carry Ventolin with me, in case I might 
need it, but I…’ [The patient wants to ask a 
question about the frequency of use.] 
Overt blocking ‘…can last a long time with your medicine.’  
[The pharmacist interrupts and this response is 
not related to the patients’ actual cue.] 
 ‘Are there other types of devices?’ Appropriate information ‘Yes, there are.’[The pharmacist gives 
information about other types.] 
  Referring ‘I will get back to you on that.’ 
 ‘Should I do it like this?’ 
[The patient shows inhalation technique.] 
Inappropriate information ‘Yes, that’s good.’ 
[The patient is not performing the technique as 
stated in guidelines.] 
 ‘Is it possible to reduce the dose of my medication 
[ICS and reliever medication]? 
Inappropriate information The pharmacy technician gives unclear and 
inconsistent information about altering the 
dosage and when to use what kind of asthma 
medication. 
Medical other ‘I noticed that there are new medicines…’ Exploration ‘Would you like to know more about them?’ 
Practical ‘Where can I get a prescription for a new spacer 
device?’ 
Appropriate information ‘You have to go to your general practitioner for 
a new spacer device’ 
Lifestyle ‘How can I quit smoking?’ 
[No lifestyle cues have been expressed.] 
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Informational cues and responses 
Informational cues are questions or indirect statements indicating that the patient is 
seeking information. An example is “I do not know if I use the inhaler correctly.” In 
addition, patients’ questions in order to gather extra information or explanation 
were also coded as informational cues (e.g. “Why?” and “What do you mean?”). 
There are four informational categories: (1) medical information about ICS and 
inhaler use, (2) other medical information, (3) practical information, and (4) 
information about lifestyle. Responses to informational cues are to some extent 
comparable to the emotional responses: (1) exploration, (2) giving appropriate 
information, (3) giving inappropriate information (i.e. incorrect, incomplete, or 
ambiguous information), (4) referral (by addressing to come back to it at a later 
moment in the visit), (5) distancing, and (6) overt blocking (Table 6.1). 
 
Interrater reliability 
Two coders were trained in using the MIARS. The main coder coded all observations 
(n=86). A second observer coded a random 10% (n=9) of the main coders’ 
observations. Reliability was determined for all cues and responses using the 
intraclass correlation coefficient (ICC). ICC reliability was good and ranged from 0.98 
to 1.00 for both emotional and informational cues and responses.
29
 
 
Medication adherence and medication beliefs 
Adherence to ICS was measured at two moments: at baseline, and 3 months after 
baseline. Adherence was assessed by a self-reported questionnaire comprising four 
dichotomous items comparable to the items from the Morisky Medication 
Adherence Scale.
30
 An example is “Do you ever forgot to take your medicine?” Each 
question can be answered with yes (0 points) or no (1 point). Scores were added up 
to generate a score between 0 and 4. A score closer to 4 indicates higher adherence. 
Only completed scales were analyzed (baseline n=86; at 3 months n=79). 
ICS beliefs were measured at three moments: at baseline, directly after the 
counseling session, and at 3 months after baseline. The Beliefs about Medicines 
Questionnaire (BMQ-specific) assessed beliefs about ICS, containing a necessity 
scale and a concerns scale.
31
 An example of a necessity item is “Without these 
medicines, I would be very ill.” An example of a concerns item is “I sometimes worry 
about long-term effects of these medicines.” Each scale consists of five 5-point 
Likert scale items, ranging from strongly disagree to strongly agree. The scores were 
added up for each scale to produce a score ranging between 5 and 25. A maximum 
of one missing per case per scale was allowed; then, the scale score was determined 
on the mean score of four items, multiplied by 5. Higher scores indicate stronger 
beliefs. 
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Statistical analysis 
Sequence analysis was performed on the sequential data by using descriptive 
statistics and scoring manually which response followed each cue, resulting in cross 
tables. To determine whether the number of cues and responses differed between 
pharmacists’ sessions and those of pharmacy technicians, two-sample proportions 
tests were carried out on each cue and response. 
To control for the clustering of patients in pharmacies, multilevel regression 
analysis was used to examine the relationships between cues and responses and 
patient outcomes in terms of medication beliefs after the counseling session and at 
follow-up 3 months after baseline, and self-reported adherence at follow-up 3 
months after baseline. Difference scores were calculated for each patient outcome 
measure (i.e. score at follow-up minus score at baseline). Because of low numbers of 
cues and responses per session, all independent variables (i.e. all types of cues and 
responses) were dichotomized according to whether a particular cue/response “did 
not occur” or “did occur” (0 vs. ≥1) during a session. Only independent variables 
were analyzed when they occurred in at least 10 sessions. This is decided in view of 
generalizability of the results, which have to be based on an adequate amount of 
cases (one session is one case in the analysis). Separate multilevel linear regression 
analyses were performed on (1) emotional cues (level 1 hints), (2) informational 
cues (medical ICS/inhaler use, medical other, and practical), (3) responses to 
emotional cues (acknowledgment and factual clarification) and (4) responses to 
informational cues (exploration, appropriate and inappropriate information), in 
relation to the difference scores of the patient outcomes measures. Multilevel 
analyses were done using MLwiN 2.25. Descriptive statistics were calculated using 
Stata 12.1. 
 
 
Results 
 
Study sample 
Of 429 patients who responded, 199 patients were allocated to the intervention 
group and were invited for a counseling session. Of these, 30 patients dropped out 
(15.1%). Reasons for drop-out were: not reachable by phone/e-mail, involuntary 
withdrawal (e.g. due to health condition), no longer using ICS, recently had a session 
about ICS or asthma, and do not want to participate anymore. Of the 169 patients 
who had a session, 86 patients reported to have asthma (symptoms). The majority 
of these asthma patients were female (67.4%). The mean age was 58.3 years 
(SD=15.0) (Table 6.2). 
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Table 6.2 Patients’, pharmacists’, and pharmacy technicians’ characteristics 
Patient characteristics Pharmacist-patient 
sessions 
(n=44) 
Technician-patient  
sessions  
(n=42) 
Total 
(n=86) 
Female gender  29(65.9%) 29(69.0%) 58 (67.4%) 
Age, years    
Mean (SD)  
(range) 
60.2 (14.0)  
(26-82) 
56.4 (15.8)  
(28-87) 
58.3 (15.0)  
(26-87) 
Age group, years    
18-44 6 (13.6%) 12 (28.6%) 18 (20.9%) 
45-64 19 (43.2%) 16 (38.1%) 35 (40.7%) 
>64 19 (43.2%) 14 (33.3%) 33 (38.4%) 
Educational level    
Low 8 (18.2%) 9 (21.4%) 17 (19.8%) 
Intermediate 17 (38.6%) 16 (38.1%) 33 (38.4%) 
High 19 (43.2%) 17 (40.5%) 36 (41.9%) 
Etnicitya    
Dutch 37 (84.1%) 35 (83.3%) 72 (83.7%) 
Western background 5 (11.4%) 5 (11.9%) 10 (11.6%) 
Non-western background 1 (2.3%) 2 (4.8%) 3 (3.5%) 
Diagnosisb    
Asthma 31 (70.5%) 28 (66.7%) 59 (68.6%) 
Asthma and COPD 13 (29.5%) 14 (33.3%) 27 (31.4%) 
Duration of ICS usea    
Between 1 and 5 years 16 (36.4%) 17 (40.5%) 33 (38.4%) 
Between 5 and 10 years 12 (27.3%) 8 (19.0%) 20 (23.3 %) 
Between 10 and 15 years 4 (9.1%) 5 (11.9%) 9 (10.5 %) 
Longer than 15 years 12 (27.3%) 11 (26.2%) 23 (26.7 %) 
ACQ scorec 
Baseline, Mean (SD) 
 
0.9 (0.8) 
 
1.0 (0.7) 
 
1.0 (0.7) 
Adherence score 
Baseline, Mean (SD) 
 
2.6 (1.4) 
 
2.9 (1.1) 
 
2.7 (1.2) 
BMQ necessity scorea 
Baseline, Mean (SD) 
 
16.2 (4.3) 
 
15.8 (3.6) 
 
16.0 (3.9) 
BMQ concerns scorea 
Baseline, Mean (SD)  
 
11.5 (4.4) 
 
12.3 (3.4) 
 
11.9 (3.9) 
Pharmacist and pharmacy 
technician characteristics 
Pharmacists 
(n=12) 
Pharmacy technicians 
(n=12) 
 
Female gender 6 (50%) 12 (100%)  
Age, years    
Mean (SD) 
(range) 
36.7 (11.5) 
(24-57) 
35.4 (11.9) 
(23-53) 
 
aOne missing in the group of technician-patient sessions. 
bBased on self-reports. 
cEleven missings: five missing in the group of pharmacists and six missing in the group of technician-patient sessions. 
 
All 86 patients with asthma filled in the questionnaire after the session, but one did 
not complete the BMQ. At 3 months after baseline 81 patients returned the follow-
up questionnaire, of which 79 patients completed the BMQ and adherence scale 
completely for analysis. 
Half of the pharmacists were male; all pharmacy technicians were female. Mean 
age of pharmacists was 36.7 years (SD=11.5), and mean age for pharmacy 
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technicians was 35.4 years (SD=11.9) (Table 6.2). Pharmacists performed on average 
3.7 counseling sessions (range 1–7 sessions) and pharmacy technicians 3.5 sessions 
(range 1–7 sessions). 
 
Frequencies of patients’ cues and pharmacists’ and pharmacy technicians’ responses 
In 63 of the 86 counseling sessions (73.3%), patients expressed cues. Of these, 37 
sessions (58.7%) were with a pharmacist and 26 sessions (41.3%) with a pharmacy 
technician. Results based on all 86 cases show that patients gave on average 0.7 
emotional cues (median=0, range: 0–5) and 1.7 informational cues (median=2, 
range: 0–11) per session, resulting in a mean of 2.3 cues (median=2, range: 0–13) 
per session. Specified by type of cue, only 31 patients (36.1%) expressed emotional 
cues, and informational cues were expressed by 55 patients (64.0%). In sessions 
with emotional cues, on average 1.9 emotional cues were expressed (median=2), 
and in sessions with informational cues, patients gave on average 2.6 informational 
cues (median=2). Mean session length was 13.8 minutes (SD=6.3) (data not shown). 
Patients more often expressed informational cues than emotional cues (70.8% 
versus 29.2%) (Table 6.3). Most cues were related to ICS and inhaler use (65.0% of 
informational cues). The majority of emotional cues were hints (93.2% of emotional 
cues). Patients gave no clear emotional expressions (level 3 cues) and no cues about 
lifestyle issues. 
Two-sample proportion tests revealed that pharmacists’ sessions did not differ 
significantly from pharmacy technicians’ sessions in the number of cues and 
responses. Both provider types most often responded to emotional cues with a 
factual clarification (49.2%) or acknowledgment (35.6%). Exploration and overt 
blocking occurred least frequently as a response to an emotional cue (both 5.9%). 
The responses to emotional cues were adequate in 40.7% of the responses (5.1% + 
35.6%). To informational cues, pharmacists and pharmacy technicians most 
frequently provided appropriate information (63.6%), followed by inappropriate 
information (20.3%) and an exploration of the cue (12.6%). 
  
Table 6.3 Frequencies of patients’ cues and pharmacists’ and pharmacy technicians’ responses 
 Frequencies n (%) 
Elements of the (adapted) MIARS Pharmacists  Pharmacy technicians Total  
Patient cues 113 (100%) 89 (100%) 202 (100%) 
Emotional cues 34 (30.1%) 25 (28.1%) 59 (29.2%) 
 Level 1 (hints)a 31 (91.2%) 24 (96.0%) 55 (93.2%) 
 Level 2 (mention) 3 (8.8%) 1 (4.0%) 4 (6.8%) 
 Level 3 (clear expression) - - - 
Informational cues 79 (69.9%) 64 (71.9%) 143(70.8%) 
 Medical ICS/inhaler usea 49 (62.0%) 44 (68.8%) 93 (65.0%) 
 Medical othera 18 (22.8%) 10 (15.6%) 28 (19.6%) 
 Practicala 12 (15.2%) 10 (15.6%) 22 (15.4%) 
 Lifestyle - - - 
Responses by pharmacists and pharmacy technicians 113 (100%) 89 (100%) 202 (100) 
On emotional cues 34 (30.1%) 25 (28.1%) 59 (29.2%) 
 Exploration 2 (5.9%) 1 (4.0%) 3 (5.1%) 
 Acknowledgementa 11 (32.4%) 10 (40.0%) 21 (35.6%) 
 Factual clarificationa 16 (47.1%) 13 (52.0%) 29 (49.2%) 
 Distancing 3 (8.8%) - 3 (5.1%) 
 Overt blocking 2 (5.9%) 1 (4.0%) 3 (5.1%) 
On informational cues 79 (69.9%) 64 (71.9%) 143 (70.8%) 
 Explorationa 10 (12.7%) 8 (12.5%) 18 (12.6%) 
 Appropriate informationa 53 (67.1%) 38 (59.4%) 91 (63.6%) 
 Inappropriate informationa 12(15.2%) 17 (26.6%) 29 (20.3%) 
 Distancing - 1 (1.6%) 1 (0.7%) 
 Overt blocking 2 (2.5%) - 2 (1.4%) 
 Referring 2 (2.5%) - 2 (1.4%) 
Note: Results are based on 63 counseling sessions (patients expressed no cues in 23 sessions). 
a
Cue/response that occurred in at least 10 sessions and is added to the regression analysis. 
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Communication sequences between patients and pharmacists and pharmacy 
technicians 
The sequence analysis depicted in Table 6.4 shows that pharmacists and pharmacy 
technicians most often responded with a factual clarification to patients’ emotional 
cues (level 1 and 2), and with acknowledgment of emotional hints (level 1). Clear 
emotional expressions (level 2) were only followed by factual clarifications (75.0%) 
or an exploration of the cue (25.0%). Informational cues were most frequently 
followed by appropriate information. When pharmacists or technicians gave an 
inappropriate information response to an informational cue, this was most of the 
time to an informational cue related to medical ICS/inhaler issues. Referring and 
distancing were only a response to cues related to the “medical other” category. 
 
Relationship between cues, responses, and medication beliefs and adherence 
No relationships were found between the expression of (emotional and 
informational) cues on the one hand, and patients’ medication beliefs and 
adherence on the other (Table 6.5). A significant relationship was found between 
responding with inappropriate information to informational cues, and concerns 
after the session (B=1.57, p<0.05); a positive difference score on the concerns scale 
indicates that concerns were higher after the visit when inappropriate information 
had been given to informational cues, compared to no inappropriate information as 
response. In addition, a significant association was found between exploration on 
informational cues and self-reported adherence 3 months after baseline (i.e. 
approximately 1 month after the session) (B=0.55, p<0.05); here a positive 
difference score on the self-reported scale indicates that exploration of 
informational cues was positively related to adherence, compared to no exploration. 
  
Table 6.4 Emotional en informational communication sequences 
 Responses by pharmacists and pharmacy technicians n (%) 
Patient emotional cues Exploration Acknowledgement Factual 
clarification 
Distancing Overt blocking 
Level 1(hints)  
(n=55) 
2 (3.6%) 21 (38.2%) 26 (47.3%) 3 (5.5%) 3 (5.5%) 
Level 2 (clear expression) 
(n=4) 
1 (25.0%) - 3 (75.0%) - - 
Patient informational cues Exploration Appropriate 
information 
Inappropriate 
information 
Distancing Overt blocking  Referring 
Medical ICS/ inhaler use (n=93) 12 (12.9%) 55 (59.1%) 25 (26.9%) - 1 (1.1%) - 
Medical other 
(n=28) 
4 (14.3%) 17 (60.7%) 3 (10.7%) 1 (3.6%) 1 (3.6%) 2(7.1%) 
Practical 
(n=22) 
2 (9.1%) 19 (86.4%) 1 (4.5%) - - - 
Note: Results are based on 63 counseling sessions (patients expressed no cues in 23 sessions). 
 
Table 6.5 Multilevel linear regressions of cues and responses on difference scores of beliefs (i.e. concerns and necessities) and self-reported adherence at follow-up 
 measurements 
 After session  Three months after baseline 
 Concerns
a 
B (SE) 
Necessitiesa B (SE)  Concernsb 
B (SE) 
Necessitiesb 
B (SE) 
Self-reported adherenceb 
B (SE) 
Cues      
Emotional cues      
 Level 1 (hints)† 0.52 (0.68) -0.55 (0.74) -1.07 (0.67) -0.44 (0.72) -0.10 (0.21) 
Informational cues      
 Medical ICS/inhaler use† 0.51 (0.66 ) 0.24 (0.73) -0.46 (0.68) 0.67 (0.71) 0.32 (0.20) 
 Medical other† -1.19 (0.77) 0.25 (0.85) 0.07 (0.79) -0.19 (0.83) -0.01 (0.23) 
 Practical† -0.78 (0.83) 0.12 (0.91) -0.14 (0.84) -0.86 (0.89) -0.13 (0.25) 
- Table 6.5 continues - 
  
- Table 6.5 continued -  
 After session  Three months after baseline 
 Concerns
a 
B (SE) 
Necessitiesa  
B (SE) 
 Concernsb 
B (SE) 
Necessitiesb 
B (SE) 
Self-reported adherenceb 
B (SE) 
Responses      
On emotional cues      
 Acknowledgement† 1.18 (0.92) 1.06 (0.99) -0.45 (0.91) 0.63 (0.95) -0.07 (0.28) 
 Factual clarification† -0.27 (0.83) -1.43 (0.90) -0.60 (0.82) -1.50 (0.86)1 0.13 (0.25) 
On informational cues      
 Exploration† -0.25 (0.87) -0.18 (0.95) 0.50 (0.87) 0.90 (0.91) 0.55 (0.25)2 
 Appropriate information† -0.53 (0.67) 0.73 (0.73) -0.10 (0.69) -0.32 (0.73) 0.12 (0.20) 
 Inappropriate information† 1.57 (0.80)3 -1.27 (0.87) 0.29 (0.81) -0.87 (0.84) -0.45 (0.23)4 
†
Categorical, dichotomized variable; reference category: no cue/response. 
an=85, 1 missing. 
bn=79, 7 missing. 
1p=0.08. 
2p=0.03. 
3p=0.049. 
4p=0.05. 
Note: Bold numbers indicate a significant p-value (p<0.05). 
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Discussion 
 
In line with other research about patients’ cues, we found that patients with asthma 
expressed few cues during planned counseling sessions at the pharmacy
18
 and more 
than one-fourth expressed no cues at all. The reason for this can be threefold. First, 
patients might have few concerns or not much need for information. The majority of 
patients in this study used ICS for longer than 5 years, which could implicate that 
they have sufficient knowledge about ICS and asthma, or perceive that they have 
this. Second, they might not have experienced the opportunity to express 
themselves. Third, patients might not have wanted or dared to express their needs. 
This reticence could be explained by findings that patients do not yet perceive 
pharmacists as a health care provider who counsels them in their medication needs 
and concerns.
32,33
 Further research is needed to determine whether patients will be 
more open in their communication toward pharmacists and pharmacy technicians in 
the future. 
When patients did express emotional cues, these cues were most of the time 
expressed as “hints,” which are, by definition, difficult to detect because of their 
implicit character. No clear expressions of cues took place. Pharmacists and 
pharmacy technicians most often responded to an emotional cue with a factual 
clarification, without further exploration of the question behind the implicit cue. 
About 60% of the responses to emotional cues were inadequate, which means that 
there is room for improvement in the detection and handling of emotional cues. 
Previous research already indicated that pharmacists’ communication is more 
medication oriented than patient-centered; the communication is often more 
focused on the (bio)medical aspects of the drug use than on affective and 
psychosocial issues.
34-36
 This could explain our finding that pharmacists and 
pharmacy technicians most often responded with factual clarification to emotional 
cues. Still, more than one out of three emotional cues was acknowledged, by 
showing empathy, reflecting, checking, or giving minimal encouragement. This 
indicates that these professionals possess the skills to handle the patients’ concerns 
adequately to some extent, and that they need to be trained to improve their skills. 
In line with the MIARS, a factual clarification was categorized as an inadequate 
response. It can be argued that a factual clarification is not as inadequate as 
distancing and overt blocking. This might be taken into account in future research. In 
this study, we decided to follow the initial categorization, because when responding 
with a factual clarification the patient’s emotion is ignored and therefore the 
response is not considered to be adequate. 
Our findings are difficult to compare directly with other cue-responding studies, 
because of dissimilarities in settings (e.g. hospital), health care providers (e.g. 
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physician or nurse), and definitions and operationalization of cues and responses.
18
 
In addition, many studies that also used the MIARS were performed among cancer 
patients.
26,37,38
 Taking this into account, other studies show comparable findings, in 
that health care providers “missed” 53–72% of emotional cues in consultations with 
patients, by inadequately responding to them.
18
 Studies that did use the MIARS 
were among nurses, and showed that 50–60.6% of their responses were.
26,37,38
 Our 
study confirms these findings, which underline the importance of improving health 
care providers’ affective behavior, that is, becoming more responsive to patients’ 
concerns. In contrast to this, a study about consultations of pharmacist prescribers 
in England found that 81% of responses to emotional cues and concerns were 
adequate.
39
 Emotional cues, concerns, and responses were measured using another 
method but comparable to the MIARS. These opposite findings can be due to 
different goals of the sessions (prescribing vs. only counseling), other patient groups 
(patients with acute and chronic conditions vs. only chronic asthmatic patients), or 
pharmacists’ experiences in communication and counseling. 
Informational cues expressed by patients were merely related to ICS and inhaler 
use, which was the main aim of the session and therefore explicable. No 
informational cues were expressed about lifestyle. Pharmacist and pharmacy 
technicians responded most often in an adequate way to informational cues by 
giving appropriate information. By doing this, they fulfilled patients’ needs for 
information. However, in one out of five informational cue responses, inappropriate 
information was given. Providing wrong or incomplete information to patients could 
lead to incorrect knowledge, which could subsequently lead to nonadherence. We 
found that the provision of inappropriate information by pharmacists and pharmacy 
technicians during the sessions was significantly related to more concerns about ICS 
after the session. This suggests that inappropriate information made patients more 
worried about using ICS. The information could have been worrisome or confusing, 
or could just not have fulfilled patients’ needs sufficiently. 
Moreover, exploration of informational cues was associated with higher 
adherence at 3 months (i.e. about 1 month after the session). By exploring an 
informational cue, health care providers examine what underlies the patient’s 
request for information and may subsequently be able to more adequately fulfill the 
patient’s informational need. The resulting increase in knowledge could explain the 
positive association with medication adherence, as knowledge is known to be one of 
the determinants of adherence. The association we found can also be explained by 
the mediating role of self-efficacy (i.e. an individual’s confidence in his or her ability 
to take medication as prescribed).
40
 
The relationships found in this study are in conformity with the stress-coping 
perspective and support the assumption that appropriate instrumental 
communication contributes to patients’ health (by improved medication 
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adherence), whereas inappropriate instrumental communication does not. We even 
found a negative effect of providing inappropriate information (i.e. an increase of 
patients’ concerns). According to the stress-coping model, instrumental 
communication intervenes on patients’ problem-oriented coping skills. Further 
research is needed to explain and interpret our findings in light of problem-solving 
coping. 
Furthermore, our findings suggest that the type of response to informational 
cues is important in relation to concern beliefs and medication adherence, whereas 
patients’ expression of cues and concerns and providers’ responses to emotional 
cues are not. This is not entirely in line with assumptions that could be drawn from 
the stress-coping model and patient-centered communication that emphasize the 
attention to patients’ emotions and the importance of affective communication. 
This could indicate that affective communication has no effect on medication beliefs 
and adherence, but does not imply that affective communication is not important 
itself. Other outcomes measures might be more relevant in relation to affective 
communication, such as patient satisfaction, quality of life, and perceived quality of 
care. 
Our findings are also in contrast with the research previously performed on the 
relationships between types of cues, responses, and other patient outcomes. Only a 
few studies looked at these relationships. For instance, some examined the 
relationship between emotional cues, responses, and patient satisfaction. Although 
one study found no associations,
41
 Bertakis et al. found that expressions of 
emotional cues (i.e. “psychosocial topics”) were related to patient satisfaction,
42
 
whereas the study of Uitterhoeve et al. indicated an association between the 
expression of emotional cues as well as adequate cue-response behavior and 
patient satisfaction.
37
 In addition, Jansen et al. found only (marginally) significant 
relations between two types of responses to emotional cues and patient recall. 
Expressions of (emotional and informational) cues and responses to informational 
cues were not related to patient recall. As stated before, these divergent findings 
might be due to dissimilarities of study settings, type of health care provider, patient 
groups, and outcome measures. Further research is needed to investigate more 
extensively the relation between emotional and informational cues and responses, 
on the one hand, and patient outcomes on the other hand. This applies to the 
pharmacy profession, as well as to other health care professions. 
Contrary to previous findings about the content and process of counseling 
sessions at the pharmacy, no differences between pharmacists’ and pharmacy 
technicians’ sessions have been found regarding the number of cues and 
responses.
19
 
Finally, there are some directions for future research. First, in this study, the 
coded response was based on the first lag after the patient’s cue. In future studies, 
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other lags might also be taken into account to study the communication and the 
relations with patient outcomes. Second, more insight is needed into the stress-
coping model. A closer look can be taken on different elements of instrumental and 
affective communication in relation to coping and patient (health) outcomes. 
Attention needs to be paid to cue-responding behaviors, as well as to more general 
patient-provider communication. At last, interventions can be developed and tested 
to improve health care providers’ skills to detect patients’ cues and respond to them 
adequately. 
 
Strengths and limitations 
To our knowledge, no previous research has explored patients’ cues and 
pharmacists’ and pharmacy technicians’ cue-responding behavior during counseling 
sessions, or the relationship between cues, responses, and patient outcomes in 
terms of medication beliefs and self-reported adherence. 
This study has some limitations. First, our findings are only based on the sessions 
in which cues and responses were expressed. However, in more than one-fourth of 
the sessions no cues were expressed. This implies that our findings are not readily 
generalizable, but only give insight into sessions in which cues and responses did 
occur. Second, selection bias might have occurred during pharmacy as well as 
patient recruitment. The health care providers in our study might have shown better 
cue-responding behavior than nonparticipants would have shown, whereas 
participating patients might have more informational needs or concerns than 
nonparticipants. This hampers the generalizability of our findings. However, when 
looking at the level of patients’ concerns at baseline, it is found that these are low 
(below midscale of 13). Because of the small number of expressed cues and 
responses, we were not able to examine all types of cues and responses in relation 
to patient outcomes, nor could we control for confounders. In addition, we 
performed many statistical tests. Therefore, we should be cautious attaching clinical 
meaning to the associations we found. Replication of this study is recommended. 
Furthermore, we are aware of the fact that after the MIARS had been developed, a 
new system called VR-CoDES is now endorsed in the field of communication 
studies.
43
 However, since our previous study about the content of counseling 
sessions at the pharmacy revealed that these sessions are for a great part 
instrumental,
19
 we decided to use the expanded MIARS that has a part to measure 
this as well. Finally, we only used a self-reported measure of adherence. Using a 
more objective measure, for instance, pharmacy refill records, was difficult, because 
ICS prescriptions are only given quarterly, and refill adherence has to be determined 
with multiple prescriptions per patient. Thus, refill adherence can only give insight 
into longer term adherence, which was not the aim of this study. 
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Conclusion 
 
Patients with asthma expressed few emotional and informational cues during 
counseling sessions at the pharmacy about ICS. Many emotional cues were missed. 
Certain responses, namely, the absence of the provision of inappropriate 
information and the exploration of informational cues, seem to be clinically relevant. 
No differences were found between pharmacists’ and pharmacy technicians’ 
sessions in cue-responding. 
 
Practice implications 
In encounters with patients, pharmacists and pharmacy technicians need to pay 
more attention to detecting patients’ emotional and informational cues and handle 
them adequately. Communication trainings could be useful in improving these 
skills.
18
 Pharmacists and pharmacy technicians have to avoid providing 
inappropriate, incomplete, and ambiguous information to patients. Finally, patients 
have to be encouraged to voice their concerns and informational needs, and need to 
know that they do not have to be reserved in doing this. 
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Summary 
 
In this thesis, we aimed to investigate patient-provider communication in 
community pharmacy practice during counseling sessions about inhaled 
corticosteroids (ICS), and to take a closer look at factors that may relate to patients’ 
adherence to ICS. More specifically, we examined patient-related factors, healthcare 
provider-related factors, and the communication during counseling sessions in a 
private consulting room. 
 
We specified the following research questions:  
 
Part one: The patient 
1. What is the relationship between medication beliefs, self-reported and refill 
adherence, and asthma symptoms in patients using inhaled corticosteroids? 
2. How do patients’ Big Five personality traits relate to medication adherence? 
Part two: The healthcare provider 
3a. How do community pharmacists’ and pharmacy technicians’ perceptions of 
patients’ ICS beliefs differ from those of patients with asthma? 
3b. How do ICS beliefs of community pharmacists, pharmacy technicians, and 
patients with asthma differ from each other?  
Part three: The communication 
4. What are the process and content of the communication during counseling 
sessions about inhaled corticosteroids at the community pharmacy? 
5. How do pharmacists and pharmacy technicians respond to informational and 
emotional cues expressed by patients with asthma about inhaled 
corticosteroids and how are these responses related to patients’ medication 
beliefs and self-reported adherence? 
 
Main findings 
In Part one we examined to what extent two patient-related psychological factors 
relate to medication adherence, i.e. medication beliefs and Big Five personality 
traits. 
 
The relationship between medication beliefs, adherence, and symptoms in patients 
with asthma using inhaled corticosteroids (Chapter 2) 
In Chapter 2 we investigated the association between medication beliefs, 
subjectively and objectively measured adherence, and symptoms in patients with 
asthma using ICS. Patients’ necessity beliefs and concerns were assessed with the 
Beliefs about Medicines Questionnaire, self-reported adherence was measured 
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using four questions about ICS use, and the Asthma Control Questionnaire assessed 
asthma symptoms. Pharmacy refill adherence was calculated using the proportion of 
days covered. Data from 93 patients with asthma revealed a positive relation 
between necessity beliefs and self-reported adherence, but we found no other 
associations between beliefs and subjective or objective adherence measures. Also 
no relation was found between self-reported and refill adherence, nor between 
adherence and asthma symptoms. patients were indicated as significantly less 
adherent by the self-report measure (24.4%) than by the objective adherence 
measure (57.8%).  
 
Relation between Big Five personality traits and medication adherence (Chapter 3) 
In Chapter 3, the literature about the relationship between Big Five personality traits 
(i.e., neuroticism, extraversion, openness, agreeableness and conscientiousness) 
and medication adherence was systematically reviewed. Insight into this might 
contribute to developing more effective tailored interventions and to determine 
which patients are more inclined to be suboptimally adherent. We included 23 
studies (28 articles) in the review. There was no consistent evidence for a 
relationship between personality traits and medication adherence, but we did find 
some indications for an association between medication adherence and neuroticism 
as well as conscientiousness. 
 
In Part two, attention was paid to the perceptions and beliefs of healthcare 
providers about ICS. 
 
Differences in ICS beliefs (Chapter 4)  
Chapter 4 describes the differences between pharmacists‘ and pharmacy 
technicians‘ perceptions of patients‘ ICS beliefs and patients’ actual ICS beliefs, and 
the differences between the ICS beliefs of pharmacists and technicians and those of 
patients with asthma. ICS necessity and concern beliefs were assessed using (an 
adapted version of) the Beliefs about Medicines Questionnaire (BMQ). Pharmacists 
and technicians filled out the BMQ for themselves, and also in the way they thought 
most of their patients would complete it. Patients with asthma filled out the BMQ as 
well. A total of 136 pharmacists, 90 pharmacy technicians, and 161 patients 
completed the questionnaire. Pharmacists and technicians thought patients had 
more concerns about ICS than patients themselves reported (p<0.0001). They also 
thought that patients had stronger beliefs in their personal need for ICS than 
patients reported (p<0.01). Pharmacists reported lower levels of concerns than 
patients (p<0.05) and both providers attributed a higher level of necessity to ICS 
than patients did (p<0.0001). 
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Pharmacists and technicians clearly overestimated the level of concerns and the 
personal need for treatment that patients with asthma have regarding ICS. They also 
have, to some extent, stronger positive beliefs about ICS than patients have.  
 
Part three focused on the communication during counseling sessions about ICS at 
the community pharmacy. 
 
The process and content of the communication during counseling sessions (Chapter 
5) 
In this chapter, we investigated how pharmacists and pharmacy technicians 
communicate about ICS with patients with asthma and/or chronic obstructive 
pulmonary disease during counseling sessions, what topics they discussed, and 
whether pharmacists and pharmacy technicians differed in their communication. In 
total, 169 sessions were video-recorded and observed. The communication 
appeared largely instrumental. However, lifestyle, psychosocial issues, and ICS 
adherence were not often discussed. The average length of the sessions differed 
between pharmacists and pharmacy technicians (16.5 minutes and 11.3 minutes, 
respectively, p<0.001), and pharmacists used on average more affective utterances 
than technicians per session (89.0 utterances and 63.7 utterances, respectively, 
p<0.001).  
 
Pharmacists’ and pharmacy technicians’ responses to patients’ informational and 
emotional cues (Chapter 6) 
We aimed to examine cue-responding behavior at the pharmacy while counseling 
about inhaled corticosteroids (ICS) in relation to medication adherence and 
medication beliefs in patients with asthma. We analyzed 86 counseling sessions. 
Patients expressed 2.3 cues per session on average, which were mostly 
informational (70.8%). Patients provided no cues in more than a quarter of the 
sessions. To emotional cues, pharmacists’ and technicians’ responded somewhat 
more often inadequately (59.3%), and to informational cues mostly appropriately 
(63.6%). We found a relationship between providing inappropriate information and 
higher concerns post counseling (p<0.05), and between cue exploration and higher 
self-reported adherence at 3 months (p<0.05).  
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General discussion 
 
In this section we discuss the main findings of this thesis, compare them with other 
scientific literature and place them into a broader perspective.  
 
Beliefs about inhaled corticosteroids 
Patients’ beliefs 
In general, we know that necessity beliefs and concerns are both important in 
influencing medication adherence.
1
 However, in Chapter 2 we found that necessity 
beliefs seem more important in relation to ICS adherence than concerns are. This 
finding has been confirmed by recent literature.
2,3
 A review by Dima et al. reported a 
consistent relationship between ICS necessity beliefs and adherence, and found 
moderate evidence for concerns.
2
 Foot et al. found greater effect sizes of necessity 
beliefs than of concerns in their relation to asthma medications in their meta-
analysis.
3
 This evidence indicates that patients’ perceptions of personal need for ICS 
play an important role in ICS adherence. In two of our studies (Chapters 2 and 4), we 
found that more than one third of patients with asthma had doubts about the 
necessity of ICS, which is a considerably large group. Menckeberg et al. even found 
that almost half of the patients in their study (46.4%) had doubts about ICS.
4
 In 
contrast, another study by Horne and Weinman reported a lower numbers of 
patients (15%).
5
 The findings that large groups of patients may doubt the necessity 
of ICS strengthens the need to improve this. 
When attempting to improve adherence, it seems important to elicit patients’ 
perceptions of their need for ICS and to strengthen this need if necessary. 
Strengthening this need can be done by first identifying patients’ illness perceptions, 
and their experiences and expectations about the treatment, as they relate to ICS 
necessity beliefs.
6
 For example, some patients with asthma hold the “no symptom, 
no asthma” belief, which means that they think that they only have asthma when 
they experience symptoms: they do not perceive asthma as a chronic disease.
7
 In 
such cases, patients do not feel a personal need to use ICS in the long-term for 
controlling asthma. In addition, when starting to use ICS, it takes one or more weeks 
to experience its anti-inflammatory effects, in contrast to reliever medications of 
which the effects are experienced almost immediately. This can also cause doubts 
about the need to use ICS persistently. Clear explanation to patients about why ICS 
should be used daily and on a long-term basis (i.e. persistently) is therefore 
essential. Furthermore, having regular consultations (i.e. at least once a year) with a 
healthcare provider is associated with higher necessity beliefs and adherence to 
asthma medication (e.g. ICS).
8
 So having periodic contacts with a healthcare 
provider seems important. 
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However, the role of concerns in relation to ICS adherence should not be 
underestimated, as previous research did find evidence for this association 
(although weaker than for necessity beliefs).
2,3,6
 Therefore, exploring and addressing 
patients’ concerns about (possible or perceived) side effects should not be 
neglected. One should also be alert to hints of concerns (i.e. ‘cues’) as well as the 
underlying reasons for patients to be worried. Providing information about side 
effects, how to reduce the risk of side effects, and reassuring patients are methods 
to reduce concerns. Furthermore, next to exploring and discussing concerns of 
patients, another solution is to make changes in the ICS treatment when patients 
suffer from their side effects (e.g. switching to another type of inhaler).
6
 
 
Pharmacists’ and pharmacy technicians’ beliefs 
In Chapter 4 we explored the perceptions of pharmacists and pharmacy technicians 
about patients’ ICS beliefs, and the pharmacists’ and technicians’ own ICS beliefs in 
comparison to patients’ ICS beliefs. Discrepancies in medication beliefs might 
influence the communication about these beliefs during patient-pharmacist 
interactions. Our results showed differences between providers’ perceptions and 
beliefs on the one hand, and patients’ beliefs on the other hand. Pharmacists and 
technicians overestimated the level of concerns and the personal need for 
treatment that patients with asthma have regarding ICS. Pharmacists and 
technicians attributed a higher level of necessity beliefs to ICS than patients did, 
while pharmacists had lower concerns about ICS than patients reported.  
The finding that pharmacists and technicians thought that patients have stronger 
necessity beliefs than patients actually report is a relevant outcome, especially in 
light of our findings discussed above. This could implicate that pharmacists and 
technicians are less likely to (continue to) ask questions about patients’ necessity 
beliefs when communicating with patients, although this seems very important. It 
also could implicate that pharmacy professionals have formed an incorrect image or 
expectation of patients with asthma. An explanation for this might be a lack of 
retrieving the information needed to make an accurate image of these patients. We 
assume that this process is working as a vicious circle. By first not exploring whether 
patients have doubts about using ICS, pharmacists and technicians might have 
formed the wrong expectation that patients have few doubts, and therefore they do 
not pay much attention to the patients’ doubts. This confirms and maintains their 
perception that patients see a higher need for using ICS than patients actually do. In 
addition, the finding that pharmacist and technicians themselves have higher ICS 
necessity beliefs than patients have might be an additional (unwitting) barrier to pay 
attention to the need for using ICS. Awareness of the found discrepancies should 
encourage pharmacists and technicians to be (more) alert to patients’ medication 
beliefs during their interactions. 
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Communication during counseling sessions 
In Chapter 5 and 6, the communication during counseling sessions about ICS was 
studied, indicating that there is room for improvement as regards the pharmacists’ 
and technicians’ communication. The instrumental and affective communication can 
be improved, both of which are important aspects to fulfill patients’ informational 
and emotional needs, respectively, as depicted in the stress-coping model (see 
Chapter 1).  
As described in Chapter 5, pharmacists and technicians discuss many important 
topics during the counseling sessions, but pay less attention to informational topics 
as lifestyle (e.g. smoking and exercise), and even more importantly, to ICS 
adherence as such. As patients find it difficult to talk about their adherence 
behavior, and healthcare providers also tend to have a reticence to elicit this,
9
 
pharmacists and technicians should address this topic more actively in an open, non-
judgmental way. Also psychosocial topics, like patients’ medication beliefs, were 
hardly addressed by pharmacists, technicians and patients. The counseling sessions 
consisted largely of instrumental communication. Yet affective communication is 
crucial for relationship building between healthcare providers and patients. 
However, the predominance of instrumental communication might not be 
problematic as long as it fits patients’ informational and affective needs, which need 
to be elicited before providing information and support.  
Next to the content of the instrumental communication, we looked (in Chapter 
6) at the informational cues expressed by patients and the cue-responding behavior 
of pharmacists and technicians. As relationships were found for informational cue-
responding behaviors with patients’ concerns and ICS adherence, appropriate 
instrumental communication seems to be of great importance during counseling 
sessions. The findings in Chapter 6 indicated that pharmacists and technicians 
relatively often ‘missed’ emotional cues (by responding inadequately to patients’ 
emotional cues). The emotional communication skills of pharmacists and technicians 
should be improved; they should become more responsive to patients’ concerns. 
After all, in patients who leave the pharmacy with the same concerns as when they 
came, distress might persist or increase unnecessarily.  
In addition, the studies in Chapters 5 and 6 showed that patients participate 
marginally during the counseling sessions in terms of question asking and cue 
expression. Patients may have had few concerns or informational needs, felt no 
opportunity to ask their questions, or may not have wanted or dared to do this. 
Pharmacists and pharmacy technicians need to encourage patients to ask more 
questions. In addition, patients could prepare their questions before the 
consultation (e.g. by writing down their questions or by using a question prompt 
sheet).  
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The results also showed that there is much variation between individual 
sessions. Different topics are discussed, the amount of affective talk between 
pharmacists and technicians is variable, and the counseling session length varies 
considerably. Although not reported in the studies, we noticed during the video-
analyses that the patient’s inhalation technique was not checked by all pharmacists 
and pharmacy technicians. Therefore we suggest to develop guidelines for the 
counseling sessions with respect to the content, while remaining flexible and 
responsive to patients’ cues, and showing more affective and psychosocial talk. 
Nonetheless, some standard information for patients is crucial for ICS adherence. 
Still, at the same time, patients differ in their need for information, and therefore 
the degree of information provision should also be adapted to patients’ needs. This 
also applies to degree of affective communication. This implies that pharmacists and 
technicians might need to be more responsive to patients’ needs; a patient-
centered approach is of importance during counseling sessions at the community 
pharmacy. Below, we explain the concept of patient-centered communication in 
more detail.  
 
Patient-centered communication 
In the last decades, much attention has been paid to patient-centered 
communication in healthcare practice as well as in research. It is now seen as a 
requirement for delivering high quality care. In general, a patient-centered approach 
is different from the traditional, more paternalistic, biomedical approach, which 
focuses on the patient’s disease and its signs rather than on the patient’s needs for 
information and support.
10
 Although patient-centered communication is an 
important concept, it is also an ambiguous concept. No clear consensus has been 
achieved in the literature about how to define patient-centered communication and 
different definitions are used. Epstein and Street (2005) provide the following 
operational definition of patient-centered communication by specifying four 
communication domains: 1) eliciting and understanding the patient’s perspective— 
concerns, ideas, expectations, needs, feelings and functioning, 2) understanding the 
patient within his or her unique psychosocial context, 3) reaching a shared 
understanding of the problem and its treatment with the patient that is concordant 
with the patient’s values, and 4) helping patients to share power and responsibility 
by involving them in choices to the degree that they wish.
11
 In this perspective it is 
always important to find out if patients have the necessary skills to contribute to 
each of these domains. 
The aim of patient-centered communication is to help healthcare providers to 
deliver care that is congruent with the patient’s needs, wants and values, and that 
facilitates patient participation in care-related decisions.
11
 A subordinate aim is to 
improve patient-related outcomes such as medication adherence, patient 
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satisfaction, and health outcomes (e.g. signs and symptoms). One might expect that 
an approach that is tailored to what a patient needs to be adherent, has more effect 
than a traditional approach. However, Mead and Bower found in their review no 
consistent relationships between patient-centered consultations and several patient 
outcomes in primary care (e.g. patient satisfaction, adherence, concerns, and health 
status).
12
 This may have been due to weaknesses in the internal and external validity 
of the included studies in the review. Similar findings have been reported more 
recently by Zandbelt et al.
13
 
 
Implications for community pharmacy practice and policy making 
The findings in this thesis provide input for community pharmacy practice and policy 
making. Although widely encouraged and studied in healthcare practice, the 
concept of patient-centered communication is relatively new for community 
pharmacy practice. Yet, it should be applied to community pharmacy practice in 
order to improve the communication with patients as part of pharmaceutical care, 
as shown by our research as well as broadly supported by scientific literature.
14-17
 
In this thesis we focused on the communication during ICS counseling sessions, 
which are part of pharmaceutical care. Other types of interaction are also relevant 
(e.g. medication reviews and dispensing at the counter). When stressing the 
importance of patient-centered counseling, there is a need to place pharmaceutical 
care more consistently in a patient-centered context.  
The implications of the findings in this thesis for community pharmacy practice 
are two-fold. On the one hand there are implications for implementing counseling 
sessions. On the other hand, there are implications for enhancing  
patient-centeredness in these sessions. Before going into the details of this, we first 
have to address that several (practical) barriers need to be taken into account to 
successfully implement and enhance counseling sessions and patient-centered 
communication, respectively.  
 
Implementation barriers related to counseling sessions and patient-centered 
communication 
First, time constraints are a major barrier to patient-centered communication and 
organizing counseling sessions. Paying more attention to patients’ needs and wants 
requires extra time, and pharmacists and technicians are usually quite busy. Second, 
patients interact with different pharmacy staff members, which might hinder the 
building of a relationship between provider and patient. Third, a lack of privacy of 
patients at the pharmacy counter (where most of the interactions take place) is a 
barrier; making use of a private consulting room is therefore a requirement. When 
patients are not aware of the existence of such a room, patients will not ask about 
this possibility. Most of the pharmacies are equipped with a consulting room (as this 
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is a formal quality requirement of the Royal Dutch Association for the Advancement 
of Pharmacy (KNMP)), however, these may not be used intensively everywhere. 
Fourth, some patients do not always visit the pharmacy themselves to have their 
prescriptions filled (e.g. someone else collects the medication or the medication is 
delivered at home by an unskilled deliverer). For the latter group, the pharmacy is a 
less suitable place for communication. Fifth, although dispensing of first 
prescriptions and medication reviews (i.e. a structured assessment of the patient’s 
multiple medicines, aimed at improving medication use and health outcomes) are 
being reimbursed, there is no reimbursement yet for performing counseling sessions 
like we have investigated. Finally, patients may be unaware of the fact that 
pharmacists and technicians perform counseling sessions, or they do not sufficiently 
perceive pharmacists and technicians as providers to consult when having questions 
or medication-related problems.
14,18
 
In the following paragraphs, we will discuss in what ways patient-centered 
communication and counseling sessions can be implemented and how some of the 
described barriers might be tackled. 
 
Implications for community pharmacy practice 
Offering counseling sessions to patients is a way to deliver more patient-centered 
pharmaceutical care, and to let pharmacists take up a more prominent role as a 
healthcare practitioner. However, spending more time on patient counseling will 
probably require more pharmacy staff capacity; pharmacists have time consuming 
managerial and administrative tasks. Hiring personnel for the administrative tasks 
facilitates pharmacists to have more time for patient counseling. Another solution is 
to hire an extra pharmacist or technician who focusses especially on patient 
counseling activities. This will need extra financing (e.g. through patient-dependent 
reimbursement,
19
 which will be explained in paragraph Implications for policy). 
Furthermore, it should be studied and decided to what kind of patients 
counseling sessions are offered, how often, and in what way. E.g. should patients be 
counseled on their own initiative, and/or should all patients with a chronic disease 
be invited for a counseling session every year, and/or should selections be made 
based on refill data indicating that patients may not be adherent to their medication 
as assessed by these data.  
 
Implications for education 
One way to enhance patient-centered communication is through education. Little 
research has been conducted to examine and enhance patient-centered 
communication in community pharmacy practice. In addition, it has not yet been 
crystallized what the concept of patient-centered communication implies for 
pharmacy practice. Therefore, Wolters et al. recently developed the so called 
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Utrecht’s Model for Patient-centered communication in the Pharmacy (the UMPA 
model), with the aim to describe the concept of patient-centered communication 
for pharmacy practice (Figure 7.1).
14
 The UMPA model is also used as a teaching 
model in the pharmaceutical curricula (undergraduate) at the Utrecht University 
(personal communication with the author).  
 
 
Figure 7.1 The UMPA model: patient-centered communication in the pharmacy about drug related 
problems (Wolters et al.14) 
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The UMPA model consists of two main parts with subordinate categories: 1) 
underlying concepts and assumptions about patient-centeredness, and 2) the 
patient-centered consultation. Wolters et al. have identified three categories of 
underlying concepts and assumptions about patient-centeredness, which relate to 
the patient, the pharmacist, and to the therapeutic relationship. On the basis of the 
findings of this thesis, we would suggest to also pay explicit attention to the 
pharmacists’ (perceptions of patients’) medication beliefs as part of pharmacists’ 
self-reflection. 
With respect to the second part of the model, the patient-centered consultation, 
the two underlying categories are shared problem-defining and shared decision-
making. The goal of shared problem-defining is to explore and understand the 
patient’s perspective, resulting in a shared understanding (by both the pharmacist 
and the patient) of the patient’s problem(s).  
Using a model such as the UMPA-model for the development of undergraduate 
communication courses might be of great importance to improve and implement 
patient-centered communication in community pharmacy. Pharmacy students will 
acquire the necessary patient-centered communication skills this way, and will apply 
them more consistently in daily practice. This applies not only to the education of 
pharmacists, but also to the education of pharmacy technicians.  
Next to undergraduate education, postgraduate trainings would be important in 
improving patient-centered communication, as shown by studies performed in 
primary care. A review by Dwamena et al. indicated that training interventions were 
generally effective in improving consultation processes such as exploring patients’ 
beliefs, discussing treatment options, showing empathy, and patients’ perceptions 
of providers’ attentiveness.
20
 This implicates that training programs can be largely 
successful in improving the communication skills of healthcare providers. 
Postgraduate communication courses for pharmacists comprising training in patient-
centered communication are therefore promising and should be developed for and 
offered to practicing pharmacists and pharmacy technicians to enhance their skills. 
Pharmacists should be encouraged to follow such training courses to further 
improve their communication skills. 
 
Implications for policy 
Stimulation and implementation of patient-centered counseling in community 
pharmacy can also be encouraged by policy makers. Although pharmacists 
consented to the Dutch Medical Treatment Act, much more than consenting to this 
act alone is needed to improve patient counseling at the pharmacy. 
For instance, Dutch government and health insurers could promote the 
extension of financial reimbursement of pharmaceutical counseling sessions. As lack 
of funding is a barrier for pharmacists to provide counseling sessions, a financial 
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incentive could work as a motivator to offer these sessions to patients more 
frequently. Although dispensing of first prescriptions and medication reviews are 
now being reimbursed, other types of counseling sessions are not. These might be 
equally important as (or even more important than) for the dispensing of first 
prescriptions or medication reviews, as counseling sessions could also be offered to 
patients who are already using the medication and who do not necessarily use 
multiple medicines, because they may also need or want counseling. A possible way 
of financing could be through patient-dependent reimbursement of pharmaceutical 
care, as recently proposed by Velzel et al.
19
 According to this plan, patients with a 
chronic disease register themselves at their own pharmacy and pay a fee which is 
reimbursed by health insurers. To cover the costs of care, patients with a higher 
need for pharmaceutical care pay a higher fee than patients with lower needs.  
In addition, the KNMP is currently developing a communication guideline for 
pharmaceutical consultations, which is based on the Calgary-Cambridge Guide 
(personal communication with the author). The Calgary-Cambridge Guide provides a 
structure for the medical interview and is based on the principles of patient-
centered communication. It is often used in communication courses for medical 
students and general practitioners and has many similarities with the 
abovementioned UMPA model. The implementation of such a guideline in pharmacy 
practice might be very useful to improve patient-centered communication during 
counseling sessions. The KNMP guideline for pharmaceutical consultations is 
currently tested in a pilot study.  
 
Implications for initiatives by community pharmacy practice 
Community pharmacists themselves could undertake initiatives to perform patient-
centered activities. An example is a Dutch community pharmacy service in The 
Hague, “Pills and talk”, a low threshold service for patients who want to talk about 
their medication with the pharmacy staff. The pharmacy team delivers care with a 
personal approach and patients have the opportunity to ask for a counseling session 
with the pharmacist or one of the technicians in a private room. Patients appreciate 
the services of this pharmacy.
21,22
  
Furthermore, as previously mentioned, patients have contact with different 
pharmacy staff members, which might be a barrier for the relationship building 
between provider and patient. Relationship building is important for establishing 
good patient-centered communication. A project that takes this into account is the 
“Farmabuddy project”, in which patients with cancer in the palliative or terminal 
phase only have contact with the same two pharmacy technicians. These technicians 
provide intensive pharmaceutical care to the patients (and their caregivers) that is 
focused on the patient.
23
 This project shows that it is possible to organize 
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pharmaceutical care in such a way that supports patients who need extra guidance 
and counseling and to overcome barriers. 
These examples demonstrate how initiatives in community pharmacy practice 
can contribute to (overcoming barriers related to) patient-centered communication, 
and that it is possible for community pharmacy staff to become more engaged in 
counseling patients. Pharmacists should be encouraged to develop or participate in 
these kinds of initiatives and projects more often. 
 
Implications for community pharmacists’ and pharmacy technicians’ role as 
healthcare providers 
The results of this thesis provide insight into how pharmacists currently perform 
their role as healthcare providers, especially in the field of communication during 
counselling sessions with patients with asthma and/or COPD. In addition, the 
communication of pharmacy technicians has been studied. If pharmacists and 
technicians want to fulfill their role as communicative healthcare providers, the 
communication of both types of providers needs to become more patient-centered. 
We have not evaluated which type of provider (pharmacist or technician) 
performs the counseling sessions better. Results of the study exploring pharmacists’ 
and pharmacy technicians cue-responding behavior (Chapter 6) indicate that there 
were no major differences in their behaviors. However, the study about process and 
content of counseling sessions (Chapter 5) did find some differences in affective and 
instrumental communication, and also found that both types of providers need to 
improve their communication skills. We suggest that patients’ characteristics (e.g. 
the complexity of the patients problem(s) or educational level) may help to 
determine which type of provider is more eligible to counsel the patient. Patients 
with complex problems could possibly be counseled better by a pharmacist, as the 
pharmacist has more biomedical knowledge.  
In addition, as the role of the pharmacists is changing, the role of the pharmacy 
technicians will probably also change (in the future). For example, pharmacy 
technicians’ tasks will also extend. A study in the UK indicated that pharmacy 
technicians are willing to expand their (clinical and management related) tasks, so 
that pharmacists may have more time for direct patient contacts.
24
 This might also 
apply to pharmacy technicians in the Netherlands, but this remains to be studied. 
Furthermore, although pharmacists have positive attitudes and intentions 
toward their role expansion as a healthcare practitioner and to become more 
patient-centered,
25
 many patients do not yet perceive pharmacists as a healthcare 
practitioner.
26-28
 However, patients recently reported that they would appreciate 
extra counseling about their medication at the community pharmacy.
29
 Therefore, 
pharmacists need to take up their role more prominently (e.g. by undertaking 
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patient-centered initiatives) so that patients become more aware of the accessibility 
of community pharmacies in the domain of patient counseling. 
 
Methodological considerations 
Some methodological considerations need to be taken into account to interpreter 
the results presented in this thesis. 
 
Observational instruments 
In Chapter 5 and 6, we used two different observational instruments to analyze the 
communication during counseling sessions, which had been recorded on videotape. 
These were the Roter Interaction Analysis System (RIAS),
30,31
 and the Medical 
Interview Aural Rating Scale (MIARS).
32,33
 By using the RIAS, we got insight into the 
content of the conversations and by using the MIARS we found information about 
the interaction between the pharmacists, technicians, and patients by analyzing 
sequences (i.e. the providers’ responses to the patients’ cues). Therefore, the 
measurements are complementary to each other. Using both instruments provided 
much important information about the communicative behaviors of patient, 
pharmacists, and pharmacy technicians.  
However, there are some limitations as both instruments were adapted to 
analyze specific elements of the sessions in our research. We subdivided the original 
RIAS categories into smaller content categories, which has no impact on the validity 
of the original categories; however, the validity of the smaller content categories 
might be lower. In addition, we expanded the original MIARS with an informational 
part, which might be less valid. Previous studies showed that the RIAS has a high 
(predictive and concurrent) validity.
30
 The adapted RIAS and MIARS have not been 
validated. The interrater reliability (determined using the interrater class coefficient) 
was good for the informational part of the MIARS, indicating the two observers 
agreed on the operationalization of the concept that was measured. 
Based on the findings of these observational instruments we have drawn 
conclusions about the degree of patient-centered communication during the 
counseling sessions. Although we found results that gave insight into the patient-
centeredness of the communication, these instruments were not specifically 
developed to measure all aspects of patient-centered communication, as we aimed 
to investigative communication in a broader sense.  
 
Study design 
The studies in this thesis used cross-sectional and observational designs, except for 
the systematic literature review in Chapter 3. This implies that the associations 
found in our studies cannot be interpreted as causal relationships (e.g. ICS 
adherence might also influence patients’ necessity beliefs). Furthermore, by using 
170 Chapter 7 
these designs we were not able to conclude whether (the degree of) patient-
centered communication by pharmacists or pharmacy technicians had an impact on 
ICS adherence, and whether the pharmacists’ and technicians’ perceptions and 
beliefs had an influence on their communication and on the medication-taking 
behaviors of their patients. However, since little was known about the topics 
investigated in our studies, our findings provide new and relevant insights into 
patients’ and providers’ medication beliefs and communication at the community 
pharmacy and can thus form the basis for further research. 
 
Selection bias 
During the recruitment of pharmacists and patients, selection bias has undoubtedly 
played a role. The pharmacists were part of The Utrecht Pharmacy Practice network 
for Education and Research (UPPER). This practice-based research network has been 
formed to support student internships and facilitate research in pharmacy 
practice.
34
 The pharmacists recruited through this network were probably not 
representative of the whole profession, as they are more engaged in this topic of 
research. Furthermore, participating pharmacists and technicians may have had 
better communication skills than pharmacists and technicians who did not want to 
participate. Finally, participating patients may also have had other characteristics 
than patients who did not wish to participate (e.g. a higher need for information 
about ICS, having more concerns, or experience a higher personal need for ICS). 
These (potential) selection biases may limit the generalizability of the findings 
presented in this thesis.  
 
Counseling sessions 
Although counseling of patients is part of the usual pharmaceutical care provided by 
pharmacists, it is open to question whether the counseling sessions studied in this 
thesis are standard services offered by every community pharmacy. Therefore, our 
results may not reflect the actual care given by pharmacists and technicians. 
However, as expected by the expansion of their role as a healthcare providers, 
pharmacists should perform these sort of counseling activities more consistently. 
This thesis provides insight into the current level of communication skills of 
pharmacists and technicians who are willing to have their behavior examined. Some 
general instructions were provided to the pharmacists and technicians about the 
counseling sessions to ensure that they knew what the aim of the session was (i.e. 
“discuss the patient’s experience with ICS use, the effectiveness and (possible) side-
effects of ICS, and whether the patient uses ICS in an appropriate way”). These 
instructions may have had effect on the content of the sessions, but as these were 
quite general we do not expect that the communication styles were influenced 
much by the instructions. 
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Recommendations for future research 
We have the following recommendations for future research: 
 Our studies focused, amongst others, on medication beliefs in relation to ICS 
adherence. Next to beliefs of patients, other patient-related factors relate to 
medication adherence that might play a role in counseling sessions, such as 
patients’ perceived self-efficacy,
35
 health (il)literacy,
36
 and perceived barriers and 
facilitators.
37,38
 Further research should make clear how pharmacists and 
technicians should take these factors into account in their contacts with patients. 
In addition, our research only gives insight into the counseling sessions about 
ICS. More research is needed into the communication styles of pharmacists and 
technicians during counseling about other drug therapies. 
 Little is still known about the influence of the pharmacists’ and technicians’ 
characteristics on patient-provider communication. In our research we got 
insight into the pharmacists’ and technicians’ ICS beliefs, and perceptions of 
patients’ ICS beliefs, but additional research is needed to know how this relates 
to provider-patient communication and to patients’ medication adherence.  
 More research into patient-centered communication at the community 
pharmacy in relation to medication beliefs, adherence and other outcomes is 
necessary, not only during counseling sessions. As most of the patient-provider 
interactions occur at the counter of the pharmacy, it is also important to get 
more insight into the degree of patient-centered communication during these 
conversations and how this can be improved. Dutch studies about 
communication at the community pharmacy counter have already shown that 
patients are not encouraged to participate actively in the conversation and that 
patients’ experiences, perceptions and preferences about prescribed 
medications are not discussed routinely.
39,40
 Therefore a training has recently 
been developed to enhance patient-centered communication at the counter.
41
 
In addition, to perform good research on patient-centeredness, consensus must 
be reached about the definition and operationalization of patient-centered 
communication.  
 Developing and evaluating evidence-based training programs and interventions 
to enhance patient-centered communication in the pharmacy is important to 
offer effective trainings to pharmacists and technicians. Next to this, 
(implementation of) tools to deliver and measure patient-centered care need to 
be evaluated. An example is the Goal-Attainment Scale (GAS), which is an 
instrument for healthcare providers to set, together with the patient, individual 
therapeutic goals in daily practice (e.g. climbing the stairs without getting out of 
breath).
42
 Implementing such tools in pharmacy practice might be useful in 
enhancing patient-centeredness. This is currently studied in the Netherlands by 
Verdoorn et al. (work in progress, SIR Institute, Leiden). 
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 More insight is needed into the effects of education at the pharmacy on 
inhalation techniques. As around 70% of the patients using inhalers demonstrate 
an incorrect inhalation technique, a focus on how to improve this technique is 
important.
43
 Better teaching techniques might be developed and validated, and 
the effects of repetitive checking of patients’ inhalation techniques by the 
pharmacy team could be studied. Also, many of the healthcare providers who 
give inhalation instructions do not demonstrate the appropriate technique 
themselves.
44
 Research on how patients are instructed at the community 
pharmacy and what can be improved is therefore important. 
 Last but not least, more research is needed into the role and task division 
between pharmacist and pharmacy technician in the provision of patient-
centered counseling in the Netherlands, and how barriers to provide patient-
centered services might be tackled.  
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Inleiding (Hoofdstuk 1) 
 
In dit proefschrift richten we ons op patiënten met astma en/of chronische 
obstructieve longziekte (COPD). Astma en COPD zijn chronische aandoeningen 
waarvoor medicijnen worden voorgeschreven die voor een langere tijd of zelfs 
levenslang moeten worden ingenomen. In het algemeen is het voor mensen met 
een chronische aandoening moeilijk hun medicijnen in de juiste frequentie en dosis 
in te nemen. Uit onderzoek blijkt dat 20% van de patiënten met een chronische 
aandoening therapieontrouw is; deze patiënten gebruiken hun medicijnen niet zoals 
voorgeschreven door de zorgverlener.  
De algemene term voor het innemen van medicatie volgens voorschrift is 
therapietrouw, in het Engels medication adherence. Het proces van therapietrouw 
bestaat uit drie fasen: starten, implementeren en stoppen. Tijdens iedere fase kan 
therapieontrouw optreden. Daarnaast kan ook het onderscheid gemaakt worden of 
een patiënt bewust of onbewust therapieontrouw is. Bij bewuste ontrouw kiest de 
patiënt er zelf voor om de therapie aan te passen, te stoppen of niet te starten, 
bijvoorbeeld vanwege bijwerkingen. Er is sprake van onbewuste therapieontrouw 
als een patiënt niet in staat is om het geneesmiddel trouw te gebruiken, 
bijvoorbeeld door vergeetachtigheid. 
De mate waarin een patiënt therapietrouw is, is gerelateerd aan verschillende 
factoren. Zo hebben patiënten verschillende medicatieopvattingen, medication 
beliefs. In dit proefschrift richten we ons op opvattingen over de medicatie voor een 
specifieke ziekte. Deze specific medication beliefs zijn onder te verdelen in 
opvattingen over de noodzaak (necessity beliefs) en zorgen (concerns). Necessity 
beliefs zijn de opvattingen van de patiënt over de persoonlijke noodzaak van de 
therapie; de patiënt kan bijvoorbeeld twijfels hebben over de noodzaak ervan. 
Concerns verwijzen naar de zorgen die patiënten kunnen hebben over mogelijke 
nadelige gevolgen van de therapie, zoals bijwerkingen. Volgens het Necessity-
Concerns framework zijn hogere necessity beliefs gerelateerd aan hogere 
therapietrouw, waarbij hogere een verband hebben met lagere therapietrouw. 
Een andere factor die gerelateerd kan zijn aan therapietrouw, is de 
communicatie tussen patiënten en zorgverleners. Het stress-coping model stelt dat 
instrumentele communicatie, het bespreken van medische en therapeutische 
informatie, belangrijk is omdat patiënten de behoefte voelen om kennis over hun 
ziekte en de therapie te hebben. Daarnaast kunnen de emotionele behoeften van de 
patiënt door affectieve communicatie vervuld worden. Emotionele behoeften zijn 
behoeften die gaan over dat een persoon zich gehoord en begrepen voelt.  
Bovendien is iedere patiënt verschillend; iedereen heeft andere 
(medicatie)opvattingen, verlangens en gevoelens. Hierdoor is het belangrijk dat de 
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communicatie op de patiënt afgestemd wordt, dit heet patiëntgerichte 
communicatie. Patiëntgerichte communicatie kan het bespreken van  
therapie(on)trouw bevorderen, een onderwerp dat momenteel weinig aan bod 
komt in gesprekken tussen zorgverlener en patiënt.  
Dit proefschrift focust zich op de openbare apotheker en de apothekersassistent. 
Er is weinig over hun communicatie bekend, terwijl hun rol als zorgverlener groter 
wordt. Een van de belangrijkste taken van apothekers is het geven van 
farmaceutische patiëntenzorg, met als doel om medicijngebruik en 
gezondheidsuitkomsten te optimaliseren. Door de opname van openbare 
apothekers in de Wet op de geneeskundige behandelingsovereenkomst (WGBO) in 
2007, hebben apothekers een expliciete rol gekregen in het geven van voorlichting 
en counseling aan patiënten met betrekking tot hun medicatiegebruik. Apothekers 
en assistenten zijn de aangewezen zorgverleners om patiënten te counselen in hun 
medicatiegebruik, omdat zij laagdrempelig zijn, de laatste zorgverleners zijn die de 
patiënt ziet als hij of zij medicatie ophaalt en omdat zij met behulp van 
aflevergegevens inzicht hebben in het medicijngebruik van de patiënt. Ook 
beschikken apothekers over een aparte spreekkamer. Hier kunnen gesprekken 
gevoerd worden met de patiënt over zijn of haar medicatiegebruik en ervaringen 
hiermee. Zulke gesprekken noemen we farmaceutische consulten. Er is nog weinig 
onderzoek gedaan naar hoe openbare apothekers en apothekersassistenten met 
patiënten communiceren tijdens deze consulten.  
Verder richten we ons in dit proefschrift specifiek op patiënten met astma en/of 
COPD die inhalatiecorticosteroïden (ICS) gebruiken. In Nederland hebben ongeveer 
610.000 mensen astma en hebben 600.000 mensen COPD. ICS zijn 
ontstekingsremmers die dagelijks en voor een langere tijd ingenomen dienen te 
worden met behulp van een inhaler. Voor astma zijn ICS de belangrijkste medicatie 
om de ziekte onder controle te houden, voor COPD hangt het af van de ernst van de 
ziekte of ICS worden voorgeschreven. Ongeveer 36% van de patiënten met astma 
en/of COPD is therapieontrouw. Daarnaast heeft 70% van deze patiëntengroep een 
verkeerde inhalatietechniek, waardoor de medicatie de longen niet goed bereikt en 
dus minder effect heeft dan bij een goede techniek. Omdat er ruimte voor 
verbetering is in het medicijngebruik van patiënten met astma en/of COPD, zijn 
openbare apothekers de aangewezen zorgverleners om patiënten voorlichting te 
geven en te counselen, aangezien zij als taak hebben patiënten inhalatie-instructies 
te geven en de medicijnen aan hen af te leveren. 
 
Doel van het onderzoek 
Het algemene doel van het onderzoek is om de patiënt-zorgverlener communicatie 
over ICS tijdens farmaceutische consulten in de openbare apotheek te onderzoeken 
180  Nederlandstalige samenvatting 
en om factoren nader te bekijken die een verband kunnen hebben met de 
therapietrouw van patiënten aan ICS. 
 
Onderzoeksvragen 
Deel één: De patiënt 
1. Wat is het verband tussen medicatieopvattingen, therapietrouw op basis  
van zelfrapportage en aflevergegevens, en astmasymptomen bij patiënten 
met astma die ICS gebruiken? 
2.  Wat is het verband tussen Big Five persoonlijkheidskenmerken van 
patiënten en therapietrouw aan medicatie? 
Deel twee: De zorgverlener 
3a. Hoe verschilt de zienswijze van openbare apothekers en 
apothekersassistenten op de opvattingen van patiënten over ICS van de 
opvattingen van patiënten met astma zelf? 
3b. Hoe verschillen de opvattingen over ICS van openbare apothekers, 
apothekersassistenten en patiënten met astma? 
Deel drie: De zorgverlener 
4.  Hoe verloopt de communicatie tijdens counseling gesprekken over ICS in de 
openbare apotheek wat betreft proces en inhoud? 
5.  Hoe reageren apothekers en apothekersassistenten op informationele en 
emotionele signalen van patiënten met astma over ICS en hoe zijn deze 
reacties gerelateerd aan medicatieopvattingen en zelfgerapporteerde  
therapietrouw? 
 
Belangrijkste bevindingen  
In deel één van dit proefschrift hebben we gekeken naar de mate waarin twee 
psychologische factoren zijn gerelateerd aan therapietrouw aan medicatie, namelijk 
medicatieopvattingen en Big Five persoonlijkheidskenmerken.  
 
Het verband tussen medicatieopvattingen, therapietrouw op basis van 
zelfrapportage en afhaaldata, en astmasymptomen bij patiënten met astma die ICS 
gebruiken (Hoofdstuk 2) 
In Hoofdstuk 2 onderzochten we het verband tussen medicatieopvattingen, 
subjectief en objectief gemeten therapietrouw, en astmasymptomen bij patiënten 
die ICS gebruiken. Necessity beliefs en concerns zijn gemeten met de Beliefs about 
Medicines Questionnaire (BMQ). Zelfgerapporteerde therapietrouw is bepaald met 
behulp van vier vragen over ICS gebruik. De Asthma Control Questionnaire is 
gebruikt om astmasymptomen vast te stellen. Therapietrouw op basis van apotheek 
afhaaldata is berekend met behulp van proportion days covered. Data van 93 
patiënten met astma zijn geanalyseerd. De resultaten lieten een positief verband 
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zien tussen necessity beliefs en zelfgerapporteerde therapietrouw. We vonden geen 
andere verbanden tussen medicatieopvattingen en therapietrouw op basis van 
zelfrapportage en aflevergegevens. Daarnaast was er geen verband tussen 
therapietrouw bepaald met zelfrapportage en bepaald met aflevergegevens, ook 
was er geen relatie tussen therapietrouw en astmasymptomen. Op basis van 
zelfrapportage werden minder patiënten (24,4%) therapietrouw bevonden dan op 
basis van aflevergegevens (57,8%). 
 
Het verband tussen Big Five persoonlijkheidskenmerken van patiënten en 
therapietrouw aan medicatie (Hoofdstuk 3) 
Hoofdstuk 3 bevat een systematisch literatuurreview over het verband tussen Big 
Five persoonlijkheidskenmerken (neuroticisme, extraversie, openheid, inschikkelijk-
heid en nauwgezetheid) en therapietrouw aan medicatie. Inzicht hierin kan 
bijdragen aan meer effectieve, persoonsgerichte interventies en om te bepalen 
welke patiënten meer geneigd zijn om niet optimaal therapietrouw te zijn. We 
includeerden 23 studies (28 artikelen) in deze review. Er was geen consistent bewijs 
voor een verband tussen persoonlijkheidskenmerken en therapietrouw aan 
medicatie; we vonden wel indicaties voor een verband tussen therapietrouw aan de 
ene kant en neuroticisme en nauwgezetheid aan de andere kant. 
 
In deel twee besteden we aandacht aan de zienswijzen en opvattingen van de 
zorgverlener met betrekking tot ICS.  
 
Verschillen in opvattingen over ICS (Hoofdstuk 4) 
Hoofdstuk 4 beschrijft of de zienswijze van apothekers en assistenten op de 
opvattingen over ICS van patiënten met astma verschilt van de opvattingen van 
patiënten met astma zelf. Daarnaast onderzoeken we de verschillen tussen de 
opvattingen over ICS van apothekers en assistenten en die van patiënten met astma. 
Necessity beliefs en concerns over ICS zijn gemeten met (een aangepaste versie van) 
de Beliefs about Medicines Questionnaire (BMQ). Apothekers vulden de BMQ in voor 
henzelf en ook zoals zij dachten dat de meeste van hun patiënten de vragenlijst in 
zouden vullen. Ook patiënten met astma vulden de vragenlijst in. In totaal vulden 
136 apothekers, 90 apothekersassistenten en 161 patiënten de vragenlijst in. 
Apothekers en assistenten dachten dat patiënten meer zorgen hadden  over ICS dan 
patiënten zelf rapporteerden. Zij dachten ook dat patiënten sterkere opvattingen 
hadden over hun persoonlijke noodzaak om ICS te gebruiken dan patiënten 
rapporteerden. Apothekers gaven aan minder zorgen te hebben dan patiënten en 
beide zorgverleners attribueerden een hogere mate van necessity aan ICS dan 
patiënten deden. Apothekers en assistenten overschatten de mate van noodzaak 
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aan ICS en de zorgen die patiënten met astma hebben. Ook hebben ze zelf, tot op 
zekere hoogte, positievere opvattingen over ICS. 
 
Deel drie focust zich op de communicatie tijdens farmaceutische consulten over ICS 
in de openbare apotheek. 
 
Het proces en de inhoud van de communicatie tijdens farmaceutische consulten 
(Hoofdstuk 5) 
In Hoofdstuk 5 behandelden we hoe apothekers en assistenten communiceren over 
ICS met patiënten met astma en/of COPD, welke onderwerpen zij bespreken, en of 
apothekers en assistenten verschillen in hun communicatie. Honderdnegenzestig 
farmaceutische consulten zijn met een videocamera opgenomen en vervolgens 
geobserveerd met het Roter Interaction Analysis System (RIAS). De communicatie 
was grotendeels instrumenteel. Echter, leefstijl, psychosociale onderwerpen en 
therapietrouw aan ICS werden niet vaak besproken. De gemiddelde duur van de 
gesprekken van de apothekers waren langer dan die van de assistenten (16,5 
minuten en 11,3 minuten, respectievelijk, p<0,001) en apothekers gebruikten 
gemiddeld meer affectieve uitingen per sessie dan assistenten (respectievelijk 89,0 
uitingen en 63,7 uitingen, p<0,001). 
 
Reacties van apothekers en assistenten op informationele en emotionele signalen 
van patiënten (Hoofdstuk 6) 
We onderzochten de informationele en  emotionele signalen (‘cues’) van patiënten 
met astma en de reacties hierop van apothekers en assistenten tijdens 
farmaceutische consulten over ICS. We analyseerden 86 sessies met de Medical 
Interview Aural Rating Scale (MIARS). Gemiddeld uitten patiënten 2,3 signalen; deze 
waren voornamelijk informationeel (70,8%). In een kwart van de sessies hadden 
patiënten geen signalen geuit. Op emotionele cues reageerden apothekers en 
assistenten vaak inadequaat (59,3%) en op informationele cues voornamelijk op een 
passende manier. We vonden een verband tussen het geven van niet passende 
informatie en hogere concerns na de sessie. Ook vonden we een verband tussen het 
exploreren van de cue en hogere zelfgerapporteerde therapietrouw na 3 maanden. 
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Discussie (Hoofdstuk 7) 
 
In Hoofdstuk 7 zijn de verschillende studies samengevat, de belangrijkste 
bevindingen besproken in vergelijking tot de bestaande wetenschappelijke literatuur 
en worden deze geplaatst in een breder perspectief.  
Het achterhalen van de opvattingen van patiënten over ICS door apothekers en 
apothekersassistenten, en het inspelen op deze opvattingen, lijken belangrijk om 
therapietrouw aan ICS te verbeteren. Met name aandacht besteden aan necessity 
beliefs lijkt essentieel, wat ook onderbouwd wordt door de literatuur. Echter mag de 
rol van concerns niet onderschat worden in relatie tot therapietrouw. Ook is het 
belangrijk dat apothekers en assistenten zich ervan bewust zijn dat hun zienswijzen 
en opvattingen met betrekking tot ICS kunnen verschillen van de opvattingen van 
patiënten. Deze verschillen kunnen (onbewust) invloed hebben op de communicatie 
met patiënten en ervoor zorgen dat er minder aandacht besteed wordt aan hun 
medicatieopvattingen. 
Verder wordt er ingegaan op de communicatie tijdens farmaceutische consulten 
en hoe deze verbeterd zou kunnen worden. Voornamelijk meer patiëntgerichte 
communicatie is belangrijk tijdens farmaceutische consulten. Hierbij wordt onder 
andere het perspectief van de patiënt (zoals de zorgen, verwachtingen, behoeften, 
gevoelens) achterhaald en begrepen. Ook is er sprake van gezamenlijke 
besluitvorming door de patiënt te betrekken in het maken van keuzes in de mate die 
hij of zij wenst. We vonden dat er veel variatie tussen de gesprekken van apothekers 
en assistenten was met betrekking tot de inhoud, affectieve communicatie, en de 
duur van de gesprekken. Ook al zijn de behoeften van de patiënt leidend in de 
communicatie, toch stellen we voor om richtlijnen te maken voor farmaceutische 
consulten voor enige houvast om farmaceutische consulten over ICS te kunnen 
voeren.  
Daarnaast gaan we in op de implicaties van onze bevindingen voor de openbare 
apotheek en het beleid. De implicaties hebben betrekking op farmaceutische 
consulten en op patiëntgerichte communicatie. Hieronder worden deze besproken. 
 
Barrières die de implementatie van  farmaceutische consulten en patiëntgerichte 
communicatie in de apotheek kunnen belemmeren 
De volgende barrières kunnen het implementeren van farmaceutische consulten en 
patiëntgerichte communicatie belemmeren: tijdsgebrek, het contact hebben met 
verschillend apotheekpersoneel kan een goede patiënt-zorgverlener relatie 
bemoeilijken, gebrek aan privacy aan de balie, iemand anders dan de patiënt haalt 
de medicatie op, geen financiële vergoeding van farmaceutische consulten, de 
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mogelijkheid dat patiënten zich mogelijk niet bewust zijn van de rol van de 
apotheker en assistent als zorgverlener die counseling geeft.  
  
Implicaties voor de openbare apotheek 
Om (meer) farmaceutische consulten te kunnen geven aan patiënten, zal de 
organisatie in de openbare apotheek moeten veranderen. Zo zal er meer 
personeelscapaciteit nodig zijn. Ook is taakherschikking tussen apothekers en 
assistenten vereist en dient er bepaald te worden wie wanneer farmaceutische 
consulten verzorgt en wie administratieve taken uitvoert. Het aannemen of 
aanwijzen van één apotheker die zich speciaal richt op patiëntcounseling is 
bijvoorbeeld een mogelijkheid. Daarnaast zal er extra financiering nodig zijn om de 
gesprekken te kunnen bekostigen. Tot slot dienen de inhoud, frequentie en 
patiëntdoelgroep van farmaceutische consulten onderzocht en bepaald te worden. 
 
Implicaties voor onderwijs 
Onderwijs kan patiëntgerichte communicatie verbeteren. Het Utrechtse model voor 
patiëntgerichte communicatie in de apotheek kan gebruikt worden voor het 
ontwikkelen van onderwijs in communicatie. Tevens is het ontwikkelen van 
effectieve postuniversitaire trainingen belangrijk, waarbij apothekers aangemoedigd 
moeten worden om dit soort communicatietrainingen te volgen. 
 
Implicaties voor beleid 
Het stimuleren en implementeren van patiëntgerichte counseling in de apotheek 
kan aangemoedigd worden door het bieden van hogere financiële vergoedingen 
door overheid en zorgverzekeraars. Een mogelijkheid van financiering is 
patiëntgebonden bekostiging van farmaceutische zorg, waarbij patiënten zich 
inschrijven bij een apotheek en een inschrijftarief betalen, net als bij de huisarts. 
Daarnaast ontwikkelt de Koninklijke Nederlandse Maatschappij ter bevordering 
der Pharmacie (KNMP) momenteel een communicatierichtlijn voor farmaceutische 
consulten die gebaseerd is op een patiëntgerichte richtlijn. Het implementeren van 
zo’n communicatierichtlijn kan patiëntgerichte communicatie verbeteren tijdens 
farmaceutische consulten.  
 
Implicaties met betrekking tot initiatieven van de openbare apotheek 
Apotheken kunnen zelf patiëntgerichte activiteiten initiëren. Voorbeelden zijn de 
apotheek ‘Pillen en praten’ en het ‘FarmaBuddy project’.  
 
Implicaties voor de rol van apothekers en apothekersassistenten 
Als apothekers en apothekersassistenten een rol als communicatieve zorgverlener 
willen uitoefenen, is het belangrijk dat hun communicatie meer patiëntgericht 
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wordt. We vonden een aantal verschillen tussen apothekers en assistenten in hun 
communicatie, maar het was geen doel van het onderzoek om te evalueren wie 
beter communiceert. Niet alleen de rol van de apotheker verandert, ook de rol van 
de apothekersassistent zal in de toekomst waarschijnlijk veranderen. Apothekers 
moeten hun rol als zorgverlener meer prominent op zich nemen en laten zien aan 
patiënten dat ze toegankelijk zijn voor het geven van counseling, zodat patiënten 
zich daar meer bewust van worden. 
 
Methodologische overwegingen  
Er zijn een aantal methodologische overwegingen met betrekking tot de validiteit 
van de aangepaste observatieschalen (RIAS en MIARS) die we hebben toegepast in 
dit onderzoek. Daarnaast hebben de meeste studies een cross-sectionele  of 
observationele onderzoeksopzet, waardoor de verbanden die we gevonden hebben 
niet kunnen worden gezien als causale verbanden. Verder is er tijdens het werven 
van apothekers en patiënten sprake geweest van selectiebias, wat de 
generaliseerbaarheid van de gevonden resultaten beperkt. Tot slot kunnen de 
algemene instructies die zijn gegeven aan apothekers en assistenten voor het 
voeren van controlegesprekken, invloed hebben gehad op de inhoud van de 
gesprekken. 
 
Aanbevelingen voor vervolgonderzoek 
Vervolgonderzoek dient zich te richten op patiëntgerelateerde factoren die invloed 
kunnen hebben op therapietrouw. Zo krijgen we inzicht in hoe therapietrouw 
verbeterd kan worden en hoe apothekers en apothekersassistenten hiermee 
rekening moeten houden tijdens gesprekken. Daarnaast is het belangrijk om te 
kijken of zorgverlenergerelateerde factoren (zoals medicatieopvattingen van 
zorgverleners) invloed hebben op de communicatie. Ook dient gekeken te worden 
naar de effecten van patiëntgerichte communicatie op patiëntuitkomsten, zoals 
medicatieopvattingen en therapietrouw. Niet alleen consulten in de spreekkamer 
moeten worden onderzocht, maar ook gesprekken aan de balie. Tevens dient 
onderzoek zich te focussen op het ontwikkelen en implementeren van effectieve 
communicatietrainingen en tools om patiëntgerichte communicatie van apothekers 
en apothekersassistenten te verbeteren. Verder is meer inzicht nodig in de invloed 
van voorlichting op de inhalatietechniek van patiënten, aangezien 70% van de 
patiënten een verkeerde inhalatietechniek heeft. Tot slot is meer onderzoek nodig 
naar de rol- en taakverdeling van apothekers en apothekersassistenten in het geven 
van patiëntgerichte counseling, en hoe barrières kunnen worden getackeld om meer  
patiëntgerichte services te kunnen verlenen. 
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Het is zover: mijn boekje is af! Ik kan het bijna niet geloven. Wat begon in 2011 met 
een eenjarig onderzoek, werd een mooi, leerzaam en uitdagend promotietraject. 
Dat er hier een boekje gedrukt en wel ligt, heb ik te danken aan verschillende 
mensen. Zonder hun bijdrage was het nooit gelukt om dit promotieonderzoek tot 
een goed einde te brengen. 
 
Allereerst wil ik mijn eerste promotor, Sandra, bedanken voor deze kans om te 
promoveren. Daarnaast stond je deur altijd voor me open. Je zorgde ervoor dat ik de 
focus hield, was altijd enthousiast en positief, en gaf me het vertrouwen om dit 
avontuur aan te gaan en af te ronden. Ik heb de afgelopen jaren zoveel van je 
geleerd, dankjewel! 
Beste Peter, mijn tweede promotor, jou wil ik bedanken voor je eigen blik en je 
deskundige inbreng, deze zijn heel waardevol geweest. Je treffende inzichten en 
opbeurende woorden, vooral tijdens de laatste fase van het schrijven van dit 
proefschrift, zal ik niet vergeten. Geniet van je pensioen!  
Beste Rolf, ook jou wil ik bedanken voor dat je als copromotor bij hebt gedragen 
aan dit onderzoek en voor de feedback die je gegeven hebt. 
 
De leden van de manuscriptcommissie, Prof. dr. Westert, Prof. dr. Das en Prof. dr. 
Bouvy wil ik bedanken voor hun tijd om mijn proefschrift te beoordelen. Prof. dr. 
van Dijk, Prof. dr. van Schayck, dr. Linn en dr. Vervloet, hartelijk bedankt dat jullie 
wilden opponeren tijdens mijn verdediging. 
 
Ook wil ik graag UPPER bedanken voor het gebruik mogen maken van het UPPER 
netwerk. Willem, bedankt voor het meedenken, benaderen en werven van 
apotheken.  
Zonder de patiënten, apothekers en apothekersassistenten die deel wilden 
nemen aan de verschillende studies had dit onderzoek nooit kunnen slagen, ook 
voor hen veel dank!   
 
Meike, bedankt voor je hulp en inbreng tijdens je scriptieonderzoek op het Nivel, 
wat tevens in een mooie publicatie heeft geresulteerd. Litje en Jorien, dankjulliewel 
voor het observeren van de vele consulten en Litje, ook dank voor je 
medeauteurschap. Nienke, bedankt voor het bijspringen tijdens de dataverzameling. 
 
Doortje, hoe bewerkelijk het soms ook leek, je hebt me telkens geholpen met het 
opmaken, nummeren, stickeren, verzenden van honderden vragenlijsten, brieven en 
uitnodigingen. Ook heb je de lay-out van mijn proefschrift verzorgd. Dank voor al je 
hulp! Richard wil ik bedanken voor het digitaliseren van alle video-opnames en Peter 
S., voor de hulp bij statistische analyses. Carlijn, Alma en Leanne, dank voor jullie 
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ondersteuning bij het maken van de vragenlijsten voor de verschillende studies. 
Mieke, bedankt voor het vertalen van de vragenlijsten en de Engelse checks, en 
Anne-Vicky, Linda en Marcus voor jullie ondersteuning vanuit het kenniscentrum. 
 
Oud-(communicatie)collega’s van het Nivel, Inge, Hanneke, Liesbeth, Mara, Ligaya, 
bedankt voor de leuke tijd, het sparren, de praatjes op de gang, en leuke congressen 
en symposia. Janneke, dankjewel voor de fijne samenwerking, het tegenlezen, en de 
gezelligheid (ook op het Radboud!). In de afgelopen jaren heb ik veel kamergenoten 
gehad: Daniël, Wil, Karin, Corelien, Petra, Martine, Tessa, Lisa, Anne-Karien, bedankt 
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